0001822359 12-31 2024 Q3 false P3Y P1Y P1Y xbrli:shares iso4217:USD iso4217:USD xbrli:shares dcgo:member xbrli:pure dcgo:bank dcgo:segment dcgo:revenueStream dcgo:lease dcgo:claim 0001822359 2024-01-01 2024-09-30 0001822359 2024-11-05 0001822359 2024-09-30 0001822359 2023-12-31 0001822359 2024-07-01 2024-09-30 0001822359 2023-07-01 2023-09-30 0001822359 2023-01-01 2023-09-30 0001822359 us-gaap:CommonStockMember 2022-12-31 0001822359 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001822359 us-gaap:RetainedEarningsMember 2022-12-31 0001822359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001822359 us-gaap:NoncontrollingInterestMember 2022-12-31 0001822359 2022-12-31 0001822359 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001822359 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001822359 2023-01-01 2023-03-31 0001822359 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001822359 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0001822359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001822359 us-gaap:CommonStockMember 2023-03-31 0001822359 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001822359 us-gaap:RetainedEarningsMember 2023-03-31 0001822359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001822359 us-gaap:NoncontrollingInterestMember 2023-03-31 0001822359 2023-03-31 0001822359 dcgo:CardiacRMSLLCMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001822359 dcgo:CardiacRMSLLCMember us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001822359 dcgo:CardiacRMSLLCMember 2023-04-01 2023-06-30 0001822359 dcgo:AmbulnzFMCNAMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001822359 dcgo:AmbulnzFMCNAMember us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001822359 dcgo:AmbulnzFMCNAMember us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001822359 dcgo:AmbulnzFMCNAMember us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0001822359 dcgo:AmbulnzFMCNAMember 2023-04-01 2023-06-30 0001822359 dcgo:HealthwroxMember us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0001822359 dcgo:HealthwroxMember 2023-04-01 2023-06-30 0001822359 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001822359 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001822359 2023-04-01 2023-06-30 0001822359 us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0001822359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001822359 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001822359 us-gaap:CommonStockMember 2023-06-30 0001822359 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001822359 us-gaap:RetainedEarningsMember 2023-06-30 0001822359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001822359 us-gaap:NoncontrollingInterestMember 2023-06-30 0001822359 2023-06-30 0001822359 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001822359 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001822359 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0001822359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001822359 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001822359 us-gaap:CommonStockMember 2023-09-30 0001822359 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001822359 us-gaap:RetainedEarningsMember 2023-09-30 0001822359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001822359 us-gaap:NoncontrollingInterestMember 2023-09-30 0001822359 2023-09-30 0001822359 us-gaap:CommonStockMember 2023-12-31 0001822359 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001822359 us-gaap:RetainedEarningsMember 2023-12-31 0001822359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001822359 us-gaap:NoncontrollingInterestMember 2023-12-31 0001822359 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001822359 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001822359 2024-01-01 2024-03-31 0001822359 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001822359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001822359 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001822359 us-gaap:CommonStockMember 2024-03-31 0001822359 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001822359 us-gaap:RetainedEarningsMember 2024-03-31 0001822359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001822359 us-gaap:NoncontrollingInterestMember 2024-03-31 0001822359 2024-03-31 0001822359 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001822359 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001822359 2024-04-01 2024-06-30 0001822359 us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0001822359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001822359 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001822359 us-gaap:CommonStockMember 2024-06-30 0001822359 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001822359 us-gaap:RetainedEarningsMember 2024-06-30 0001822359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001822359 us-gaap:NoncontrollingInterestMember 2024-06-30 0001822359 2024-06-30 0001822359 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001822359 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001822359 us-gaap:NoncontrollingInterestMember 2024-07-01 2024-09-30 0001822359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001822359 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001822359 us-gaap:CommonStockMember 2024-09-30 0001822359 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001822359 us-gaap:RetainedEarningsMember 2024-09-30 0001822359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001822359 us-gaap:NoncontrollingInterestMember 2024-09-30 0001822359 dcgo:AmbulnzFMCNAMember 2024-01-01 2024-09-30 0001822359 dcgo:AmbulnzFMCNAMember 2023-01-01 2023-09-30 0001822359 dcgo:CardiacRMSLLCMember 2024-01-01 2024-09-30 0001822359 dcgo:CardiacRMSLLCMember 2023-01-01 2023-09-30 0001822359 2021-11-05 0001822359 2021-11-05 2021-11-05 0001822359 us-gaap:PrivatePlacementMember 2021-11-05 0001822359 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2024-07-01 2024-09-30 0001822359 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2023-07-01 2023-09-30 0001822359 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2024-01-01 2024-09-30 0001822359 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2023-01-01 2023-09-30 0001822359 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2024-09-30 0001822359 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2023-12-31 0001822359 dcgo:CustomerOneMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2024-07-01 2024-09-30 0001822359 dcgo:CustomerOneMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2024-07-01 2024-09-30 0001822359 dcgo:CustomerTwoMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2024-07-01 2024-09-30 0001822359 dcgo:CustomerTwoMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2024-07-01 2024-09-30 0001822359 dcgo:CustomerOneMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2024-01-01 2024-09-30 0001822359 dcgo:CustomerOneMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2024-01-01 2024-09-30 0001822359 dcgo:CustomerTwoMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2024-01-01 2024-09-30 0001822359 dcgo:CustomerTwoMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2024-01-01 2024-09-30 0001822359 dcgo:CustomerOneMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2023-07-01 2023-09-30 0001822359 dcgo:CustomerOneMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2023-07-01 2023-09-30 0001822359 dcgo:CustomerTwoMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2023-07-01 2023-09-30 0001822359 dcgo:CustomerTwoMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2023-07-01 2023-09-30 0001822359 dcgo:CustomerOneMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2023-01-01 2023-09-30 0001822359 dcgo:CustomerOneMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2023-01-01 2023-09-30 0001822359 dcgo:CustomerTwoMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2023-01-01 2023-09-30 0001822359 dcgo:CustomerTwoMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2023-01-01 2023-09-30 0001822359 dcgo:VendorOneMember us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsProductLineMember 2024-07-01 2024-09-30 0001822359 dcgo:VendorOneMember us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsProductLineMember 2023-07-01 2023-09-30 0001822359 dcgo:VendorOneMember us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsProductLineMember 2024-01-01 2024-09-30 0001822359 dcgo:VendorOneMember us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsProductLineMember 2023-01-01 2023-09-30 0001822359 dcgo:RyanBrothersFortAtkinsonLLCMember 2022-08-09 0001822359 dcgo:RyanBrothersFortAtkinsonLLCMember 2022-08-09 2022-08-09 0001822359 dcgo:RyanBrothersFortAtkinsonLLCMember 2024-07-01 2024-09-30 0001822359 dcgo:RyanBrothersFortAtkinsonLLCMember 2023-07-01 2023-09-30 0001822359 dcgo:RyanBrothersFortAtkinsonLLCMember 2024-01-01 2024-09-30 0001822359 dcgo:RyanBrothersFortAtkinsonLLCMember 2023-01-01 2023-09-30 0001822359 dcgo:RyanBrothersFortAtkinsonLLCMember 2023-01-01 2023-12-31 0001822359 dcgo:RyanBrothersFortAtkinsonLLCMember 2024-09-30 0001822359 dcgo:RyanBrothersFortAtkinsonLLCMember 2023-12-31 0001822359 dcgo:ExceptionalMedicalTransportationLLCMember 2022-07-13 0001822359 dcgo:ExceptionalMedicalTransportationLLCMember 2022-07-13 2022-07-13 0001822359 dcgo:ExceptionalMedicalTransportationLLCMember 2024-07-01 2024-09-30 0001822359 dcgo:ExceptionalMedicalTransportationLLCMember 2024-01-01 2024-09-30 0001822359 dcgo:ExceptionalMedicalTransportationLLCMember 2023-07-01 2023-09-30 0001822359 dcgo:ExceptionalMedicalTransportationLLCMember 2023-01-01 2023-09-30 0001822359 dcgo:ExceptionalMedicalTransportationLLCMember 2023-01-01 2023-12-31 0001822359 dcgo:ExceptionalMedicalTransportationLLCMember 2024-09-30 0001822359 dcgo:ExceptionalMedicalTransportationLLCMember 2023-12-31 0001822359 dcgo:LocationMedicalServicesLLCMember 2022-12-09 0001822359 dcgo:LocationMedicalServicesLLCMember 2023-01-01 2023-09-30 0001822359 dcgo:LocationMedicalServicesLLCMember 2024-07-01 2024-09-30 0001822359 dcgo:LocationMedicalServicesLLCMember 2023-07-01 2023-09-30 0001822359 dcgo:LocationMedicalServicesLLCMember 2024-01-01 2024-09-30 0001822359 dcgo:LocationMedicalServicesLLCMember 2024-09-30 0001822359 dcgo:LocationMedicalServicesLLCMember 2023-12-31 0001822359 dcgo:CardiacRMSLLCMember 2023-03-31 0001822359 dcgo:CardiacRMSLLCMember dcgo:TrueUpPaymentMember 2023-03-31 0001822359 dcgo:CardiacRMSLLCMember dcgo:EarnOutPaymentMember 2023-03-31 0001822359 dcgo:CardiacRMSLLCMember 2023-03-31 2023-03-31 0001822359 dcgo:CardiacRMSLLCMember 2024-07-01 2024-09-30 0001822359 dcgo:CardiacRMSLLCMember 2023-07-01 2023-09-30 0001822359 dcgo:CardiacRMSLLCMember 2024-05-29 2024-05-29 0001822359 dcgo:CardiacRMSLLCMember 2024-09-30 0001822359 dcgo:CardiacRMSLLCMember 2023-12-31 0001822359 2024-01-01 0001822359 us-gaap:BuildingMember 2024-09-30 0001822359 srt:MinimumMember us-gaap:EquipmentMember 2024-09-30 0001822359 srt:MaximumMember us-gaap:EquipmentMember 2024-09-30 0001822359 srt:MinimumMember us-gaap:VehiclesMember 2024-09-30 0001822359 srt:MaximumMember us-gaap:VehiclesMember 2024-09-30 0001822359 dcgo:MedicalEquipmentMember 2024-09-30 0001822359 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2024-09-30 0001822359 country:US 2024-07-01 2024-09-30 0001822359 country:US 2023-07-01 2023-09-30 0001822359 country:US 2024-01-01 2024-09-30 0001822359 country:US 2023-01-01 2023-09-30 0001822359 country:GB 2024-07-01 2024-09-30 0001822359 country:GB 2023-07-01 2023-09-30 0001822359 country:GB 2024-01-01 2024-09-30 0001822359 country:GB 2023-01-01 2023-09-30 0001822359 dcgo:MobileHealthServicesSegmentMember 2024-07-01 2024-09-30 0001822359 dcgo:MobileHealthServicesSegmentMember 2023-07-01 2023-09-30 0001822359 dcgo:MobileHealthServicesSegmentMember 2024-01-01 2024-09-30 0001822359 dcgo:MobileHealthServicesSegmentMember 2023-01-01 2023-09-30 0001822359 dcgo:TransportationServicesSegmentMember 2024-07-01 2024-09-30 0001822359 dcgo:TransportationServicesSegmentMember 2023-07-01 2023-09-30 0001822359 dcgo:TransportationServicesSegmentMember 2024-01-01 2024-09-30 0001822359 dcgo:TransportationServicesSegmentMember 2023-01-01 2023-09-30 0001822359 dcgo:RNDHealthServicesIncMember 2021-10-26 0001822359 dcgo:RNDHealthServicesIncMember 2021-10-26 2021-10-26 0001822359 dcgo:RNDHealthServicesIncMember 2024-01-01 2024-09-30 0001822359 dcgo:RNDHealthServicesIncMember 2023-01-01 2023-12-31 0001822359 dcgo:NationalProvidersAssociationLLCMember 2021-11-01 0001822359 dcgo:NationalProvidersAssociationLLCMember 2021-11-01 2021-11-01 0001822359 dcgo:NationalProvidersAssociationLLCMember 2021-12-21 2021-12-21 0001822359 dcgo:RNDHealthServicesIncMember 2023-12-31 0001822359 dcgo:RNDHealthServicesIncMember 2024-09-30 0001822359 us-gaap:TransportationEquipmentMember 2024-09-30 0001822359 us-gaap:TransportationEquipmentMember 2023-12-31 0001822359 dcgo:MedicalEquipmentMember 2023-12-31 0001822359 us-gaap:OfficeEquipmentMember 2024-09-30 0001822359 us-gaap:OfficeEquipmentMember 2023-12-31 0001822359 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001822359 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001822359 us-gaap:BuildingMember 2023-12-31 0001822359 us-gaap:LandMember 2024-09-30 0001822359 us-gaap:LandMember 2023-12-31 0001822359 dcgo:LocationMedicalServicesLLCMember 2022-12-09 2022-12-09 0001822359 dcgo:LocationMedicalServicesLLCMember 2023-01-01 2023-12-31 0001822359 dcgo:LocationMedicalServicesLLCMember 2024-04-02 2024-04-02 0001822359 dcgo:CardiacRMSLLCMember 2023-01-01 2023-12-31 0001822359 dcgo:AmbulnzFMCNorthAmericaLLCMember 2023-04-01 2023-04-01 0001822359 dcgo:AmbulnzFMCNorthAmericaLLCMember 2023-01-01 2023-12-31 0001822359 dcgo:RapidReliableTestingMember 2023-05-10 2023-05-10 0001822359 dcgo:AmbulnzCOLLCMember 2024-07-01 2024-07-01 0001822359 2023-03-30 2024-07-02 0001822359 dcgo:AmbulnzCOLLCMember 2024-07-01 0001822359 dcgo:AmbulnzFMCNorthAmericaLLCMember 2023-04-01 0001822359 2024-07-01 0001822359 2023-01-01 2023-12-31 0001822359 us-gaap:ComputerSoftwareIntangibleAssetMember 2024-09-30 0001822359 us-gaap:ComputerSoftwareIntangibleAssetMember 2024-01-01 2024-09-30 0001822359 dcgo:OperatingLicensesMember 2024-09-30 0001822359 dcgo:OperatingLicensesMember 2024-01-01 2024-09-30 0001822359 us-gaap:SoftwareDevelopmentMember srt:MinimumMember 2024-09-30 0001822359 us-gaap:SoftwareDevelopmentMember srt:MaximumMember 2024-09-30 0001822359 us-gaap:SoftwareDevelopmentMember 2024-09-30 0001822359 us-gaap:SoftwareDevelopmentMember 2024-01-01 2024-09-30 0001822359 dcgo:MaterialContractsMember 2024-09-30 0001822359 dcgo:MaterialContractsMember 2024-01-01 2024-09-30 0001822359 us-gaap:CustomerRelationshipsMember srt:MinimumMember 2024-09-30 0001822359 us-gaap:CustomerRelationshipsMember srt:MaximumMember 2024-09-30 0001822359 us-gaap:CustomerRelationshipsMember 2024-09-30 0001822359 us-gaap:CustomerRelationshipsMember 2024-01-01 2024-09-30 0001822359 us-gaap:TrademarksMember srt:MinimumMember 2024-09-30 0001822359 us-gaap:TrademarksMember srt:MaximumMember 2024-09-30 0001822359 us-gaap:TrademarksMember 2024-09-30 0001822359 us-gaap:TrademarksMember 2024-01-01 2024-09-30 0001822359 dcgo:NonCompeteAgreementMember 2024-09-30 0001822359 dcgo:NonCompeteAgreementMember 2024-01-01 2024-09-30 0001822359 dcgo:TradeCreditAgreementsMember 2024-09-30 0001822359 dcgo:TradeCreditAgreementsMember 2024-01-01 2024-09-30 0001822359 us-gaap:ComputerSoftwareIntangibleAssetMember 2023-12-31 0001822359 us-gaap:ComputerSoftwareIntangibleAssetMember 2023-01-01 2023-12-31 0001822359 dcgo:OperatingLicensesMember 2023-12-31 0001822359 dcgo:OperatingLicensesMember 2023-01-01 2023-12-31 0001822359 us-gaap:SoftwareDevelopmentMember srt:MinimumMember 2023-12-31 0001822359 us-gaap:SoftwareDevelopmentMember srt:MaximumMember 2023-12-31 0001822359 us-gaap:SoftwareDevelopmentMember 2023-12-31 0001822359 us-gaap:SoftwareDevelopmentMember 2023-01-01 2023-12-31 0001822359 dcgo:MaterialContractsMember 2023-12-31 0001822359 dcgo:MaterialContractsMember 2023-01-01 2023-12-31 0001822359 us-gaap:CustomerRelationshipsMember srt:MinimumMember 2023-12-31 0001822359 us-gaap:CustomerRelationshipsMember srt:MaximumMember 2023-12-31 0001822359 us-gaap:CustomerRelationshipsMember 2023-12-31 0001822359 us-gaap:CustomerRelationshipsMember 2023-01-01 2023-12-31 0001822359 us-gaap:TrademarksMember srt:MinimumMember 2023-12-31 0001822359 us-gaap:TrademarksMember srt:MaximumMember 2023-12-31 0001822359 us-gaap:TrademarksMember 2023-12-31 0001822359 us-gaap:TrademarksMember 2023-01-01 2023-12-31 0001822359 dcgo:NonCompeteAgreementMember 2023-12-31 0001822359 dcgo:NonCompeteAgreementMember 2023-01-01 2023-12-31 0001822359 dcgo:TradeCreditAgreementsMember 2023-12-31 0001822359 dcgo:TradeCreditAgreementsMember 2023-01-01 2023-12-31 0001822359 2022-11-01 2022-11-01 0001822359 us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrMember 2022-11-01 2022-11-01 0001822359 us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2022-11-01 2022-11-01 0001822359 us-gaap:RevolvingCreditFacilityMember 2022-11-01 2022-11-01 0001822359 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2023-12-31 0001822359 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2024-02-08 2024-02-08 0001822359 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2024-02-27 2024-02-27 0001822359 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2024-03-04 2024-03-04 0001822359 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2024-03-18 2024-03-18 0001822359 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2024-09-30 0001822359 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2024-07-01 2024-09-30 0001822359 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2023-07-01 2023-09-30 0001822359 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2024-01-01 2024-09-30 0001822359 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2023-01-01 2023-09-30 0001822359 us-gaap:LetterOfCreditMember 2023-10-20 0001822359 us-gaap:LetterOfCreditMember 2023-10-20 2023-10-20 0001822359 srt:MinimumMember 2024-09-30 0001822359 srt:MaximumMember 2024-09-30 0001822359 srt:MinimumMember 2023-12-31 0001822359 srt:MaximumMember 2023-12-31 0001822359 dcgo:NotesPayableMember 2024-07-01 2024-09-30 0001822359 dcgo:NotesPayableMember 2023-07-01 2023-09-30 0001822359 dcgo:NotesPayableMember 2024-01-01 2024-09-30 0001822359 dcgo:NotesPayableMember 2023-01-01 2023-09-30 0001822359 2022-01-01 2022-12-31 0001822359 us-gaap:CorporateMember 2024-07-01 2024-09-30 0001822359 dcgo:MobileHealthServicesSegmentMember 2024-09-30 0001822359 dcgo:TransportationServicesSegmentMember 2024-09-30 0001822359 us-gaap:CorporateMember 2024-09-30 0001822359 us-gaap:CorporateMember 2023-07-01 2023-09-30 0001822359 dcgo:MobileHealthServicesSegmentMember 2023-09-30 0001822359 dcgo:TransportationServicesSegmentMember 2023-09-30 0001822359 us-gaap:CorporateMember 2023-09-30 0001822359 us-gaap:CorporateMember 2024-01-01 2024-09-30 0001822359 us-gaap:CorporateMember 2023-01-01 2023-09-30 0001822359 country:US 2024-09-30 0001822359 country:US 2023-12-31 0001822359 country:GB 2024-09-30 0001822359 country:GB 2023-12-31 0001822359 dcgo:CardiacRMSLLCMember 2024-07-19 0001822359 dcgo:CardiacRMSLLCMember 2024-07-19 2024-07-19 0001822359 dcgo:A2022ProgramMember 2022-05-24 0001822359 dcgo:A2022ProgramMember 2022-04-01 2022-06-30 0001822359 dcgo:A2022ProgramMember 2022-10-01 2022-12-31 0001822359 dcgo:PriorRepurchaseProgramMember 2024-01-30 0001822359 dcgo:PriorRepurchaseProgramMember 2024-01-30 2024-01-30 0001822359 dcgo:NewRepurchaseProgramMember 2024-08-05 0001822359 us-gaap:CommonClassAMember 2021-12-31 0001822359 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2024-01-01 2024-09-30 0001822359 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2024-01-01 2024-09-30 0001822359 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001822359 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001822359 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001822359 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001822359 us-gaap:RestrictedStockUnitsRSUMember srt:MinimumMember 2024-01-01 2024-09-30 0001822359 us-gaap:RestrictedStockUnitsRSUMember srt:MaximumMember 2024-01-01 2024-09-30 0001822359 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001822359 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001822359 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001822359 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001822359 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001822359 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001822359 us-gaap:PerformanceSharesMember srt:MinimumMember 2024-01-01 2024-09-30 0001822359 us-gaap:PerformanceSharesMember srt:MaximumMember 2024-01-01 2024-09-30 0001822359 us-gaap:PerformanceSharesMember 2023-12-31 0001822359 us-gaap:PerformanceSharesMember 2024-01-01 2024-09-30 0001822359 us-gaap:PerformanceSharesMember 2024-09-30 0001822359 us-gaap:PerformanceSharesMember 2024-07-01 2024-09-30 0001822359 us-gaap:PerformanceSharesMember 2023-01-01 2023-09-30 0001822359 us-gaap:PerformanceSharesMember 2023-07-01 2023-09-30 0001822359 2019-01-01 2019-01-01 0001822359 us-gaap:RelatedPartyMember dcgo:LegalServicePaymentsMember 2023-12-31 0001822359 us-gaap:RelatedPartyMember dcgo:LegalServicePaymentsMember 2024-09-30 0001822359 us-gaap:RelatedPartyMember dcgo:SubcontractorPaymentsMember 2024-07-01 2024-09-30 0001822359 us-gaap:RelatedPartyMember dcgo:SubcontractorPaymentsMember 2024-01-01 2024-09-30 0001822359 us-gaap:RelatedPartyMember dcgo:SubcontractorPaymentsMember 2023-07-01 2023-09-30 0001822359 us-gaap:RelatedPartyMember dcgo:SubcontractorPaymentsMember 2023-01-01 2023-09-30 0001822359 us-gaap:RelatedPartyMember dcgo:SubcontractorPaymentsMember 2024-09-30 0001822359 us-gaap:RelatedPartyMember dcgo:SubcontractorPaymentsMember 2023-12-31 0001822359 dcgo:FormerChiefExecutiveOfficerMember us-gaap:RelatedPartyMember 2024-01-01 2024-09-30 0001822359 dcgo:FormerChiefExecutiveOfficerMember dcgo:TransitionServicesAgreementPaymentsMember 2024-07-01 2024-09-30 0001822359 dcgo:FormerChiefExecutiveOfficerMember dcgo:TransitionServicesAgreementPaymentsMember 2024-01-01 2024-09-30 0001822359 dcgo:FormerChiefExecutiveOfficerMember dcgo:TransitionServicesAgreementPaymentsMember 2023-07-01 2023-09-30 0001822359 dcgo:FormerChiefExecutiveOfficerMember dcgo:TransitionServicesAgreementPaymentsMember 2023-01-01 2023-09-30 0001822359 us-gaap:RelatedPartyMember dcgo:TransitionServicesAgreementPaymentsMember 2024-09-30 0001822359 us-gaap:RelatedPartyMember dcgo:TransitionServicesAgreementPaymentsMember 2023-12-31 0001822359 dcgo:DirectorAndChairOfTheBoardMember dcgo:ConsultingAgreementConsiderationMember 2024-03-07 2024-03-07 0001822359 us-gaap:RestrictedStockUnitsRSUMember dcgo:DirectorAndChairOfTheBoardMember dcgo:ConsultingAgreementConsiderationMember 2024-07-01 2024-09-30 0001822359 us-gaap:RestrictedStockUnitsRSUMember dcgo:DirectorAndChairOfTheBoardMember dcgo:ConsultingAgreementConsiderationMember 2024-01-01 2024-09-30 0001822359 dcgo:DirectorAndChairOfTheBoardMember us-gaap:RelatedPartyMember dcgo:ConsultingAgreementConsiderationMember 2023-12-31 0001822359 dcgo:DirectorAndChairOfTheBoardMember us-gaap:RelatedPartyMember dcgo:ConsultingAgreementConsiderationMember 2024-09-30 0001822359 dcgo:FormerBoardOfDirectorsChairmanMember us-gaap:RelatedPartyMember 2024-09-26 2024-09-26 0001822359 dcgo:FormerBoardOfDirectorsChairmanMember us-gaap:RelatedPartyMember dcgo:ConsultingAgreementConsiderationMember 2024-09-30 0001822359 dcgo:FormerBoardOfDirectorsChairmanMember us-gaap:RelatedPartyMember dcgo:ConsultingAgreementConsiderationMember 2023-12-31 0001822359 dcgo:CaliforniaLaborActionsMember 2023-03-30 2023-03-30 0001822359 us-gaap:SubsequentEventMember us-gaap:LetterOfCreditMember 2024-10-20 0001822359 us-gaap:SubsequentEventMember us-gaap:LetterOfCreditMember 2024-10-20 2024-10-20 0001822359 dcgo:BaseRateLoanMember us-gaap:RevolvingCreditFacilityMember us-gaap:SubsequentEventMember 2024-11-01 0001822359 dcgo:SOFRLoanMember us-gaap:RevolvingCreditFacilityMember us-gaap:SubsequentEventMember 2024-11-01 2024-11-01 0001822359 dcgo:FireflyHealthIncMember us-gaap:SubsequentEventMember 2024-11-01 2024-11-01 0001822359 dcgo:FireflyHealthIncMember us-gaap:SeriesCPreferredStockMember us-gaap:SubsequentEventMember 2024-11-01
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2024
OR
¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number: 001-39618
DocGo Inc.
(Exact Name of Registrant as Specified in Its Charter)

Delaware |  | 85-2515483
(State or Other Jurisdiction of Incorporation or Organization) |  | (I.R.S. Employer Identification Number)
35 West 35 th Street, Floor 6 New York, New York |  | 10001
(Address of Principal Executive Offices) |  | (Zip Code)

(844) 443-6246
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name, Former Address and Former Fiscal Year, If Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class |  | Trading Symbol(s) |  | Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share |  | DCGO |  | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | x |  | Accelerated filer | ¨
Non-accelerated filer | ¨ |  | Smaller reporting company | ¨
|  |  | Emerging growth company | ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x
As of November 5, 2024, 102,050,510 shares of the registrant’s common stock, par value $0.0001 per share, were issued and outstanding.

Table of Contents
Table of Contents

| Page
PART I - FINANCIAL INFORMATION |
Item 1. Financial Statements | 1
Item 2. Management’s Discussion and Analysis of Financial Condition and Result of Operations | 40
Item 3. Quantitative and Qualitative Disclosures About Market Risk | 58
Item 4. Controls and Procedures | 59
PART II - OTHER INFORMATION |
Item 1. Legal Proceedings | 61
Item 1A. Risk Factors | 61
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | 61
Item 3. Defaults Upon Senior Securities | 62
Item 4. Mine Safety Disclosures | 62
Item 5. Other Information | 62
Item 6. Exhibits | 63
Signatures | 64

i

Table of Contents
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements

Condensed Consolidated Balance Sheets as of Sep tember 30, 2024 (Unaudited) and December 31, 2023 | 2
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the Three and Nine Months Ended September 30, 2024 and 2023 | 3
Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three and Nine Months Ended September 30, 2024 and 2023 | 4
Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023 | 6
Notes to Unaudited Condensed Consolidated Financial Statements | 8

1

Table of Contents
DocGo Inc. and Subsidiaries
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

| September 30, 2024 |  | December 31, 2023
| Unaudited |  | Audited
ASSETS |  |  |
Current assets: |  |  |
Cash and cash equivalents | $ | 89,458,388 |  |  | $ | 59,286,147 |
Accounts receivable, net of allowance for credit loss of $6,455,874 and $6,276,454 as of September 30, 2024 and December 31, 2023, respectively | 233,712,723 |  |  | 262,083,462 |
Prepaid expenses and other current assets | 5,154,906 |  |  | 17,499,953 |
Total current assets | 328,326,017 |  |  | 338,869,562 |
Property and equipment, net | 15,284,753 |  |  | 16,835,484 |
Intangibles, net | 34,996,541 |  |  | 37,682,928 |
Goodwill | 47,862,242 |  |  | 47,539,929 |
Restricted cash | 19,120,110 |  |  | 12,931,839 |
Operating lease right-of-use assets | 12,489,767 |  |  | 9,580,535 |
Finance lease right-of-use assets | 14,605,119 |  |  | 12,003,919 |
Equity method investments | 634,100 |  |  | 553,573 |
Deferred tax assets | 17,131,328 |  |  | 11,888,539 |
Other assets | 3,432,562 |  |  | 2,565,649 |
Total assets | $ | 493,882,539 |  |  | $ | 490,451,957 |
LIABILITIES AND STOCKHOLDERS’ EQUITY |  |  |
Current liabilities: |  |  |
Accounts payable | $ | 35,141,454 |  |  | $ | 19,827,258 |
Accrued liabilities | 59,968,606 |  |  | 91,340,609 |
Line of credit | 30,000,000 |  |  | 25,000,000 |
Notes payable, current | 26,374 |  |  | 28,131 |
Due to seller | 138,275 |  |  | 7,823,009 |
Contingent consideration | 16,744,521 |  |  | 19,792,982 |
Operating lease liability, current | 3,776,159 |  |  | 2,773,020 |
Finance lease liability, current | 4,435,324 |  |  | 3,534,073 |
Total current liabilities | 150,230,713 |  |  | 170,119,082 |
Notes payable, non-current | 21,336 |  |  | 41,586 |
Operating lease liability, non-current | 9,172,259 |  |  | 7,223,941 |
Finance lease liability, non-current | 9,554,694 |  |  | 7,896,392 |
Total liabilities | 168,979,002 |  |  | 185,281,001 |
Commitments and contingencies |  |  |
Stockholders’ equity: |  |  |
Common stock ($0.0001 par value; 500,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 101,980,995 and 104,055,168 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively) | 10,198 |  |  | 10,406 |
Additional paid-in-capital | 321,028,986 |  |  | 320,693,866 |
Retained earnings (accumulated deficit) | 1,860,643 |  |  | (21,394,310) |
Accumulated other comprehensive income | 2,313,518 |  |  | 1,484,905 |
Total stockholders’ equity attributable to DocGo Inc. and Subsidiaries | 325,213,345 |  |  | 300,794,867 |
Noncontrolling interests | (309,808) |  |  | 4,376,089 |
Total stockholders’ equity | 324,903,537 |  |  | 305,170,956 |
Total liabilities and stockholders’ equity | $ | 493,882,539 |  |  | $ | 490,451,957 |

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.
2

Table of Contents
DocGo Inc. and Subsidiaries
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
Revenues, net | $ | 138,684,814 |  |  | $ | 186,552,910 |  |  | $ | 495,722,059 |  |  | $ | 425,042,373 |
Expenses: |  |  |  |  |  |  |
Cost of revenues (exclusive of depreciation and amortization, which is shown separately below) | 88,764,282 |  |  | 131,502,046 |  |  | 322,645,933 |  |  | 296,346,420 |
Operating expenses: |  |  |  |  |  |  |
General and administrative | 28,784,850 |  |  | 33,619,962 |  |  | 103,716,978 |  |  | 93,637,516 |
Depreciation and amortization | 4,177,534 |  |  | 4,336,267 |  |  | 12,561,973 |  |  | 11,816,657 |
Legal and regulatory | 3,295,139 |  |  | 3,545,820 |  |  | 11,622,438 |  |  | 9,588,997 |
Technology and development | 3,145,834 |  |  | 3,235,301 |  |  | 7,903,752 |  |  | 7,673,269 |
Sales, advertising and marketing | 379,778 |  |  | 1,605,559 |  |  | 1,109,072 |  |  | 2,598,192 |
Total expenses | 128,547,417 |  |  | 177,844,955 |  |  | 459,560,146 |  |  | 421,661,051 |
Income from operations | 10,137,397 |  |  | 8,707,955 |  |  | 36,161,913 |  |  | 3,381,322 |
Other income (expense): |  |  |  |  |  |  |
Interest (expense) income, net | (505,085) |  |  | 346,376 |  |  | (1,387,743) |  |  | 1,677,420 |
Change in fair value of contingent liability | (44,520) |  |  | 159,974 |  |  | (370,712) |  |  | 159,974 |
Loss on equity method investments | (82,742) |  |  | (95,503) |  |  | (229,923) |  |  | (301,362) |
(Loss) gain on remeasurement of operating and finance leases | (6,163) |  |  | 4,834 |  |  | (32,052) |  |  | 4,834 |
(Loss) gain on disposal of fixed assets | (28,681) |  |  | (9,983) |  |  | 36,717 |  |  | (163,452) |
Other income (expense) | (435,825) |  |  | 43,353 |  |  | 146,058 |  |  | (661,825) |
Total other income (expense) | (1,103,016) |  |  | 449,051 |  |  | (1,837,655) |  |  | 715,589 |
Net income before income tax provision | 9,034,381 |  |  | 9,157,006 |  |  | 34,324,258 |  |  | 4,096,911 |
Provision for income taxes | (4,488,828) |  |  | (4,526,767) |  |  | (13,316,752) |  |  | (2,041,843) |
Net income | 4,545,553 |  |  | 4,630,239 |  |  | 21,007,506 |  |  | 2,055,068 |
Net (loss) income attributable to noncontrolling interests | (952,348) |  |  | (134,682) |  |  | (2,247,447) |  |  | 2,767,084 |
Net income (loss) attributable to stockholders of DocGo Inc. and Subsidiaries | 5,497,901 |  |  | 4,764,921 |  |  | 23,254,953 |  |  | (712,016) |
Other comprehensive income |  |  |  |  |  |  |
Foreign currency translation adjustment | 934,774 |  |  | (582,471) |  |  | 828,613 |  |  | 66,965 |
Total comprehensive income (loss) | $ | 6,432,675 |  |  | $ | 4,182,450 |  |  | $ | 24,083,566 |  |  | $ | (645,051) |
Net income (loss) per share attributable to DocGo Inc. and Subsidiaries - Basic | $ | 0.05 |  |  | $ | 0.05 |  |  | $ | 0.23 |  |  | $ | (0.01) |
Weighted-average shares outstanding - Basic | 102,067,579 |  | 103,874,845 |  | 102,573,664 |  | 103,351,345
Net income (loss) per share attributable to DocGo Inc. and Subsidiaries - Diluted | $ | 0.05 |  |  | $ | 0.05 |  |  | $ | 0.22 |  |  | $ | (0.01) |
Weighted-average shares outstanding - Diluted | 106,290,929 |  | 104,993,729 |  | 106,797,014 |  | 103,351,345

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.
3

Table of Contents
DocGo Inc. and Subsidiaries
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

|  | Common Stock |  |  | Additional Paid-in- Capital |  | Retained Earnings (Accumulated Deficit) |  | Accumulated Other Comprehensive Income |  | Noncontrolling Interests |  | Total Stockholders’ Equity
|  | Shares |  | Amount |  |  |  |  |  |
Balance - December 31, 2022 |  | 102,411,162 |  | $ | 10,241 |  |  |  | $ | 301,451,435 |  |  | $ | (28,972,216) |  |  | $ | 741,206 |  |  | $ | 5,696,725 |  |  | $ | 278,927,391 |
Exercise of stock options |  | 96,101 |  | 10 |  |  |  | 249,705 |  |  | — |  |  | — |  |  | — |  |  | 249,715 |
UK Ltd. restricted stock |  | — |  | — |  |  |  | 167,175 |  |  | — |  |  | — |  |  | — |  |  | 167,175 |
Stock-based compensation |  | 424,911 |  | 42 |  |  |  | 8,181,549 |  |  | — |  |  | — |  |  | — |  |  | 8,181,591 |
Health liquidation |  | — |  | — |  |  |  | — |  |  | 70,284 |  |  | — |  |  | — |  |  | 70,284 |
Net loss attributable to noncontrolling interests |  | — |  | — |  |  |  | — |  |  | — |  |  | — |  |  | (453,120) |  |  | (453,120) |
Foreign currency translation |  | — |  | — |  |  |  | — |  |  | — |  |  | 243,658 |  |  | — |  |  | 243,658 |
Net loss attributable to stockholders of DocGo Inc. and Subsidiaries |  | — |  | — |  |  |  | — |  |  | (3,465,670) |  |  | — |  |  | — |  |  | (3,465,670) |
Balance - March 31, 2023 |  | 102,932,174 |  | $ | 10,293 |  |  |  | $ | 310,049,864 |  |  | $ | (32,367,602) |  |  | $ | 984,864 |  |  | $ | 5,243,605 |  |  | $ | 283,921,024 |
Acquisition of CRMS |  | 117,330 |  |  | 12 |  |  |  | 1,000,000 |  |  | — |  |  | — |  |  | — |  |  | 1,000,012 |
Acquisition of FMC NA |  | 360,145 |  |  | 36 |  |  |  | (1,432,963) |  |  | 649,167 |  |  | — |  |  | (3,213,956) |  |  | (3,997,716) |
Acquisition of Healthworx |  | — |  |  | — |  |  |  | — |  |  | — |  |  | — |  |  | (1,296,553) |  |  | (1,296,553) |
Exercise of stock options |  | 260,410 |  |  | 26 |  |  |  | 706,379 |  |  | — |  |  | — |  |  | — |  |  | 706,405 |
Stock based compensation, net of tax settled in shares |  | 92,033 |  |  | 9 |  |  |  | 1,778,001 |  |  | — |  |  | — |  |  | — |  |  | 1,778,010 |
Net income attributable to noncontrolling interests |  | — |  |  | — |  |  |  | — |  |  | — |  |  | — |  |  | 3,354,886 |  |  | 3,354,886 |
Foreign currency translation |  | — |  |  | — |  |  |  | — |  |  | — |  |  | 405,778 |  |  | — |  |  | 405,778 |
Net loss attributable to stockholders of DocGo Inc. and Subsidiaries |  | — |  |  | — |  |  |  | — |  |  | (2,011,267) |  |  | — |  |  | — |  |  | (2,011,267) |
Balance - June 30, 2023 |  | 103,762,092 |  | $ | 10,376 |  |  |  | $ | 312,101,281 |  |  | $ | (33,729,702) |  |  | $ | 1,390,642 |  |  | $ | 4,087,982 |  |  | $ | 283,860,579 |
Exercise of stock options |  | 88,837 |  |  | 8 |  |  |  | 425,995 |  |  | — |  |  | — |  |  | — |  |  | 426,003 |
Cashless exercise of options |  | 6,374 |  |  | 1 |  |  |  | (1) |  |  | — |  |  | — |  |  | — |  |  | — |
Stock based compensation |  | 30,650 |  |  | 3 |  |  |  | 3,335,707 |  |  | — |  |  | — |  |  | — |  |  | 3,335,710 |
Shares withheld for taxes |  | (13,414) |  |  | (1) |  |  |  | (117,644) |  |  | — |  |  | — |  |  | — |  |  | (117,645) |
Net loss attributable to noncontrolling interests |  | — |  |  | — |  |  |  | — |  |  | — |  |  | — |  |  | (134,682) |  |  | (134,682) |
Foreign currency translation |  | — |  |  | — |  |  |  | — |  |  | — |  |  | (582,471) |  |  | — |  |  | (582,471) |
Net income attributable to stockholders of DocGo Inc. and Subsidiaries |  | — |  |  | — |  |  |  | — |  |  | 4,764,921 |  |  | — |  |  | — |  |  | 4,764,921 |
Balance - September 30, 2023 |  | 103,874,539 |  | $ | 10,387 |  |  |  | $ | 315,745,338 |  |  | $ | (28,964,781) |  |  | $ | 808,171 |  |  | $ | 3,953,300 |  |  | $ | 291,552,415 |

4

Table of Contents

|  | Common Stock |  |  | Additional Paid-in- Capital |  | Retained Earnings (Accumulated Deficit) |  | Accumulated Other Comprehensive Income |  | Noncontrolling Interests |  | Total Stockholders’ Equity
|  | Shares |  | Amount |  |  |  |  |  |
Balance - December 31, 2023 |  | 104,055,168 |  | $ | 10,406 |  |  |  | $ | 320,693,866 |  |  | $ | (21,394,310) |  |  | $ | 1,484,905 |  |  | $ | 4,376,089 |  |  | $ | 305,170,956 |
Common stock repurchased |  | (1,255,614) |  | (126) |  |  |  | (4,877,433) |  |  | — |  |  | — |  |  | — |  |  | (4,877,559) |
Stock-based compensation |  | 165,688 |  | 17 |  |  |  | 4,340,388 |  |  | — |  |  | — |  |  | — |  |  | 4,340,405 |
Shares withheld for taxes |  | (3,747) |  | — |  |  |  | (20,946) |  |  | — |  |  | — |  |  | — |  |  | (20,946) |
Net loss attributable to noncontrolling interests |  | — |  | — |  |  |  | — |  |  | — |  |  | — |  |  | (624,070) |  |  | (624,070) |
Foreign currency translation |  | — |  | — |  |  |  | — |  |  | — |  |  | (140,134) |  |  | — |  |  | (140,134) |
Net income attributable to stockholders of DocGo Inc. and Subsidiaries |  | — |  | — |  |  |  | — |  |  | 11,227,449 |  |  | — |  |  | — |  |  | 11,227,449 |
Balance - March 31, 2024 |  | 102,961,495 |  | $ | 10,297 |  |  |  | $ | 320,135,875 |  |  | $ | (10,166,861) |  |  | $ | 1,344,771 |  |  | $ | 3,752,019 |  |  | $ | 315,076,101 |
Common stock repurchased |  | (1,395,957) |  | (140) |  |  |  | (4,904,312) |  |  | — |  |  | — |  |  | — |  |  | (4,904,452) |
Stock-based compensation |  | 181,136 |  | 18 |  |  |  | 2,417,092 |  |  | — |  |  | — |  |  | — |  |  | 2,417,110 |
Shares withheld for taxes |  | (64,334) |  | (7) |  |  |  | (245,379) |  |  | — |  |  | — |  |  | — |  |  | (245,386) |
Exercise of stock options |  | 430 |  | — |  |  |  | 684 |  |  | — |  |  | — |  |  | — |  |  | 684 |
Net loss attributable to noncontrolling interests |  | — |  | — |  |  |  | — |  |  | — |  |  | — |  |  | (671,029) |  |  | (671,029) |
Dividends paid to noncontrolling interest |  | — |  | — |  |  |  | — |  |  | — |  |  | — |  |  | (250,000) |  |  | (250,000) |
Foreign currency translation |  | — |  | — |  |  |  | — |  |  | — |  |  | 33,973 |  |  | — |  |  | 33,973 |
Net income attributable to stockholders of DocGo Inc. and Subsidiaries |  | — |  | — |  |  |  | — |  |  | 6,529,603 |  |  | — |  |  | — |  |  | 6,529,603 |
Balance - June 30, 2024 |  | 101,682,770 |  | $ | 10,168 |  |  |  | $ | 317,403,960 |  |  | $ | (3,637,258) |  |  | $ | 1,378,744 |  |  | $ | 2,830,990 |  |  | $ | 317,986,604 |
Common stock repurchased |  | (356,113) |  | (35) |  |  |  | (1,296,152) |  |  | — |  |  | — |  |  | — |  |  | (1,296,187) |
Stock-based compensation |  | 112,100 |  | 11 |  |  |  | 2,874,416 |  |  | — |  |  | — |  |  | — |  |  | 2,874,427 |
Shares withheld for taxes |  | (36,112) |  | (4) |  |  |  | (107,975) |  |  | — |  |  | — |  |  | — |  |  | (107,979) |
CRMS True-up Payment |  | 578,350 |  | 58 |  |  |  | 1,814,287 |  |  | — |  |  | — |  |  | — |  |  | 1,814,345 |
Acquisition of Ambulnz CO |  | — |  | — |  |  |  | 340,450 |  |  | — |  |  | — |  |  | (2,188,450) |  |  | (1,848,000) |
Net loss attributable to noncontrolling interests |  | — |  | — |  |  |  | — |  |  | — |  |  | — |  |  | (952,348) |  |  | (952,348) |
Foreign currency translation |  | — |  | — |  |  |  | — |  |  | — |  |  | 934,774 |  |  | — |  |  | 934,774 |
Net income attributable to stockholders of DocGo Inc. and Subsidiaries |  | — |  | — |  |  |  | — |  |  | 5,497,901 |  |  | — |  |  | — |  |  | 5,497,901 |
Balance - September 30, 2024 |  | 101,980,995 |  | $ | 10,198 |  |  |  | $ | 321,028,986 |  |  | $ | 1,860,643 |  |  | $ | 2,313,518 |  |  | $ | (309,808) |  |  | $ | 324,903,537 |

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.
5

Table of Contents
DocGo Inc. and Subsidiaries
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

| Nine Months Ended September 30,
| 2024 |  | 2023
CASH FLOWS FROM OPERATING ACTIVITIES: |  |  |
Net income | $ | 21,007,506 |  |  | $ | 2,055,068 |
Adjustments to reconcile net income to net cash provided by (used in) operating activities: |  |  |
Depreciation of property and equipment | 4,282,940 |  |  | 4,697,717 |
Amortization of intangible assets | 4,884,337 |  |  | 4,295,958 |
Amortization of finance lease right-of-use assets | 3,394,696 |  |  | 2,822,982 |
(Gain) loss on disposal of fixed assets | (36,717) |  |  | 163,452 |
Deferred income tax | (5,242,787) |  |  | 1,049,236 |
Loss on equity method investments | 229,923 |  |  | 301,362 |
Bad debt expense | 3,857,474 |  |  | (311,441) |
Stock-based compensation | 9,755,455 |  |  | 15,161,847 |
Loss (gain) on remeasurement of operating and finance leases | 32,052 |  |  | (4,834) |
Loss on liquidation of business | — |  |  | 70,284 |
Change in fair value of contingent consideration | 370,712 |  |  | (159,974) |
Changes in operating assets and liabilities: |  |  |
Accounts receivable | 19,837,507 |  |  | (103,483,997) |
Prepaid expenses and other current assets | 12,333,127 |  |  | (336,093) |
Other assets | (1,086,913) |  |  | 696,984 |
Accounts payable | 15,326,159 |  |  | (12,640,920) |
Accrued liabilities | (31,495,516) |  |  | 27,319,258 |
Net cash provided by (used in) operating activities | 57,449,955 |  |  | (58,303,111) |
CASH FLOWS FROM INVESTING ACTIVITIES: |  |  |
Acquisition of property and equipment | (2,940,843) |  |  | (4,360,807) |
Acquisition of intangibles | (2,228,233) |  |  | (2,478,808) |
Acquisition of businesses | — |  |  | (20,203,464) |
Equity method investments | (310,450) |  |  | (150,510) |
Proceeds from disposal of property and equipment | 178,535 |  |  | 274,210 |
Net cash used in investing activities | (5,300,991) |  |  | (26,919,379) |
CASH FLOWS FROM FINANCING ACTIVITIES: |  |  |
Proceeds from revolving credit line | 45,000,000 |  |  | — |
Repayments of revolving credit line | (40,000,000) |  |  | — |
Repayments of notes payable | (22,007) |  |  | (529,583) |
Due to seller | (3,008,976) |  |  | (8,417,936) |
Acquisition of noncontrolling interest | (1,848,000) |  |  | — |
Earnout payments on contingent liabilities | (1,600,029) |  |  | — |
Dividends paid to noncontrolling interest | (250,000) |  |  | — |
Proceeds from exercise of stock options | 684 |  |  | 1,549,298 |
Payments for taxes related to shares withheld for employee taxes | (374,311) |  |  | (2,166,982) |
Common stock repurchased | (11,078,198) |  |  | — |
Payments on obligations under finance lease | (3,118,054) |  |  | (2,293,330) |
Net cash used in financing activities | (16,298,891) |  |  | (11,858,533) |
Effect of exchange rate changes on cash and cash equivalents | 510,439 |  |  | 227,887 |
Net increase (decrease) in cash and restricted cash | 36,360,512 |  |  | (96,853,136) |
Cash and restricted cash at beginning of period | 72,217,986 |  |  | 164,109,074 |
Cash and restricted cash at end of period | $ | 108,578,498 |  |  | $ | 67,255,938 |

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.
6

Table of Contents
DocGo Inc. and Subsidiaries
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(CONTINUED)

| Nine Months Ended September 30,
| 2024 |  | 2023
Supplemental disclosure of cash and non-cash transactions: |  |  |
Cash paid for interest | $ | 1,507,026 |  |  | $ | 179,430 |
Cash paid for interest on finance lease liabilities | $ | 560,926 |  |  | $ | 394,443 |
Cash paid for income taxes | $ | 6,542,733 |  |  | $ | 4,223,810 |
Right-of-use assets obtained in exchange for lease liabilities | $ | 10,980,341 |  |  | $ | 2,407,938 |
Remeasurement of finance lease right-of-use asset due to lease modification | $ | 300,000 |  |  | $ | — |
Fixed assets acquired in exchange for notes payable | $ | — |  |  | $ | 1,369,060 |
Supplemental non-cash investing and financing activities: |  |  |
Acquisition of remaining FMC NA through due to seller and issuance of stock | $ | — |  |  | $ | 7,000,000 |
Acquisition of CRMS through issuance of stock | $ | — |  |  | $ | 1,000,000 |
CRMS True-up Payment through issuance of stock | $ | 1,814,345 |  |  | $ | — |
Receivable exchanged for trade credits | $ | — |  |  | $ | 1,500,000 |
Pre-acquisition receivables written off through due to seller | $ | 4,675,758 |  |  | $ | — |
Reconciliation of cash and restricted cash |  |  |
Cash | $ | 89,458,388 |  |  | $ | 52,922,517 |
Restricted cash | 19,120,110 |  |  | 14,333,421 |
Total cash and restricted cash shown in statement of cash flows | $ | 108,578,498 |  |  | $ | 67,255,938 |

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.
7

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1. Description of Organization and Business Operations
Background
On November 5, 2021, DocGo Inc., a Delaware corporation, then known as Motion Acquisition Corp. (collectively with its subsidiaries, the “Company”), consummated a business combination pursuant to that certain Agreement and Plan of Merger, dated March 8, 2021 (the “Merger Agreement”), by and among the Company, Motion Merger Sub Corp., a Delaware corporation and a direct wholly owned subsidiary of the Company (“Merger Sub”), and Ambulnz, Inc., a Delaware corporation (“Ambulnz”). The transactions contemplated by the Merger Agreement are referred to herein as the “Business Combination.” In connection with the closing of the Business Combination, the Company changed its name from Motion Acquisition Corp. to DocGo Inc.
As contemplated by the Merger Agreement and as described in the Company’s definitive proxy statement/consent solicitation/prospectus filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 14, 2021, Merger Sub merged with and into Ambulnz, with Ambulnz continuing as the surviving corporation. As a result of the Business Combination, Ambulnz became a wholly owned subsidiary of the Company and each share of Series A preferred stock of Ambulnz, no par value, Class A common stock of Ambulnz, no par value, and Class B common stock of Ambulnz, no par value, was cancelled and converted into the right to receive a portion of the merger consideration issuable as common stock of the Company, par value $0.0001 (“Common Stock”), pursuant to the terms and conditions set forth in the Merger Agreement.
In connection with the Business Combination, the Company raised $158,000,000 of net proceeds. This amount consisted of (i) $43,400,000 of cash held in the Company’s trust account established in connection with its initial public offering, net of the Company’s transaction costs and underwriters’ fees of $9,600,000, and (ii) $114,600,000 of cash from the sale of shares of Common Stock to certain investors at a price of $10.00 per share in a private placement that closed concurrently with the Business Combination (the “PIPE Financing”), net of $10,400,000 in transaction costs in connection with the PIPE Financing. These transaction costs consisted of banking, legal and other professional fees, which were recorded as a reduction to additional paid-in capital.
Ambulnz was originally formed in Delaware on June 17, 2015 as Ambulnz, LLC, a limited liability company. On November 1, 2017, with an effective date of January 1, 2017, Ambulnz converted its legal structure from a limited liability company to a C-corporation and changed its name to Ambulnz, Inc. Ambulnz is the sole owner of Ambulnz Holdings, LLC (“Holdings”), which was formed in the state of Delaware on August 5, 2015 as a limited liability company. Holdings is the owner of multiple operating entities incorporated in various states in the United States (“U.S.”) as well as within England and Wales, United Kingdom (“U.K.”).
The Business
The Company is a mobile healthcare services company that uses proprietary dispatch and communication technology to help provide (i) quality mobile, in-person medical treatment directly to patients in the comfort of their homes, workplaces and other non-traditional locations and (ii) healthcare transportation in major metropolitan cities in the U.S. and the U.K.
The Company conducts business in three operating segments: Mobile Health Services, Transportation Services and Corporate. Mobile Health Services include a wide variety of healthcare services performed at homes, offices and other locations and event services such as on-site healthcare support at sporting events and concerts. This segment also provides total care management solutions to large, typically underserved, population groups primarily through arrangements with municipalities, which include healthcare services as well as ancillary services, such as shelter. Transportation Services encompass both emergency response and non-emergency transport services. Non-emergency transport services include ambulance transports and wheelchair transports. Net revenue from Transportation Services is derived from the transportation of patients based on billings to third party payors and healthcare facilities. The Company’s Corporate segment primarily represents shared services and personnel that support both the Mobile Health Services and Transportation Services segments. It contains operating expenses such as information technology costs, certain insurance costs and the compensation costs of senior and executive leadership. None of the Company’s revenues or cost of revenues are reported within the Corporate segment.
8

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and applicable rules and regulations of the SEC regarding interim financial reporting. Certain information and disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Consolidated Financial Statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.
The Consolidated Balance Sheet as of December 31, 2023 included herein was derived from the audited financial statements as of that date but does not include all disclosures including notes required by U.S. GAAP.
Principles of Consolidation
The unaudited Condensed Consolidated Financial Statements include the accounts and operations of DocGo Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated upon consolidation. Noncontrolling interests (“NCI”) on the unaudited Condensed Consolidated Financial Statements represent a portion of consolidated joint ventures and variable interest entities (“VIEs”) in which the Company does not have direct equity ownership. Certain amounts in the prior periods’ unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity and Condensed Consolidated Statements of Cash Flows have been reclassified to conform to the current period presentation.
The Business Combination was accounted for as a reverse recapitalization in accordance with U.S. GAAP (the “Reverse Recapitalization”). Under this method of accounting, the Company was treated as the “acquired” company for financial reporting purposes. Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of Ambulnz stock for the net assets of the Company, accompanied by a recapitalization. The net assets of the Company are stated at historical cost, with no goodwill or other intangible assets recorded. The consolidated assets, liabilities and results of operations prior to the Reverse Recapitalization are those of Ambulnz. The shares and corresponding capital amounts and earnings per share available for common stockholders prior to the Business Combination have been retroactively restated as shares reflecting the exchange ratio (645.1452 to 1) established in the Business Combination. Further, Ambulnz was determined to be the accounting acquirer in the transaction, and as such, the acquisition is considered a business combination under Accounting Standards Codification (“ASC”) Topic 805, Business Combinations (“ASC 805”) and was accounted for using the acquisition method of accounting.
In accordance with ASC 810, Consolidation (“ASC 810”), the Company assesses whether it has a variable interest in legal entities in which it has a financial interest and, if so, whether or not those entities are VIEs. For those entities that qualify as VIEs, ASC 810 requires the Company to determine if the Company is the primary beneficiary of the VIE, and if so, to consolidate the VIE.
The Company holds variable interests in legal entities that contract with physicians and other health professionals that provide services on behalf of the Company. These entities are considered VIEs since they do not have sufficient equity to finance their activities without additional subordinated financial support. An enterprise having a controlling financial interest in a VIE must consolidate the VIE if it is the primary beneficiary, meaning it has (1) the power to direct the activities of the VIE that most significantly impacts the VIE’s economic performance (power) and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE (benefits). The Company has the power and rights to control all activities of its VIEs and funds and absorbs all losses of its VIEs. The Company has determined that it is the primary beneficiary of its VIEs and therefore appropriately consolidates its VIEs.
Net income (loss) for the Company’s VIEs was $(67,785) and $(103,378) for the three months ended September 30, 2024 and 2023, respectively, and $(425,668) and $16,839 for the nine months ended September 30, 2024 and 2023, respectively. Total assets amounted to $11,844,062 and $4,364,274 as of September 30, 2024 and December 31, 2023, respectively. Total liabilities were $12,717,312 and $4,811,857 as of September 30, 2024 and December 31, 2023, respectively. The Company’s VIEs’ total stockholders’ deficit was $873,250 and $447,583 as of September 30, 2024 and December 31, 2023, respectively.
9

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
Foreign Currency
The Company’s functional currency is the U.S. dollar. The functional currency of the Company’s foreign operation is the British pound. Assets and liabilities of the Company’s foreign operation denominated in the British pound are translated at the spot rate in effect at the applicable reporting date, except for equity accounts, which are translated at historical rates. The unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) are translated at the weighted average rate of exchange during the applicable period. The resulting unrealized cumulative translation adjustment for the three months ended September 30, 2024 and 2023 were $934,774 and $(582,471), respectively, and $828,613 and $66,965 for the nine months ended September 30, 2024 and 2023, respectively.
Use of Estimates
The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses; the disclosure of contingent assets and liabilities in its financial statements; and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to revenue recognition related to the allowance for credit loss, stock-based compensation, calculations related to the incremental borrowing rate for the Company’s lease agreements, estimates related to ongoing lease terms, software development costs, impairment of long-lived assets, goodwill and indefinite-lived intangible assets, business combinations, reserve for losses within the Company’s insurance deductibles, income taxes and deferred income tax. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources.
Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations could be adversely affected.
Self-Insurance Reserves
The Company self-insures a number of risks, including, but not limited to, workers’ compensation, general liability, auto liability and certain employee-related healthcare benefits. Standard actuarial procedures and data analysis are used to estimate the liabilities associated with these risks on an undiscounted basis. The recorded liabilities reflect the ultimate cost for claims incurred but not paid and any estimable administrative run-out expenses related to the processing of these outstanding claim payments. On a regular basis, the liabilities are evaluated for appropriateness with claims reserve valuations. To limit exposure to some risks, the Company maintains insurance coverage with varying limits and retentions, including stop-loss insurance coverage for workers’ compensation, general liability and auto liability.
Concentration of Credit Risk and Off-Balance Sheet Risk
The Company is potentially subject to concentration of credit risk with respect to its cash, cash equivalents and restricted cash, which the Company attempts to minimize by maintaining cash, cash equivalents and restricted cash with institutions of sound financial quality. At times, cash balances may exceed limits federally insured by the Federal Deposit Insurance Corporation (“FDIC”). The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the funds are held. The Company has no financial instruments with off-balance sheet risk of loss.
Major Customers
The Company had one customer that accounted for approximately 41% of revenues and 34% of net accounts receivable and another customer that accounted for 21% of revenues and 44% of net accounts receivable for the three months ended September 30, 2024. The Company had one customer that accounted for approximately 36% of revenues and 34% of net accounts receivable and another customer that accounted for 31% of revenues and 44% of net accounts receivable for the nine months ended September 30, 2024.
The Company had one customer that accounted for approximately 33% of revenues and 36% of net accounts receivable and another customer that accounted for approximately 32% of revenues and 28% of accounts receivable for the three months ended September 30, 2023. The Company had one customer that accounted for approximately 37% of revenues and
10

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
28% of net accounts receivable and another customer that accounted for approximately 17% of revenues and 36% of accounts receivables for the nine months ended September 30, 2023.
Major Vendor
The Company had one vendor that accounted for approximatel y 19% and 20% of total cost for the three months ended September 30, 2024 and 2023, respectively. The Company expects to maintain this relationship with the vendor and believes the services provided by this vendor are available from alternative sources.
The Company had one vendor that accounted for approximately 18% and 13% of total cost for the nine months ended September 30, 2024 and 2023, respectively. The Company expects to maintain this relationship with the vendor and believes the services provided from this vendor are available from alternative sources.
Reclassifications
Certain reclassifications of amounts previously reported have been made to the accompanying unaudited Condensed Consolidated Financial Statements to maintain consistency between periods presented. The reclassifications had no impact on previously reported net income or retained earnings.
Cash and Cash Equivalents
Cash and cash equivalents include all highly liquid investments with an original maturity of three months or less. The Company maintains most of its cash and cash equivalents with financial institutions in the U.S. The Company’s accounts at financial institutions in the U.S. are insured by the FDIC and are in excess of FDIC insured limits. The Company had cash balances of approximate ly $5,064,084 and $3,699,793 with foreign financial institutions on September 30, 2024 and December 31, 2023, respectively.
Restricted Cash
Cash and cash equivalents subject to contractual restrictions and not readily available are classified as restricted cash in the unaudited Condensed Consolidated Balance Sheets. Restricted cash is classified as either a current or non-current asset depending on the restriction period. The Company is required to pledge or otherwise restrict a portion of cash and cash equivalents as collateral for self-insurance exposures and a standby letter of credit as required by its insurance carrier (see Note 9).
The Company utilizes a combination of insurance and self-insurance programs, including a wholly owned captive insurance entity, to provide for the potential liabilities for certain risks, including workers’ compensation, automobile liability, general liability and professional liability. Liabilities associated with the risks that are retained by the Company within its high deductible limits are not discounted and are estimated, in part, by considering claims experience, exposure and severity factors and other actuarial assumptions. The Company has commercial insurance in place for catastrophic claims above its deductible limits.
ARM Insurance, Inc., a Vermont-based wholly owned captive insurance subsidiary of the Company, charges the operating subsidiaries premiums to insure the retained workers’ compensation, automobile liability, general liability and professional liability exposures. Pursuant to Vermont insurance regulations, ARM Insurance, Inc. maintains certain levels of cash and cash equivalents related to its self-insurance exposures.
The Company also maintains certain cash balances related to its insurance programs, which are held in a self-depleting trust and restricted as to withdrawal or use by the Company other than to pay or settle self-insured claims and costs. These amounts are reflected in “Restricted cash” in the accompanying unaudited Condensed Consolidated Balance Sheets.
Fair Value of Financial Instruments
ASC 820, Fair Value Measurements, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.
11

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:
Level 1: Quoted prices in active markets for identical assets or liabilities.
Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.
Level 3: Unobservable inputs that are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.
Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2024 and December 31, 2023. For certain financial instruments, including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, restricted cash, accounts payable, accrued expenses, and due to seller, the carrying amounts approximate their fair values as they are short term in nature. The notes payable are presented at their carrying value, which, based on borrowing rates currently available to the Company for loans with similar terms, approximates their fair values.
Level 3 instruments are valued based on unobservable inputs that are supported by little or no market activity and reflect the Company’s own assumptions in measuring fair value. Future changes in fair value of the contingent consideration, as a result of changes in significant inputs such as the discount rate and estimated probabilities of financial milestone achievements, could have a material effect on the unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) and Condensed Consolidated Balance Sheets in the period of the change.
In connection with the acquisition of Ryan Bros. Fort Atkinson, LLC (“Ryan Brothers”), the Company recorded $4,000,000 in contingent consideration to be paid based on the completion of certain performance obligations over a 24-month period. The Company recorded a change in fair value of contingent consideration in the amount of $33,453 and $(159,974) for the three months ended September 30, 2024 and 2023, respectively, and $86,056 and $(159,974) for the nine months ended September 30, 2024 and 2023, respectively. During the year ended December 31, 2023, the Company made a payment for the first installment due on the contingent liability in the amount of $1,840,026. The estimated contingent consideration amount payable for Ryan Brothers was $1,907,074 and $1,821,018 as of September 30, 2024 and December 31, 2023, respectively (see Note 4).
In connection with the acquisition of Exceptional Medical Transportation, LLC (“Exceptional”), the Company also agreed to pay up to $2,000,000 in contingent consideration upon meeting certain performance conditions within two years of the closing date of such acquisition. The Company recorded a change in fair value of contingent consideration in the amount of $11,067 and $(13,763) for the three and nine months ended September 30, 2024, respectively. The Company did not record a change in fair value of contingent consideration for the three and nine months ended September 30, 2023. During the year ended December 31, 2023, the Company made a payment for the first installment due on the contingent liability in the amount of $426,655. The estimated contingent consideration amount payable for Exceptional was $265,538 and $279,301 as of September 30, 2024 and December 31, 2023, respectively (see Note 4).
In connection with the acquisition of Location Medical Services, LLC (“LMS”), the Company recorded $2,475,540 in contingent consideration to be paid upon LMS meeting certain performance conditions in 2023. The Company did not record a change in fair value of contingent consideration for the three and nine months ended September 30, 2024 and 2023. The Company made a payment of $600,029 during the nine months ended September 30, 2024. The Company did not record any foreign exchange movem ent for the three months ended September 30, 2024, but recorded a foreign exchange movement of $(90,834) for the three months ended September 30, 2023. The Company recorded foreign exchange movements of $(4,798) and $20,730 for the nine months ended September 30, 2024 and 2023, respectively. There was no remaining contingent liability bal ance as of September 30, 2024 and a contingent liability balance of $604,827 as of December 31, 2023 (see Note 4).
In connection with the acquisition of Cardiac RMS, LLC (“CRMS”), the Company recorded $15,822,190 in contingent consideration, consisting of an estimated true-up payment of $2,088,243 to be paid in 2024 based on the attainment of full-year 2023 EBIDTA targets (the “True-Up Payment”) and estimated earn out payments amounting to $13,733,947. The earn out payments are to be paid out over 36 months, beginning in 2025, for the remaining 49% equity of CRMS, based on
12

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
CRMS’ attainment of full-year EBITDA targets. The Company did not record a change in fair value of contingent consideration for the three months ended September 30, 2024, but recorded a change in fair value of contingent consideration in the amount of $298,419 for the nine months ended September 30, 2024. The Company did not record a change in fair value of contingent consideration for the three and nine months ended September 30, 2023. On May 29, 2024, the Company made a portion of the True-up Payment in the amount of $1,000,000. During the three and nine months ended September 30, 2024, the Company issued $1,814,345 in Common Stock, or 578,350 shares, constituting the remainder of the True-up Payment. The estimated contingent consideration amount payable for CRMS was $14,571,909 and $17,087,835 as of September 30, 2024 and December 31, 2023, respectively (see Note 4).
Accounts Receivable
The Company contracts with hospitals, healthcare facilities, businesses, state and local government entities, and insurance providers to provide Mobile Health Services and Transportation Services at specified rates. These rates are either on a per procedure or per transport basis, or on an hourly or daily basis. Accounts receivable consist of billings for healthcare and transportation services provided to patients. Billings typically are either paid or settled on the patient’s behalf by health insurance providers, managed care organizations, treatment facilities, government sponsored programs or businesses or patients directly. The Company generally does not require collateral for accounts receivable.
Accounts receivable are net of insurance provider contractual allowances, which are estimated at the time of billing based on contractual terms or other arrangements. The Company maintains an allowance for credit losses for accounts receivable, net which is recorded as an offset to accounts receivable, net and changes in this allowance are recorded within general and administrative expenses in the unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). The carrying amount of accounts receivable represents the maximum credit risk exposure of these assets. On a quarterly basis, in accordance with Federal Accounting Standards Board (“FASB”) ASC 326, Measurement of Credit Losses on Financial Instruments (“ASC 326”), the Company evaluates the collectability of outstanding accounts receivable balances to determine an allowance for credit loss that reflects its best estimate of the lifetime expected credit losses. Individual uncollectible accounts are written off against the allowance when collection of the individual account does not appear probable.
Under the current expected credit loss impairment model, the Company develops and documents its allowance for credit losses on its trade receivables based on a single portfolio segment. The Company assesses collectability by aggregating and reviewing accounts receivable on a collective basis for customers that share similar risk characteristics. Additionally, when accounts receivable do not share risk characteristics with other accounts receivables, management will evaluate such accounts receivable for expected credit loss on an individual specific identification basis when the Company identifies specific customers with known disputes or collectability issues. Due to the short-term nature of the Company’s accounts receivables, the estimate of expected credit loss is based on the aging of accounts using an aging schedule as of period ends. In determining the amount of the allowance for credit losses, the Company considers historical collection history based on past due status, the current aging of receivables, customer-specific credit risk factors including their current financial condition, current market conditions, and probable future economic conditions which inform adjustments to historical loss patterns.
As of January 1, 2024, the Company held a beginning balance in its allowance for credit losses on accounts receivable of $6,276,454. The Company recognized an additional provision for credit losses of $3,270,217 and write offs of $(3,090,797) during the year. The Company’s balance in its allowance for credit losses amounted to $6,455,874 as of September 30, 2024.
Property and Equipment
Property and equipment are stated at cost, net of accumulated depreciation and amortization. When an item is sold or retired, the costs and related accumulated depreciation or amortization are eliminated, and the resulting gain or loss, if any, is recorded in operating expenses in the unaudited Condensed Consolidated Statement of Operations and Comprehensive
13

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
Income. The Company provides for depreciation and amortization using the straight-line method over the estimated useful lives of the respective assets. A summary of estimated useful lives is as follows:

|  | Estimated Useful Life
Buildings |  | 39 years
Office equipment and furniture |  | 3-7 years
Vehicles |  | 5-8 years
Medical equipment |  | 5 years
Leasehold improvements |  | Shorter of useful life of asset or lease term

Expenditures for repairs and maintenance are expensed as incurred. Expenditures that improve an asset or extend its estimated useful life are capitalized.
Software Development Costs
Costs incurred during the preliminary project stage, maintenance costs and routine updates and enhancements of products are expensed as incurred. The Company capitalizes software development costs intended for internal use in accordance with ASC 350-40, Internal-Use Software. Costs incurred in developing the application of its software and costs incurred to upgrade or enhance product functionalities are capitalized when it is probable that the expenses would result in future economic benefits to the Company and the functionalities and enhancements are used for their intended purpose. Capitalized software costs are amortized over its useful life.
Estimated useful life of software development activities are reviewed annually or whenever events or changes in circumstances indicate that intangible assets may be impaired and adjusted as appropriate to reflect upcoming development activities that may include significant upgrades or enhancements to the existing functionality.
Business Combinations
The Company accounts for its business combinations under the provisions of ASC 805-10, Business Combinations (“ASC 805-10”), which requires that the acquisition method of accounting be used for all business combinations. Assets acquired and liabilities assumed, including noncontrolling interests, are recorded at the date of acquisition at their respective fair values. ASC 805-10 also specifies criteria that intangible assets acquired in a business combination must meet to be recognized and reported apart from goodwill.
Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. If the business combination provides for contingent consideration, the Company records the contingent consideration at fair value at the acquisition date and any changes in fair value after the acquisition date are accounted for as measurement-period adjustments. Changes in fair value of contingent consideration resulting from events after the acquisition date, such as earn-outs, are recognized as follows: (1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or (2) if the contingent consideration is classified as a liability, the changes in fair value are recognized in earnings. For transactions that are business combinations, the Company evaluates the existence of goodwill or a gain from a bargain purchase. The Company capitalizes acquisition-related costs and fees associated with asset acquisitions and immediately expenses acquisition-related costs and fees associated with business combinations.
The estimated fair value of net assets to be acquired, including the allocation of the fair value to identifiable assets and liabilities, is determined using established valuation techniques. Management uses assumptions based on historical knowledge of the business and projected financial information of the target. These assumptions may vary based on future events, perceptions of different market participants and other factors outside the control of management, and such variations may be significant to estimated values.
Impairment of Long-Lived Assets
The Company evaluates the recoverability of the recorded amount of long-lived assets, primarily property and equipment and finite-lived intangible assets, whenever events or changes in circumstance indicate that the recorded amount of an asset may not be fully recoverable. An impairment is assessed when the undiscounted expected future cash flows derived from
14

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
an asset are less than its carrying amount. If an asset is determined to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds its fair value. Assets targeted for disposal are reported at the lower of the carrying amount or fair value less cost to sell.
Goodwill and Indefinite-Lived Intangible Assets
Goodwill represents the excess of the total purchase consideration over the fair value of the identifiable assets acquired and liabilities assumed in a business combination. Goodwill and indefinite-lived intangible assets are not amortized but are tested for impairment at the reporting unit level annually on December 31 or more frequently if events or changes in circumstances indicate that it is more likely than not to be impaired. These events include: (i) severe adverse industry or economic trends; (ii) significant company-specific actions, including exiting an activity in conjunction with restructuring of operations; (iii) current, historical or projected deterioration of the Company’s financial performance; or (iv) a sustained decrease in the Company’s market capitalization, as indicated by its publicly quoted share price, below its net book value.
Line of Credit
The costs associated with the Company’s line of credit are deferred and recognized over the term of the line of credit as interest expense. Interest expense on outstanding balances is expensed as incurred.
Related Party Transactions
The Company defines related parties as affiliates of the Company, entities for which investments are accounted for by the equity method, trusts for the benefit of employees, principal owners (beneficial owners of more than 10% of the voting interest), management, members of immediate families of principal owners or management and other parties with which the Company may deal with if one party controls or can significantly influence management or the operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.
Related party transactions are recorded within operating expenses in the Company’s unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). For details regarding the related party transactions that occurred during the three and nine months ended September 30, 2024 and 2023, refer to Note 16.
Revenue Recognition
On January 1, 2019, the Company adopted ASC 606, Revenue from Contracts with Customers (“ASC 606”).
To determine revenue recognition for contractual arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (1) identify each contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when (or as) the relevant performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services the Company provides to the customer.
The Company generates revenues from the provision of (1) Mobile Health Services and (2) Transportation Services. Since the customer simultaneously receives and consumes the benefits provided by the Company as the performance obligations are fulfilled, the Company satisfies performance obligations immediately. The Company has utilized the “right to invoice” expedient, which allows an entity to recognize revenue in the amount of consideration to which the entity has the right to invoice when the amount that the Company has the right to invoice corresponds directly to the value transferred to the customer.
The transaction price associated with the Company’s contracts with customers is generally determined based on fixed and determinable amounts of consideration as specified in a contract, which includes a fixed base rate and/or fixed mileage rate. For Transportation Services arrangements with billings to third party payors and healthcare facilities, this may also include variable consideration in instances where it is considered probable that a significant reversal of cumulative revenue recognized will not occur. For these services, revenues are recorded net of estimated contractual allowances for claims subject to contracts with responsible paying entities. The Company estimates contractual allowance at the time of billing based on contractual terms, historical collections or other arrangements. The Company also estimates the amount unbilled at month end and recognizes such amounts as revenue, based on available data and customer history. The Company utilizes the expected value method when estimating its variable consideration. The assumptions utilized in estimating variable
15

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
consideration include the Company’s previous experience with similar contracts and history of collection rates on prior trips that have been performed. The Company reevaluates its variable consideration at each reporting period.
Nature of the Company’s Services
Revenue is primarily derived from:
i.Mobile Health Services: These services include a wide variety of healthcare services performed at homes, offices and other locations and event services such as on-site healthcare support at sporting events and concerts. This segment also provides total care management solutions to large, typically underserved population groups, primarily through arrangements with municipalities, which include healthcare services as well as ancillary services, such as shelter.
ii.Transportation Services: These services encompass both emergency response and non-emergency transport services. Non-emergency transport services include ambulance transports and wheelchair transports. Net revenue from Transportation Services is derived from the transportation of patients based on billings to third party payors and healthcare facilities.
For Mobile Health Services, the performance of the services and any related support activities in the majority of the Company’s contracts are a single performance obligation under ASC 606. Mobile Health Services are typically billed based on a fixed rate (i.e., time and materials separately or combined) fee structure taking into consideration staff and materials utilized. The Company also concluded that Transportation Services and any related support activities are a single performance obligation under ASC 606.
As the performance associated with such services is known and quantifiable at the end of a period in which the services occurred (i.e., monthly or quarterly), revenues are typically recognized in the respective period performed. The typical billing cycle for Mobile Health Services and Transportation Services is same day to five days with payments generally due within 30 days. For large municipal customers in the Mobile Health Services segment, invoices are generally produced on a monthly basis, in arrears, and are generally due within 30-60 days of when they are submitted to the customer. The majority of the Company’s Mobile Health Services and Transportation Services each represent a single performance obligation. Therefore, allocation is not necessary as the transaction price (fees) for the services provided is standard and explicitly stated in the contractual fee schedule and/or invoice. For contracts with multiple distinct performance obligations, the Company allocates the transaction price based on their agreed-upon price to the individually identified performance obligations in the contract. The Company monitors and evaluates all contracts on a case-by-case basis to determine if multiple performance obligations are present in a contractual arrangement.
For Mobile Health Services, the customer also generally simultaneously receives and consumes the benefits provided by the Company as the performance obligations are fulfilled. Therefore, the Company satisfies performance obligations at the same time. For certain Mobile Health Services that have a fixed fee arrangement and are provided over time, revenue is recognized over time as the services are provided to the customer. For Transportation Services, since the customer simultaneousl y receives and consumes the benefits provided by the Company as the performance obligations are fulfilled, the Company satisfies performance obligations at the same time. For Transportation Services, where the customer pays fixed rate usage-based fees, the actual usage in the period represents the best measure of progress.
16

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
In the following table, revenues are disaggregated as follows:

Revenue Breakdown |  | Three Months Ended September 30, |  | Nine Months Ended September 30,
|  | 2024 |  | 2023 |  | 2024 |  | 2023
Primary Geographical Markets |  |  |  |  |  |  |  |
United States |  | $ | 123,429,213 |  |  | $ | 174,076,595 |  |  | $ | 453,328,633 |  |  | $ | 385,589,261 |
United Kingdom |  | 15,255,601 |  |  | 12,476,315 |  |  | 42,393,426 |  |  | 39,453,112 |
Total revenues |  | $ | 138,684,814 |  |  | $ | 186,552,910 |  |  | $ | 495,722,059 |  |  | $ | 425,042,373 |
Major Segments/Service Lines |  |  |  |  |  |  |  |
Mobile Health Services |  | $ | 90,663,433 |  |  | $ | 139,340,467 |  |  | $ | 351,346,919 |  |  | $ | 292,351,835 |
Transportation Services |  | 48,021,381 |  |  | 47,212,443 |  |  | 144,375,140 |  |  | 132,690,538 |
Total revenues |  | $ | 138,684,814 |  |  | $ | 186,552,910 |  |  | $ | 495,722,059 |  |  | $ | 425,042,373 |

Stock-Based Compensation
The Company maintains a stock incentive plan under which the Company may issue incentive and non-qualified stock options, restricted stock units and performance-based stock units. The Company accounts for stock-based compensation using the provisions of ASC 718, Stock-Based Compensation, which requires the recognition of the fair value of stock-based compensation. The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company accounts for forfeitures as they occur. For performance-based awards, expense is recognized over the period from the grant date to the estimated attainment date, which is the derived service period of the award, if management determines that it is probable that the performance-based vesting conditions will be achieved. All stock-based compensation costs are recorded in operating expenses in the unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss).
Earnings per Share
Earnings per share represents the net income attributable to stockholders divided by the weighted-average number of shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised or converted into Common Stock during the reporting periods. Potential dilutive Common Stock equivalents consist of the incremental shares of Common Stock issuable upon conversion of stock options, unvested RSUs and PSUs. In reporting periods in which the Company has a net loss, the effect is considered anti-dilutive and excluded from the diluted earnings per share calculation.
17

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
The following table presents the calculation of basic and diluted net income per share to stockholders of DocGo Inc. and Subsidiaries:

| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
Net income (loss) attributable to stockholders of DocGo Inc. and Subsidiaries | 5,497,901 |  |  | 4,764,921 |  |  | 23,254,953 |  |  | (712,016) |
Weighted-average shares outstanding - Basic | 102,067,579 |  |  | 103,874,845 |  |  | 102,573,664 |  |  | 103,351,345 |
Effect of dilutive options | 4,223,350 |  |  | 1,118,884 |  |  | 4,223,350 |  |  | 1,118,884 |
Weighted-average shares outstanding - Diluted | 106,290,929 |  |  | 104,993,729 |  |  | 106,797,014 |  |  | 103,351,345 |
Net income (loss) per share attributable to DocGo Inc. and Subsidiaries - Basic | 0.05 |  |  | 0.05 |  |  | 0.23 |  |  | (0.01) |
Net income (loss) per share attributable to DocGo Inc. and Subsidiaries - Diluted | 0.05 |  |  | 0.05 |  |  | 0.22 |  |  | (0.01) |
Anti-dilutive employee share-based awards excluded | 7,267,649 |  |  | 10,191,301 |  |  | 7,267,649 |  |  | 10,191,301 |

Equity Method Investment
The Company uses the equity method to account for investments in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee but does not exercise control. The Company’s judgment regarding its level of influence over an equity method investee includes considering key factors, such as ownership interest, representation on the board of directors and participation in policy-making decisions.
Under the equity method, the Company’s investment is initially measured at cost and subsequently increased or decreased to recognize the Company’s share of income and losses of the investee, capital contributions and distributions and impairment losses. The Company periodically reviews the investments for other than temporary declines in fair value below cost or more frequently when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.
On October 26, 2021, the Company acquired a 50% interest in RND Health Services Inc. (“RND”) for $655,876. During the nine months ended September 30, 2024 and the year ended December 31, 2023, the Company made additional investments amounting to $310,450 and $298,932, respectively. The Company’s carrying value in RND, an equity method investee, is reflected in the caption “Equity method investments” in the unaudited Condensed Consolidated Balance Sheets. Changes in value of RND are recorded in “Loss on equity method investments” in the unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss).
On November 1, 2021, the Company acquired a 20% interest in National Providers Association, LLC (“NPA”) for $30,000. Effective December 21, 2021, three members withdrew from NPA, resulting in the remaining two members obtaining the remaining ownership percentage. As of September 30, 2024 and December 31, 2023, the Company owned 50% of NPA. The Company’s carrying value in NPA, an equity method investee, is reflected in the caption “Equity method investments” in the unaudited Condensed Consolidated Balance Sheets. Changes in value of NPA are recorded in “Loss on equity method investments” in the unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss).
Leases
The Company categorizes leases at its inception as either operating or finance leases based on the criteria in ASC 842, Leases (“ASC 842”). The Company adopted ASC 842 on January 1, 2019, using the modified retrospective approach, and has established a right-of-use asset and a current and non-current lease liability for each lease arrangement identified. The lease liability is recorded at the present value of future lease payments discounted using the discount rate that approximates the Company’s incremental borrowing rate for the lease established at the commencement date, and the right-of-use asset is measured as the lease liability plus any initial direct costs, less any lease incentives received before commencement. The Company recognizes a single lease cost, so that the remaining cost of the lease is allocated over the remaining lease term on a straight-line basis.
18

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
The Company has lease arrangements for vehicles, equipment and facilities. These leases typically have original terms not exceeding 10 years and in some cases contain multi-year renewal options, none of which are reasonably certain of exercise. The Company’s lease arrangements may contain both lease and non-lease components. The Company has elected to combine and account for lease and non-lease components as a single lease component. The Company has incorporated residual value obligations in leases for which there are such occurrences. Regarding short-term leases, ASC 842-10-25-2 permits an entity to make a policy election not to apply the recognition requirements of ASC 842 to short-term leases. The Company has elected not to apply the ASC 842 recognition criteria to any leases that qualify as short-term leases.
Income Taxes
Income taxes are recorded in accordance with ASC 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or its tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.
Recently Issued Accounting Standards Not Yet Adopted
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure (“ASU 2023-07”). ASU 2023-07 updates reportable segment disclosure requirements, primarily through requiring enhanced disclosures about significant segment expenses and information used to assess segment performance. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07 on its disclosures.
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 includes amendments requiring enhanced income tax disclosures, primarily related to standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The guidance is effective for fiscal years beginning after December 15, 2024, with early adoption permitted, and should be applied either prospectively or retrospectively. The Company is currently evaluating the impact of adopting ASU 2023-09 on its disclosures.
3. Property and Equipment, Net
Property and equipment, net as of September 30, 2024 and December 31, 2023 are as follows:

| September 30, 2024 |  | December 31, 2023
Transportation equipment | $ | 17,532,777 |  |  | $ | 17,438,072 |
Medical equipment | 8,775,453 |  |  | 7,104,161 |
Office equipment and furniture | 4,238,478 |  |  | 3,701,657 |
Leasehold improvements | 862,525 |  |  | 709,619 |
Buildings | 527,283 |  |  | 527,283 |
Land | 37,800 |  |  | 37,800 |
| 31,974,316 |  |  | 29,518,592 |
Less: Accumulated depreciation | (16,689,563) |  |  | (12,683,108) |
Property and equipment, net | $ | 15,284,753 |  |  | $ | 16,835,484 |

19

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
During the nine months ended September 30, 2024, the Company disposed of assets with a cost of $608,983 and accumulated depreciation of $400,349 for proceeds of $246,615. The Company recorded a gain on disposal of assets of $37,981 for the nine months ended September 30, 2024.
The Company recorded depreciation expense of $1,374,975 and $1,625,070 for the three months ended September 30, 2024 and 2023, respectively.
The Company recorded depreciation expense of $4,282,940 and $4,697,717 for the nine months ended September 30, 2024 and 2023, respectively.
4. Acquisition of Businesses
Exceptional Medical Transportation, LLC
On July 13, 2022, Holdings acquired 100% of the outstanding shares of common stock of Exceptional, a provider of medical transportation services, in exchange for $13,708,333, consisting of $7,708,333 in cash at closing and $6,000,000 payable over a 24-month period following the closing date of the acquisition. The Company also agreed to pay up to $2,000,000 in contingent consideration upon meeting certain performance conditions within two years of the closing date of such acquisition.
During the nine months ended September 30, 2024, the Company wrote off $1,315,691 pre-acquisition accounts receivable through due to seller, the liability established during acquisition. Additionally, the Company paid $3,000,000 of the $6,000,000 remaining purchase price payable as of December 31, 2023 and paid the remaining $3,000,000 as of September 30, 2024. There were no remaining purchase price payable as of September 30, 2024 and a purchase price payable of $3,000,000 as of December 31, 2023. As of September 30, 2024 and December 31, 2023, there was remaining due to seller balance pertaining to pre-acquisition accounts receivable of $138,275 and $1,453,966, respectively.
The Company recorded a change in fair value of contingent consideration in the amount of $11,067 and $(13,763) for the three and nine months ended September 30, 2024, respectively. The Company did not record a change in fair value of contingent consideration for the three and nine months ended September 30, 2023. During the year ended December 31, 2023, the Company made a payment for the first installment due on the contingent liability in the amount of $426,655. The estimated contingent consideration amount payable for Exceptional was $265,538 and $279,301 as of September 30, 2024 and December 31, 2023, respectively.
Ryan Bros. Fort Atkinson, LLC
On August 9, 2022, Holdings acquired 100% of the outstanding shares of common stock of Ryan Brothers, a provider of medical transportation services, in exchange for an aggregate purchase price of $11,422,252, consisting of $7,422,252 in cash at closing and an estimated $4,000,000 in contingent consideration to be paid out over 24 months, commencing on August 1, 2022, based on performance of certain obligations.
During the nine months ended September 30, 2024, the Company wrote off $3,360,067 pre-acquisition accounts receivable through due to seller, the liability established during acquisition. Additionally, the Company made payments in the amount of $8,976 on the remaining purchase price payable during the nine months ended September 30, 2024. There was no remaining due to seller balance as of September 30, 2024 and a due to seller balance of $3,369,043 as of December 31, 2023.
The Company recorded a change in fair value of contingent consideration in the amount of $33,453 and $(159,974) for the three months ended September 30, 2024 and 2023, respectively, and $86,056 and $(159,974) for the nine months ended September 30, 2024 and 2023, respectively. During the year ended December 31, 2023, the Company made a payment for the first installment due on the contingent liability in the amount of $1,840,026. The estimated contingent consideration amount payable for Ryan Brothers was $1,907,074 and $1,821,018 as of September 30, 2024 and December 31, 2023, respectively.
Location Medical Services, LLC
On December 9, 2022, Holdings, through its indirect wholly owned subsidiary Ambulnz U.K. Ltd. (“UK Ltd.”), acquired 100% of the outstanding shares of common stock of LMS. The aggregate purchase price consisted of $302,450 in cash consideration. The Company also agreed to pay LMS an additional $11,279,201 in deferred consideration and an estimated $2,475,540 in contingent consideration upon LMS meeting certain performance conditions in 2023.
20

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
Additionally, the Company paid $11,279,201 of deferred consideration to LMS during the year ended December 31, 2023. As of September 30, 2024 and December 31, 2023, there was no remaining due to seller amounts outstanding.
The Company did not record a change in fair value of contingent consideration for the three and nine months ended September 30, 2024 and 2023 but recorded foreign exchange movements of $0 and $(90,834) for the three months ended September 30, 2024 and 2023, respectively, and $(4,798) and $20,730 for the nine months ended September 30, 2024 and 2023, respectively. On April 2, 2024, the Company paid the remaining contingent consideration balance in the amount of $600,029. There was no remaining contingent liability balance as of September 30, 2024 and a contingent liability balance of $604,827 as of December 31, 2023.
Cardiac RMS, LLC
On March 31, 2023, Holdings acquired 51% of the outstanding shares of common stock of CRMS, a provider of cardiac implantable electronic device remote monitoring and virtual care management services. The closing consideration of $10,000,000 consisted of $9,000,000 in cash and $1,000,000 worth of shares of Common Stock issued in a private placement transaction. The Company also agreed to pay additional consideration following the initial closing, consisting of an estimated True-up Payment of $2,088,243 to be paid in 2024 based on the attainment of full-year 2023 EBITDA targets and estimated earn out payments amounting to $13,733,947. The earn out payments are to be paid out over 36 months, beginning in 2025, for the remaining 49% equity of CRMS, based on CRMS’ attainment of full-year EBITDA targets. $5,000,000 of such further probable consideration is to be paid in cash and the remaining $10,822,190 is to be paid in shares of Common Stock. Acquisition costs are included in general and administrative expenses and totaled $229,937 for the year ended December 31, 2023.
The Company did not record a change in fair value of contingent consideration for the three months ended September 30, 2024, but recorded a change in fair value of contingent consideration in the amount of $298,419 for the nine months ended September 30, 2024. The Company did not record a change in fair value of contingent consideration for the three and nine months ended September 30, 2023. On May 29, 2024, the Company paid a portion of the True-up Payment in the amount of $1,000,000. During the three and nine months ended September 30, 2024, the Company issued $1,814,345 in Common Stock, or 578,350 shares, constituting the remainder of the True-up Payment. The estimated contingent consideration amount payable for CRMS was $14,571,909 and $17,087,835 as of September 30, 2024 and December 31, 2023, respectively.
Ambulnz-FMC North America LLC
On April 1, 2023, the Company acquired the remaining outstanding shares of common stock of Ambulnz-FMC North America LLC (“FMC NA”), a prominent healthcare company that focuses on providing vital products and services for patients suffering from kidney diseases and renal failure, from its joint venture with Holdings in exchange for $4,000,000 in cash and $3,000,000 in Common Stock. Acquisition costs are included in general and administrative expenses totaling $35,560 for the year ended December 31, 2023.
Healthworx LLC
On May 10, 2023, the Company acquired the remaining outstanding shares of common stock of Healthworx LLC (“Healthworx”), a provider of management, administration and support services to service providers focused on medical testing and diagnostic screening, from its joint venture with Rapid Reliable Testing, LLC in exchange for $1,385,156 in cash.
Ambulnz CO, LLC
On July 1, 2024, the Company acquired the remaining noncontrolling interest in its Ambulnz CO, LLC (“Ambulnz CO”) joint venture from the University of Colorado Health in exchange for $1,848,000 in cash.
The following table presents the assets acquired and liabilities assumed at the date of the acquisitions:
21

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)

|  | Ambulnz CO |  | FMC NA |  | CRMS |  | Total
Consideration: |  |  |  |  |  |  |  |
Cash consideration |  | $ | 1,848,000 |  |  | $ | 4,000,000 |  |  | $ | 9,000,000 |  |  | $ | 14,848,000 |
Stock consideration |  | — |  |  | 3,000,000 |  |  | 1,000,000 |  |  | 4,000,000 |
Due to seller |  | — |  |  | — |  |  | — |  |  | — |
Amounts held under an escrow account |  | — |  |  | — |  |  | — |  |  | — |
Contingent liability |  | — |  |  | — |  |  | 15,822,190 |  |  | 15,822,190 |
Total consideration |  | $ | 1,848,000 |  |  | $ | 7,000,000 |  |  | $ | 25,822,190 |  |  | $ | 34,670,190 |
Recognized amounts of identifiable assets acquired and liabilities assumed |  |  |  |  |  |  |  |
Cash |  | $ | — |  |  | $ | — |  |  | $ | 1,574,604 |  |  | $ | 1,574,604 |
Accounts receivable |  | — |  |  | — |  |  | 2,033,533 |  |  | 2,033,533 |
Other current assets |  | — |  |  | — |  |  | 293,478 |  |  | 293,478 |
Property, plant and equipment |  | — |  |  | — |  |  | — |  |  | — |
Intangible assets |  | — |  |  | — |  |  | 15,930,000 |  |  | 15,930,000 |
Total identifiable assets acquired |  | — |  |  | — |  |  | 19,831,615 |  |  | 19,831,615 |
Accounts payable |  | — |  |  | — |  |  | 28,978 |  |  | 28,978 |
Due to seller |  | — |  |  | — |  |  | 2,448,460 |  |  | 2,448,460 |
Other current liabilities |  | — |  |  | — |  |  | 174,177 |  |  | 174,177 |
Total liabilities assumed |  | — |  |  | — |  |  | 2,651,615 |  |  | 2,651,615 |
Noncontrolling interests |  | 2,188,450 |  |  | 2,567,037 |  |  | — |  |  | 4,755,487 |
Goodwill |  | — |  |  | — |  |  | 8,642,190 |  |  | 8,642,190 |
Additional paid-in-capital |  | (340,450) |  |  | 4,432,963 |  |  | — |  |  | 4,092,513 |
Total purchase price |  | $ | 1,848,000 |  |  | $ | 7,000,000 |  |  | $ | 25,822,190 |  |  | $ | 34,670,190 |

22

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
Pro Forma Disclosures
The following unaudited pro forma combined financial information for the three and nine months ended September 30, 2023 gives effect to the acquisitions disclosed above as if they had occurred on January 1, 2023. The pro forma information is not necessarily indicative of the results of operations that actually would have occurred under the ownership and management of the Company. The figures presented below for the three months ended September 30, 2023 represent the actual results of the Company, as the financial results of CRMS were consolidated in the Company’s results of operations for the entirety of the period.

|  | Three Months Ended September 30, 2023 |  | Nine Months Ended September 30, 2023
Revenue |  | $ | 186,552,910 |  |  | $ | 428,155,992 |
Net income |  | 4,630,239 |  |  | 3,093,862 |

The unaudited pro forma combined financial information presented above includes the accounting effects of the acquisitions, including, to the extent applicable, amortization charges from acquired intangible assets, depreciation of property and equipment that have been revalued, transaction costs, interest expense and the related tax effects.
5. ABC Transaction and Held for Sale
In 2022, the Company started discussions regarding the potential liquidation process of Ambulnz Health, LLC (“Health”) through an assignment for the benefit of creditors (“ABC”), with a targeted timeline for the transaction to be fully closed by December 31, 2022. The conversation involved operations, human resources, external legal counsel, and Amb, LLC, a California limited liability company (the “Assignee”). Due to operational processes, the filing was extended and finalized on February 3, 2023.
An ABC is a liquidation process governed by state law (California law in this instance) that is an alternative to a bankruptcy case under federal law. Prior to commencing the ABC, Health ceased business operations and all of its employees were terminated and treated in accordance with California law. In the ABC, all of Health’s assets were transferred to the Assignee, who acts as a fiduciary for creditors and in a capacity equivalent to that of a bankruptcy trustee. The Assignee is responsible for liquidating the assets. Similar to a bankruptcy case, there was a claims process. Creditors of Health received notice of the ABC and a proof of claim form and were required to submit a proof of claim in order to participate in distribution of net liquidation proceeds by the Assignee.
As of December 31, 2022, Health met the criteria to be classified as held for sale. As a result, the Company was required to record the respective assets and liabilities at the lower of carrying value or fair value, less any costs to sell and present the related assets and liabilities as separate line items in the Condensed Consolidated Balance Sheets.
The intercompany receivables and intercompany payables were eliminated in the Company’s Condensed Consolidated Balance Sheet as of December 31, 2022.
6. Goodwill
The Company recorded an aggregate of $8,642,190 in goodwill in connection with its acquisitions in the year ended December 31, 2023.
The Company also updated the carrying value of the goodwill in its unaudited Condensed Consolidated Balance Sheets to reflect the foreign currency translation adjustment. The carrying value of goodwill amounted to $47,862,242 as of
23

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
September 30, 2024. The changes in the carrying value of goodwill for the nine months ended September 30, 2024 are as noted in the table below:

|  | Carrying Value
Balance as of December 31, 2023 |  | $ | 47,539,929 |
Foreign currency translation adjustment |  | 322,313 |
Balance as of September 30, 2024 |  | $ | 47,862,242 |

7. Intangibles
Intangible assets consisted of the following as of September 30, 2024 and December 31, 2023:

| September 30, 2024
| Estimated Useful Life (Years) |  | Gross Carrying Amount |  | Additions |  | Accumulated Amortization |  | Net Carrying Amount
Computer software | 5 years |  | $ | 247,828 |  |  | $ | — |  |  | $ | (241,191) |  |  | $ | 6,637 |
Operating licenses | Indefinite |  | 9,399,004 |  |  | — |  |  | — |  |  | 9,399,004 |
Internally developed software | 4-5 years |  | 10,078,087 |  |  | 2,109,239 |  |  | (11,264,266) |  |  | 923,060 |
Material contracts | Indefinite |  | 62,550 |  |  | — |  |  | — |  |  | 62,550 |
Customer relationships | 8-9 years |  | 28,337,524 |  |  | 112,260 |  |  | (5,745,054) |  |  | 22,704,730 |
Trademark | 8-15 years |  | 427,531 |  |  | (2,942) |  |  | (94,029) |  |  | 330,560 |
Non-compete agreements | 5 years |  | 100,000 |  |  | — |  |  | (30,000) |  |  | 70,000 |
Trade credits | 5 years |  | 1,500,000 |  |  | — |  |  | — |  |  | 1,500,000 |
|  |  | $ | 50,152,524 |  |  | $ | 2,218,557 |  |  | $ | (17,374,540) |  |  | $ | 34,996,541 |

| December 31, 2023
| Estimated Useful Life (Years) |  | Gross Carrying Amount |  | Additions |  | Accumulated Amortization |  | Net Carrying Amount
Computer software | 5 years |  | $ | 247,828 |  |  | $ | — |  |  | $ | (235,967) |  |  | $ | 11,861 |
Operating licenses | Indefinite |  | 8,799,004 |  |  | 600,000 |  |  | — |  |  | 9,399,004 |
Internally developed software | 4-5 years |  | 8,284,058 |  |  | 1,794,029 |  |  | (8,821,563) |  |  | 1,256,524 |
Material contracts | Indefinite |  | 62,550 |  |  | — |  |  | — |  |  | 62,550 |
Customer relationships | 8-9 years |  | 12,397,954 |  |  | 15,939,570 |  |  | (3,334,925) |  |  | 25,002,599 |
Trademark | 8-15 years |  | 389,469 |  |  | 38,062 |  |  | (62,141) |  |  | 365,390 |
Non-compete agreements | 5 years |  | — |  |  | 100,000 |  |  | (15,000) |  |  | 85,000 |
Trade credits | 5 years |  | — |  |  | 1,500,000 |  |  | — |  |  | 1,500,000 |
|  |  | $ | 30,180,863 |  |  | $ | 19,971,661 |  |  | $ | (12,469,596) |  |  | $ | 37,682,928 |

The intangible assets include an immaterial foreign currency translation adjustment in the amount of $29,019 for the nine months ended September 30, 2024. Intangible asset balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income. During the nine months ended September 30, 2024, the Company disposed of intangible assets with a cost of $1,540 and accumulated amortization of $276. The Company recorded a loss on disposal of intangible assets of $1,264 for the nine months ended September 30, 2024. The Company also reclassified certain intangible assets with a cost of $30,361 and
24

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
accumulated amortization of $8,136 to “legal and regulatory” expenses within the unaudited Condensed Statements of Operations and Comprehensive Income (Loss) .
The Company recorded amortization expense of $1,605,483 and $1,515,378 for the three months ended September 30, 2024 and 2023, respectively.
The Company recorded amortization expense of $4,884,337 and $4,295,958 for the nine months ended September 30, 2024 and 2023, respectively.
Future amortization expense at September 30, 2024 for the next five years and in the aggregate are as follows:

| Amortization Expense
2024, remaining | $ | 1,003,942 |
2025 | 3,838,416 |
2026 | 3,334,528 |
2027 | 3,315,044 |
2028 | 3,288,838 |
Thereafter | 9,254,219 |
Total | $ | 24,034,987 |

8. Accrued Liabilities
Accrued liabilities consisted of the following as of September 30, 2024 and December 31, 2023:

| September 30, 2024 |  | December 31, 2023
Accrued general expenses | $ | 19,634,415 |  |  | $ | 27,001,232 |
Accrued workers' compensation and other insurance liabilities | 19,349,940 |  |  | 12,881,902 |
Accrued subcontractors | 10,165,705 |  |  | 37,858,755 |
Accrued payroll | 7,460,342 |  |  | 6,464,192
Accrued bonus | 2,311,077 |  | 4,784,005 |
Other current liabilities | 1,047,127 |  |  | 2,350,523 |
Total accrued liabilities | $ | 59,968,606 |  |  | $ | 91,340,609 |

9. Line of Credit
On November 1, 2022, the Company entered into a credit agreement (as amended, the “Credit Agreement”) with two banks, with one bank in the capacity as a lender and the administrative agent (collectively with the other lender, the “Lenders”). The Credit Agreement provides for a revolving credit facility in the initial aggregate principal amount of $90,000,000 (the “Revolving Facility”). The Revolving Facility includes the ability for the Company to request an increase to the commitment by an additional amount of up to $50,000,000, though no Lender (nor the Lenders collectively) is obligated to increase its respective commitments. Borrowings under the Revolving Facility bear interest at a per annum rate equal to: (i) at the Company’s option, (x) the base rate or (y) the adjusted term SOFR rate, plus (ii) the applicable margin. The applicable margins are based on the Company’s consolidated net leverage ratio, adjusted on a quarterly basis. The initial applicable margins are 1.25% for an adjusted term SOFR loan and 0.25% for a base rate loan and will be updated based on the Company’s consolidated net leverage ratio. The Revolving Facility matures on November 1, 2027, the five-year anniversary of the closing date. The Revolving Facility is secured by a first-priority lien on substantially all of the Company’s present and future personal assets and intangible assets. The Revolving Facility is subject to certain financial covenants such as a net leverage ratio and interest coverage ratio, as defined in the Credit Agreement.
As of December 31, 2023, there was a $25,000,000 outstanding balance on the Revolving Facility. The Company drew down an additional $15,000,000 on February 8, 2024 under the Revolving Facility. On February 27, 2024, the Company paid the $40,000,000 Revolving Facility balance. On March 4, 2024, the Company drew down $15,000,000 and made an
25

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
additional $15,000,000 draw on March 18, 2024. As of September 30, 2024, the outstanding balance of the Revolving Facility was $30,000,000 and the unused portion of the Revolving Facility was $60,000,000. The Company incurred $587,721 and $0 in interest charges relating to its Revolving Facility for the three months ended September 30, 2024 and 2023, respectively, and $1,625,408 and $0 for the nine months ended September 30, 2024 and 2023, respectively, which is reflected in interest (expense) income on the Company’s unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss).
Standby Letter of Credit
On October 20, 2023, the Company obtained an unconditional and irrevocable letter of credit from a financial institution in the amount of $1,080,000. The letter of credit expires on the one-year anniversary of the closing date, or October 20, 2024, and is renewed automatically for successive one-year periods, unless earlier terminated by the institution. As of September 30, 2024, no am ounts had been drawn.
10. Notes Payable
The Company has various loans with finance companies with monthly installments aggregating $2,325, inclusive of interest ranging from 2.5% through 4.8%. The loan notes mature at various times through 2026 and are secured by transportation equipment.
The following table summarizes the Company’s notes payable:

| September 30, 2024 |  | December 31, 2023
Equipment and financing loans payable, between 2.5% and 4.8% interest and maturing between May 2026 and August 2026 | $ | 47,710 |  |  | $ | 69,717 |
Total notes payable | 47,710 |  |  | 69,717 |
Less: current portion of notes payable | 26,374 |  |  | 28,131 |
Total non-current portion of notes payable | $ | 21,336 |  |  | $ | 41,586 |

Interest expense was $484 and $48,794 for the three months ended September 30, 2024 and 2023, respectively.
Interest expense was $1,912 and $110,203 for the nine months ended September 30, 2024 and 2023, respectively.
Future minimum annual maturities of notes payable as of September 30, 2024 are as follows:

| Notes Payable
2024, remaining | $ | 6,536 |
2025 | 26,531 |
2026 | 14,643 |
Total maturities | 47,710 |
Current portion of notes payable | (26,374) |
Long-term portion of notes payable | $ | 21,336 |

11. Business Segment Information
The Company conducts business in three operating segments: Mobile Health Services, Transportation Services and Corporate. In accordance with ASC 280, Segment Reporting, operating segments are components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision makers, the Company’s Chief Executive Officer and Chief Financial Officer, in deciding how to allocate resources and assessing performance. Prior to 2023, the Company reported in two segments, because the Company’s entities have two main revenue streams. Beginning with the first quarter of 2023, the Company began reporting in three operating segments, adding a Corporate segment to allow for analysis of shared services and personnel that support both the Mobile Health Services and Transportation Services segments. Previously, these costs had been allocated almost entirely to the Transportation Services segment. All
26

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
of the Company’s revenues and cost of revenues continue to be reported within the Transportation Services and Mobile Health Services segments. The Corporate segment contains operating expenses such as information technology costs, certain insurance costs and the compensation costs of senior and executive leadership. The segment reporting for the prior-year period has been adjusted to conform to the new methodology, for the purposes of allowing a clearer analysis of year-over-year performance. The Company’s Chief Executive Officer and Chief Financial Officer evaluate the Company’s financial information and resources and assess the performance of these resources by revenue stream and by operating income or loss performance.
The accounting policies of the segments are the same as the accounting policies of the Company as a whole. The Company evaluates the performance of its Mobile Health Services, Transportation Services and Corporate segments based primarily on results of operations.
Operating results for the business segments of the Company are as follows:

| Mobile Health Services |  | Transportation Services |  | Corporate |  | Total
Three Months Ended September 30, 2024 |  |  |  |  |  |  |
Revenues | $ | 90,663,433 |  |  | $ | 48,021,381 |  |  | $ | — |  |  | $ | 138,684,814 |
Income (loss) from operations | 21,936,967 |  |  | (75,242) |  |  | (11,724,328) |  |  | 10,137,397 |
Total assets | 400,568,190 |  |  | 66,844,610 |  |  | 26,469,739 |  |  | 493,882,539 |
Depreciation and amortization expense | 1,172,458 |  |  | 2,114,380 |  |  | 890,696 |  |  | 4,177,534 |
Stock compensation | 1,237,924 |  |  | 34,123 |  |  | 1,883,139 |  |  | 3,155,186 |
Long-lived assets | 44,590,633 |  |  | 70,488,506 |  |  | 10,159,283 |  |  | 125,238,422 |
Capital expenditures | 640,499 |  |  | 3,054,429 |  |  | 536,262 |  |  | 4,231,190 |
Three Months Ended September 30, 2023 |  |  |  |  |  |  |
Revenues | $ | 139,340,467 |  |  | $ | 47,212,443 |  |  | $ | — |  |  | $ | 186,552,910 |
Income (loss) from operations | 21,109,619 |  |  | 503,687 |  |  | (12,905,351) |  |  | 8,707,955 |
Total assets | 225,084,373 |  |  | 129,796,548 |  |  | 64,903,221 |  |  | 419,784,142 |
Depreciation and amortization expense | 1,193,187 |  |  | 2,333,426 |  |  | 809,654 |  |  | 4,336,267 |
Stock compensation | 274,108 |  |  | 136,472 |  |  | 2,950,129 |  |  | 3,360,709 |
Long-lived assets | 48,554,087 |  |  | 66,160,925 |  |  | 11,305,286 |  |  | 126,020,298 |
Capital expenditures | 1,692,902 |  |  | 3,016,381 |  |  | 783,422 |  |  | 5,492,705 |

| Mobile Health Services |  | Transportation Services |  | Corporate |  | Total
Nine Months Ended September 30, 2024 |  |  |  |  |  |  |
Revenues | $ | 351,346,919 |  |  | $ | 144,375,140 |  |  | $ | — |  |  | $ | 495,722,059 |
Income (loss) from operations | 80,173,235 |  |  | (1,153,908) |  |  | (42,857,414) |  |  | 36,161,913 |
Total assets | 400,568,190 |  |  | 66,844,610 |  |  | 26,469,739 |  |  | 493,882,539 |
Depreciation and amortization expense | 3,556,537 |  |  | 6,256,783 |  |  | 2,748,653 |  |  | 12,561,973 |
Stock compensation | 4,473,099 |  |  | 228,196 |  |  | 5,054,160 |  |  | 9,755,455 |
Long-lived assets | 44,590,633 |  |  | 70,488,506 |  |  | 10,159,283 |  |  | 125,238,422 |
Capital expenditures | 897,284 |  |  | 10,085,457 |  |  | 2,202,787 |  |  | 13,185,528 |
Nine Months Ended September 30, 2023 |  |  |  |  |  |  |
Revenues | $ | 292,351,835 |  |  | $ | 132,690,538 |  |  | $ | — |  |  | $ | 425,042,373 |
Income (loss) from operations | 52,081,169 |  |  | 853,164 |  |  | (49,553,011) |  |  | 3,381,322 |
Total assets | 225,084,373 |  |  | 129,796,548 |  |  | 64,903,221 |  |  | 419,784,142 |
Depreciation and amortization expense | 3,111,497 |  |  | 6,137,364 |  |  | 2,567,796 |  |  | 11,816,657 |
Stock compensation | 573,930 |  |  | 612,077 |  |  | 13,975,840 |  |  | 15,161,847 |
Long-lived assets | 48,554,087 |  |  | 66,160,925 |  |  | 11,305,286 |  |  | 126,020,298 |
Capital expenditures | 28,109,057 |  |  | 16,460,730 |  |  | 3,159,172 |  |  | 47,728,959 |

27

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
Long-lived assets include property and equipment, goodwill, intangible assets, operating lease right-of-use assets and finance lease right-of-use assets.
Geographic Information
The following table summarizes long-lived assets by geographic location as of September 30, 2024 and December 31, 2023:

| September 30, 2024 |  | December 31, 2023
Primary Geographical Markets |  |  |
United States | $ | 104,965,979 |  |  | $ | 103,779,506 |
United Kingdom | 20,272,443 |  |  | 19,863,289 |
Total long-lived assets | $ | 125,238,422 |  |  | $ | 123,642,795 |

Revenues by geographic location are included in Note 2.
12. Equity
Unregistered Sales of Equity Securities
On July 19, 2024, in connection with the CRMS acquisition, the Company issued $1,814,345 in Common Stock, or 578,350 shares, constituting the remainder of the True-up Payment. The True-up Payment was based on CRMS’ attainment of full-year EBITDA targets for 2023 (see Note 4).
Share Repurchase Program
On May 24, 2022, the Company’s Board of Directors (the “Board of Directors” or the “Board”) authorized a share repurchase program to purchase up to $40,000,000 of Common Stock (the “2022 Program”). During the second and fourth quarter of 2022, the Company repurchased 536,839 shares of its Common Stock for $3,731,712. These shares were subsequently cancelled. The 2022 Program, which did not obligate the Company to repurchase a specific number of shares, expired on November 24, 2023.
On January 30, 2024, the Board of Directors authorized a new share repurchase program to purchase up to $36,000,000 in shares of Common Stock during a six-month period that ended July 30, 2024 (the “Prior Repurchase Program”). The Prior Repurchase Program did not obligate the Company to repurchase a specific number of shares.
On August 5, 2024, following the expiration of the previously authorized share repurchase program on July 30, 2024, the Board effectively extended the Prior Repurchase Program by authorizing a new share repurchase program (the “New Repurchase Program”) on the same terms and conditions as the Prior Repurchase Program other than expiration, pursuant to which the Company may purchase up to $26,000,000 in shares of Common Stock, which was the approximate amount remaining under the Prior Repurchase Program at its expiration. The New Repurchase Program expires on December 31, 2024 and may be suspended, extended, modified or discontinued at any time without prior notice.
Under the terms of the New Repurchase Program, the Company may purchase shares of Common Stock on a discretionary basis from time to time through open market repurchases or privately negotiated transactions or through other means, including by entering into Rule 10b5-1 trading plans or accelerated share repurchase programs, in each case, during an “open window” and when the Company does not possess material non-public information.
The timing, manner, price and amount of shares repurchased under the New Repurchase Program depends on a variety of factors, including stock price, trading volume, market conditions, corporate and regulatory requirements and other general business considerations. The New Repurchase Program may be modified, suspended or discontinued at any time without prior notice.
Repurchases under the New Repurchase Program may be funded from the Company’s existing cash and cash equivalents, future cash flow or proceeds of borrowings or debt offerings.
28

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
During the three months ended September 30, 2024, the Company repurchased and subsequently cancelled 356,113 shares of Common Stock for $1,296,187. There were no shares repurchased during the three months ended September 30, 2023.
During the nine months ended September 30, 2024, the Company repurchased and subsequently cancelled 3,007,684 shares of Common Stock for $11,078,198. There were no shares repurchased during the nine months ended September 30, 2023.
13. Stock-Based Compensation
Stock Options
In 2021, the Company established the DocGo Inc. 2021 Equity Incentive Plan (the “Plan”), which replaced Ambulnz, Inc.’s 2017 Equity Incentive Plan. The Plan initially reserved 16,607,894 shares of Common Stock for issuance under the Plan. The Company’s stock options generally vest on various terms based on continuous services over periods ranging from three to five years. The stock options are subject to time vesting requirements through 2028 and are nontransferable. Stock options granted have a maximum contractual term of 10 years. As of September 30, 2024, approximately 3.9 million employee stock options had vested.
The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. Before the consummation of the Business Combination, the management of Ambulnz took the average of several publicly traded companies that were representative of Ambulnz’ size and industry in order to estimate its expected stock volatility. Subsequent to the Business Combination, the Company utilized publicly available pricing. The expected term of the options represented the period of time the instruments were expected to be outstanding. The Company based the risk-free interest rate on the rate payable on the U.S. Treasury securities corresponding to the expected term of the awards at the date of grant. Expected dividend yield was zero based on the fact that the Company had not historically paid and does not intend to pay a dividend in the foreseeable future.
The following assumptions were used to compute the fair value of the stock option grants during the nine months ended September 30, 2024 and 2023:

| Nine Months Ended September 30,
| 2024 |  | 2023
Risk-free interest rate | 4.19% - 4.54% |  | 4.10% - 4.87%
Expected term (in years) | 5.57 |  | 6.25
Volatility | 61%-71%% |  | 52%-62%
Dividend yield | — | % |  | — | %

The following table summarizes the Company’s stock option activity under the Plan during the nine months ended September 30, 2024:

| Options Shares |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Life in Years |  | Aggregate Intrinsic Value
Balance as of December 31, 2023 | 11,942,264 |  |  | $ | 7.36 |  |  | 8.16 |  | $ | 3,961,556 |
Granted/vested | 278,350 |  |  | 2.54 |  |  | — |  |  | — |
Exercised | (430) |  |  | 1.59 |  |  | — |  |  | — |
Cancelled | (4,016,371) |  |  | 7.70 |  |  | — |  |  | — |
Balance as of September 30, 2024 | 8,203,813 |  |  | 7.06 |  |  | 7.48 |  | 1,487,826 |
Options vested and exercisable as of September 30, 2024 | 3,910,463 |  |  | $ | 6.66 |  |  | 6.86 |  | $ | 1,433,639 |

29

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
The aggregate intrinsic value in the above table is calculated as the difference between the fair value of the Common Stock price and the exercise price of the stock options. The weighted average grant date fair value per share for stock option grants during the nine months ended September 30, 2024 and the year ended December 31, 2023 was $2.54 and $7.93, respectively.
For the three months ended September 30, 2024 and 2023, the total recorded stock-based compensation related to stock option awards granted was $1,448,151, and $3,027,577, respectively.
For the nine months ended September 30, 2024 and 2023, the total recorded stock-based compensation related to stock option awards granted was $4,688,997 and $8,787,375, respectively.
On September 30, 2024 and December 31, 2023, the total unrecognized compensation related to unvested stock option awards granted was $13,027,394 and $29,058,756, respectively, which the Company expects to recognize over a weighted-average period of approximately 1.49 years.
Restricted Stock Units
The fair value of restricted stock units (“RSUs”) is determined on the date of grant. The Company records compensation expenses in the unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) on a straight-line basis over the vesting period for RSUs. The vesting period for employees and members of the Board of Directors ranges from one to four years.
Activity under RSUs during the nine months ended September 30, 2024 was as follows:

| RSUs |  | Weighted- Average Grant Date Fair Value Per RSU
Balance as of December 31, 2023 | 2,424,095 |  |  | $ | 5.61 |
Granted | 1,077,884 |  | 2.78 |
Vested | (458,923) |  | 4.23 |
Forfeited | (151,880) |  |  | 4.93 |
Balance as of September 30, 2024 | 2,891,176 |  | 5.04 |
Vested and unissued as of September 30, 2024 | 2,617 |  |  | 10.03 |
Non-vested as of September 30, 2024 | 2,888,559 |  |  | $ | 5.04 |

The total grant-date fair value of RSUs granted during the nine months ended September 30, 2024 was $3,780,430.
For the three months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense related to RSUs of $1,426,271 and $25,000, respectively.
For the nine months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense related to RSUs of $4,242,065 and $1,416,338, respectively.
On September 30, 2024, and December 31, 2023, the total unrecognized compensation related to unvested RSUs granted was $11,711,097 and $12,602,662, respectively, which is expected to be recognized over a weighted-average period of approximately 1.8 years.
Performance-based Restricted Stock Units
The fair value of performance-based restricted stock units (“PSUs”) is determined on the date of grant. The Company records compensation expense in the unaudited Condensed Consolidated Statement of Operations and Comprehensive
30

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
Income (Loss) on a straight-line basis over the vesting period for PSUs. The vesting period for PSUs ranges from one to four years.
Activity under PSUs during the nine months ended September 30, 2024 was as follows:

| PSUs |  | Weighted- Average Grant Date Fair Value Per PSU
Balance as of December 31, 2023 | 1,085,270 |  |  | $ | 5.16 |
Granted | — |  |  | — |
Vested | — |  |  | — |
Forfeited | — |  |  | — |
Performance adjustment | (217,054) |  | — |
Balance as of September 30, 2024 | 868,216 |  | 5.16 |
Vested and unissued as of September 30, 2024 | — |  |  | — |
Non-vested as of September 30, 2024 | 868,216 |  |  | $ | 5.16 |

There were no PSUs granted during the three and nine months ended September 30, 2024.
For the three and nine months ended September 30, 2024, the Company recorded stock-based compensation expense related to PSUs of $280,764 and $824,393, respectively, which are included in accrued liabilities.
For the three and nine months ended September 30, 2023, no stock-based compensation expense related to PSUs were recorded.
As of September 30, 2024 and December 31, 2023, the total unrecognized compensation related to unvested PSUs granted was $3,582,775 and $5,527,166, respectively, which is expected to be recognized over a weighted-average period of approximately 3.2 years.
14. Leases
The Company has lease arrangements for properties, vehicles and transportation equipment. Certain leases contain options to purchase, extend or terminate the lease. Determining the lease term and amount of lease payments to include in the calculation of the right-of-use asset and lease obligations for leases containing options requires the use of judgment to determine whether the exercise of an option is reasonably certain and whether the optional period and payments should be included in the calculation of the associated right-of-use asset and lease obligation. In making such determination, the Company considers all relevant economic factors.
The Company’s lease agreements generally do not provide an implicit borrowing rate. Therefore, the Company used a benchmark approach to derive an appropriate imputed discount rate. The Company benchmarked itself against other companies of similar credit ratings and comparable quality and derived imputed rates, which were used to discount its real estate lease liabilities. The Company used estimated borrowing rates of 6% on January 1, 2019 for all leases that commenced prior to that date for office spaces, vehicles and transportation equipment.
31

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
Lease Cost
The table below comprises lease expenses for the three and nine months ended September 30, 2024 and 2023:

|  | Three Months Ended September 30, |  | Nine Months Ended September 30,
|  | 2024 |  | 2023 |  | 2024 |  | 2023
Components of total lease cost: |  |  |  |  |  |  |  |
Operating lease expense |  | $ | 1,009,108 |  |  | $ | 697,050 |  |  | $ | 2,775,887 |  |  | $ | 2,319,282 |
Finance lease expense: |  |  |  |  |  |  |  |
Amortization of right-of-use assets |  | 1,197,076 |  |  | 1,195,719 |  |  | 3,394,696 |  |  | 2,822,982 |
Interest on lease liabilities |  | 194,099 |  |  | 135,392 |  |  | 560,926 |  |  | 394,443 |
Finance lease expense |  | 1,391,175 |  |  | 1,331,111 |  |  | 3,955,622 |  |  | 3,217,425 |
Short-term lease expense |  | 594,729 |  |  | 452,538 |  |  | 1,484,186 |  |  | 1,156,886 |
Total lease cost |  | $ | 2,995,012 |  |  | $ | 2,480,699 |  |  | $ | 8,215,695 |  |  | $ | 6,693,593 |

Lease Payments
The table below presents lease payments for the three and nine months ended September 30, 2024 and 2023:

|  | Three Months Ended September 30, |  | Nine Months Ended September 30,
|  | 2024 |  | 2023 |  | 2024 |  | 2023
Components of total lease payments: |  |  |  |  |  |  |  |
Operating lease payment |  | $ | 890,740 |  |  | $ | 697,050 |  |  | $ | 2,669,422 |  |  | $ | 2,319,282 |
Finance lease payment |  | 1,088,265 |  |  | 782,808 |  |  | 3,118,054 |  |  | 2,293,330 |
Total lease payments |  | $ | 1,979,005 |  |  | $ | 1,479,858 |  |  | $ | 5,787,476 |  |  | $ | 4,612,612 |

Operating Leases
The Company is obligated to make rental payments under non-cancellable operating leases for office, dispatch station space and transportation equipment, expiring at various dates through 2034. Under the terms of the leases, the Company is also obligated for its proportionate share of real estate taxes, insurance and maintenance costs of the property.
Loss on Lease Remeasurement
During the year, the Company reassessed the use of some office spaces, resulting in the termination of two leased office spaces. The Company recorded a loss from remeasurement of operating lease of $6,163 and $13,469 during the three and nine months ended September 30, 2024, respectively.
There were no gains or losses recorded relating to remeasurement of operating leases for the three and nine months ended September 30, 2023.
32

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
Lease Position as of September 30, 2024
Right-of-use assets and lease liabilities for the Company’s operating leases were recorded in the unaudited Condensed Consolidated Balance Sheets as follows:

| September 30, 2024 |  | December 31, 2023
Assets |  |  |
Lease right-of-use assets | $ | 12,489,767 |  |  | $ | 9,580,535 |
Total lease assets | $ | 12,489,767 |  |  | $ | 9,580,535 |
Liabilities |  |  |
Current liabilities: |  |  |
Lease liability - current portion | $ | 3,776,159 |  |  | $ | 2,773,020 |
Noncurrent liabilities: |  |  |
Lease liability, net of current portion | 9,172,259 |  |  | 7,223,941 |
Total lease liability | $ | 12,948,418 |  |  | $ | 9,996,961 |

Lease Terms and Discount Rate
The table below presents certain information related to the weighted average remaining lease term and the weighted average discount rate for the Company’s operating leases as of September 30, 2024:

Weighted average remaining lease term (in years) - operating leases | 3.90
Weighted average discount rate - operating leases | 5.83 | %

Undiscounted Cash Flows
Future minimum lease payments under the operating leases as of September 30, 2024 were as follows:

| Operating Leases
2024, remaining | $ | 1,109,227 |
2025 | 4,412,071 |
2026 | 3,604,641 |
2027 | 2,391,396 |
2028 | 1,765,274 |
Thereafter | 1,277,710 |
Total future minimum lease payments | 14,560,319 |
Less effects of discounting | (1,611,901) |
Present value of future minimum lease payments | $ | 12,948,418 |

Finance Leases
The Company leases vehicles under non-cancellable finance lease agreements with a liability of $13,990,018 and $11,430,465 as of September 30, 2024 and December 31, 2023, respectively, and accumulated depreciation of $9,896,278 and $11,679,823 as of September 30, 2024 and December 31, 2023, respectively.
33

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
Loss on Lease Remeasurement
During the year, the Company returned a number of leased vehicles, resulting in the termination of contract of these leased vehicles. The Company recorded a loss on remeasurement of finance lease of $0 and $18,583 during the three and nine months ended September 30, 2024, respectively.
For the three and nine months ended September 30, 2023, the Company terminated leased vehicles which resulted in a $4,834 gain on remeasurement of finance leases.
Lease Position as of September 30, 2024
Right-of-use assets and lease liabilities for the Company’s finance leases were recorded in the unaudited Condensed Consolidated Balance Sheets as follows:

| September 30, 2024 |  | December 31, 2023
Assets |  |  |
Lease right-of-use assets | $ | 14,605,119 |  |  | $ | 12,003,919 |
Total lease assets | $ | 14,605,119 |  |  | $ | 12,003,919 |
Liabilities |  |  |
Current liabilities: |  |  |
Lease liability - current portion | $ | 4,435,324 |  |  | $ | 3,534,073 |
Noncurrent liabilities: |  |  |
Lease liability, net of current portion | 9,554,694 |  |  | 7,896,392 |
Total lease liability | $ | 13,990,018 |  |  | $ | 11,430,465 |

Lease Terms and Discount Rate
The table below presents certain information related to the weighted average remaining lease term and the weighted average discount rate for the Company’s finance leases as of September 30, 2024:

Weighted average remaining lease term (in years) - finance leases | 3.45
Weighted average discount rate - finance leases | 5.69 | %

Undiscounted Cash Flows
Future minimum lease payments under the finance leases as of September 30, 2024 are as follows:

| Finance Leases
2024, remaining | $ | 1,321,296 |
2025 | 5,010,486 |
2026 | 4,175,450 |
2027 | 2,856,492 |
2028 | 1,670,204 |
Thereafter | 428,898 |
Total future minimum lease payments | 15,462,826 |
Less effects of discounting | (1,472,808) |
Present value of future minimum lease payments | $ | 13,990,018 |

34

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
15. Other Income (Expense)
The Company recognized $(1,103,016) and $449,051 of other income (expense) for the three months ended September 30, 2024 and 2023, respectively, as set forth in the table below.
The Company recognized $(1,837,655) and $715,589 of other income (expense) for the nine months ended September 30, 2024 and 2023, respectively, as set forth in the table below.

| Three Months Ended |  | Nine Months Ended
| September 30, |  | September 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
Other income (expense) |  |  |  |  |  |  |
Interest (expense) income, net | $ | (505,085) |  |  | $ | 346,376 |  |  | $ | (1,387,743) |  |  | $ | 1,677,420 |
Change in fair value of contingent liability | (44,520) |  |  | 159,974 |  |  | (370,712) |  |  | 159,974 |
Loss on equity method investments | (82,742) |  |  | (95,503) |  |  | (229,923) |  |  | (301,362) |
(Loss) gain on remeasurement of operating and finance leases | (6,163) |  |  | 4,834 |  |  | (32,052) |  |  | 4,834 |
(Loss) gain on disposal of fixed assets | (28,681) |  |  | (9,983) |  |  | 36,717 |  |  | (163,452) |
ABC litigation | — |  |  | — |  |  | — |  |  | (1,000,000) |
Other income (expense) | (435,825) |  |  | 43,353 |  |  | 146,058 |  |  | 338,175 |
Total other income (expense) | $ | (1,103,016) |  |  | $ | 449,051 |  |  | $ | (1,837,655) |  |  | $ | 715,589 |

16. Related Party Transactions
Historically, the Company has been involved in transactions with various related parties.
Legal Services
Ely D. Tendler is compensated for his services to the Company as General Counsel and Secretary through payments to Ely D. Tendler Strategic & Legal Services PLLC (“EDTSLS”), a law firm owned by Mr. Tendler. All payments made to EDTSLS by the Company were for Mr. Tendler's services to the Company as General Counsel and Secretary. No other services were provided by EDTSLS to the Company. The Company's payments to EDTSLS for Mr. Tendler's services totaled $412,353 and $204,700 for the three months ended September 30, 2024 and 2023, respectively, and $1,033,273 and $674,970 for the nine months ended September 30, 2024 and 2023, respectively.
There were no amounts included in accounts payable and accrued liabilities as of September 30, 2024 and December 31, 2023 related to legal services.
Subcontractor Services
PrideStaff provides subcontractor services to the Company. PrideStaff is owned by a former operations manager of the Company and his spouse, and therefore, is a related party. The Company made subcontractor payments to PrideStaff totaling $7,685 and $148,304 for the three and nine months ended September 30, 2024, respectively. There were no payments made for the three and nine months ended September 30, 2023, respectively.
Included in accounts payable were $1,679 and $0 due to related parties as of September 30, 2024 and December 31, 2023, respectively. Included in accrued liabilities were $1,679 and $0 due to related parties as of September 30, 2024 and December 31, 2023 related to subcontractor services.
Transition Services Agreement
On October 11, 2023, the Company and Anthony Capone, who resigned as Chief Executive Officer of the Company on
35

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
September 15, 2023, entered into a separation and transition services agreement (the “Transition Agreement”). Pursuant to the Transition Agreement, Mr. Capone served as a consultant to the Company until March 15, 2024 (such period, the “Capone Consulting Period”) to advise on matters relating to business continuity and processes and transition his institutional knowledge with respect to operational and other departmental functions.
As compensation for his services during the Capone Consulting Period, and subject to his compliance with the Transition Agreement, including the execution and non-revocation of a general release of claims in favor of the Company, Mr. Capone received a monthly consulting fee of $45,000 and subsidized premiums for continued group health plan coverage for the duration of the Capone Consulting Period. Mr. Capone did not receive new equity awards or incentive compensation under the Company’s equity incentive compensation program during the Capone Consulting Period. The Transition Agreement further acknowledges and affirms that Mr. Capone will be bound by and comply with certain restrictive covenants. The Company made payments to Mr. Capone under the Transition Agreement totaling $0 and $180,000 for the three and nine months ended September 30, 2024, respectively. There were no payments made for the three and nine months ended September 30, 2023, respectively.
Included in accounts payable were $0 and $45,000 due to related parties as of September 30, 2024 and December 31, 2023, respectively related to this Transition Agreement. There were no amounts included in accrued liabilities as of September 30, 2024 and December 31, 2023 related to the Transition Agreement.
Consulting Agreement - Stan Vashovsky
On March 7, 2024, the Company entered into a separation and consulting agreement (the “Vashovsky Consulting Agreement”) with Stan Vashovsky, who retired as a director and Chair of the Board effective March 31, 2024. Pursuant to the Vashovsky Consulting Agreement, Mr. Vashovsky will continue to serve as a consultant to the Company until March 31, 2025 (such period, the “Vashovsky Consulting Period”). During the Vashovsky Consulting Period, Mr. Vashovsky will provide advisory services as may be requested from time to time by the Company’s executive officers or the Board of Directors and assist with maintaining the Company’s existing customer and investor relationships and, as consideration for his services, receive an equity grant during each quarter of the Vashovsky Consulting Period having a grant date fair value of approximately $35,000. In consideration for a release of claims, Mr. Vashovsky will also be eligible to receive Company-subsidized healthcare coverage for the duration of the Vashovsky Consulting Period. The Vashovsky Consulting Agreement further acknowledges and affirms that Mr. Vashovsky will be bound by and comply with certain restrictive covenants. The Company granted approximately $70,000 in RSUs to Mr. Vashovsky under the Vashovsky Consulting Agreement for the three and nine months ended September 30, 2024.
There were no amounts included in accounts payable and accrued liabilities as of September 30, 2024 and December 31, 2023, related to the Vashovsky Consulting Agreement.
Consulting Agreement - Steven Katz
On September 26, 2024, the Company entered into a transition consulting agreement (the “Katz Consulting Agreement”) with Steven Katz, who resigned as a director and independent Chair of the Board of Directors effective October 1, 2024. Pursuant to the Katz Consulting Agreement, Mr. Katz will serve as a consultant to the Company until December 31, 2024 (the “Katz Consulting Period”). During the Katz Consulting Period, Mr. Katz will provide transition advisory services relating to the Board and its committees as may be requested from time to time by the Company’s executive officers or the Board of Directors.
As compensation for his services during the Katz Consulting Period, and subject to his compliance with the Katz Consulting Agreement, Mr. Katz will receive consulting fees in the amount of (i) $2,500 per month plus (ii) $400 for each hour of services rendered in excess of five hours during each month. During the Katz Consulting Period, Mr. Katz’s equity awards will also continue to vest under the Plan.
There were no amounts included in accounts payable and accrued liabilities as of September 30, 2024 and December 31, 2023 related to the Katz Consulting Agreement.
36

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
17. Income Taxes
As a result of the Company’s history of net operating losses, the Company had historically provided for a full valuation allowance against its deferred tax assets for assets that were not more-likely-than-not to be realized. The Company’s provision for income taxes for the three months ended September 30, 2024 and 2023 were $4,488,828 and $4,526,767, respectively, and $13,316,752 and $2,041,843 for the nine months ended September 30, 2024 and 2023, respectively. In determining the quarterly provision for income taxes, the Company uses an estimated annual effective tax rate adjusted for discrete items. This rate is based on the Company's expected annual income, statutory tax rates and best estimates of non-taxable and non-deductible income and expense items.
18. 401(k) Plan
The Company established a 401(k) plan in January 2022 that qualifies as a deferred compensation arrangement under Section 401 of the Internal Revenue Code. All U.S. employees that complete two months of service with the Company are eligible to participate in the plan. The Company did not make any employer contributions to this plan as of September 30, 2024.
19. Legal Proceedings
From time to time, the Company may be involved as a defendant in legal actions that arise in the normal course of business. In the opinion of management, the Company has adequate legal defense on all legal actions, and the results of any such proceedings would not materially impact the unaudited Condensed Consolidated Financial Statements of the Company. The Company provides disclosure and records loss contingencies in accordance with the loss contingencies accounting guidance. In accordance with such guidance, the Company establishes accruals for such matters when potential losses become probable and can be reasonably estimated. If the Company determines that a loss is reasonably possible and the loss or range of loss can be estimated, the Company discloses the possible loss in the unaudited Condensed Consolidated Financial Statements.
California Labor Actions
On March 30, 2023, Paul Lowe v. Rapid Reliable Testing, LLC, et al. was filed in the Los Angeles Superior Court (the “Lowe Action”). The complaint alleges various wage and hour claims on behalf of the plaintiff and a putative class. The complaint also alleges a derivative class claim for violations of California’s Unfair Competition Law and seeks to bring a representative action pursuant to California’s Private Attorneys General Act of 2004 (“PAGA”).
In addition, Corielyn Marie Hall v. Rapid Reliable Testing, LLC, et al. involves two separate actions filed in the Los Angeles Superior Court by plaintiff Corielyn Hall (collectively with the Lowe Action, the “California Labor Actions”). The first action is a class complaint filed on December 14, 2023. Similar to the Lowe Action, it alleges various wage and hour claims on behalf of the plaintiff and a putative class and asserts a derivative class claim for violations of California’s Unfair Competition Law. The second action brought by Corielyn Hall was filed on February 20, 2024 and brings claims under PAGA.
At the time of this filing, the Company is participating in early mediation with the plaintiffs in the California Labor Actions. Given the overlapping claims and time periods presented in the California Labor Actions, these actions will be mediated concurrently in an effort to reach a global resolution. The Company believes there are substantial defenses to the claims alleged in California Labor Actions. Due to the early stage of these proceedings, the Company cannot reasonably estimate the potential range of loss, if any. The Company intends to vigorously defend itself against these claims if they cannot be resolved during mediation.
Stockholder Actions
On October 27, 2023, Joe Naclerio, individually and purportedly on behalf of all others similarly situated, filed a putative class action complaint for violation of federal securities laws in the U.S. District Court for the Southern District of New York against the Company, its then-Chairman and former Chief Executive Officer, another former Chief Executive Officer, current Chief Financial Officer and former Chief Financial Officer (who currently serves as Executive Vice President of Strategy). On January 17, 2024, the Court appointed the Genesee County Employees’ Retirement System as the Lead Plaintiff. On March 18, 2024, the Lead Plaintiff filed an amended complaint against the Company, its now former
37

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
Chairman and Chief Executive Officer, another former Chief Executive Officer and former Chief Financial Officer (who currently serves as Executive Vice President of Strategy). On June 21, 2024, the defendants moved to dismiss the amended complaint. The motion was fully briefed in September 2024. Due to the early stage of this proceeding, the Company cannot reasonably estimate the potential range of loss, if any. The Company disputes the allegations of wrongdoing and intends to defend itself vigorously in this matter.
On May 30, 2024 and on July 15, 2024, two purported shareholder derivative actions were filed against certain current and former officers and directors of the Company. The Company is named as a nominal defendant in both actions, and the complaints name the Company’s current board of directors, including its Chief Executive Officer and General Counsel, along with two former Chief Executive Officers, the Company’s Chief Financial Officer and Treasurer and its Executive Vice President of Strategy. These actions were filed by Ryne Shetterly in U.S. District Court for the Southern District of New York (the “Shetterly Action”), and Salma Daboul in the Supreme Court for the State of New York (the “Daboul Action”). Both actions purport to assert claims for breach of fiduciary duty and other related claims on behalf of the Company. Both assert factual allegations substantially similar to those asserted in the securities class action matter discussed above, seeking various forms of monetary and injunctive relief. On August 29, 2024, the U.S. District Court for the Southern District of New York issued an order to transfer the Shetterly Action to the United States District Court for the District of Delaware. At the time of this filing, no defendants have been served in the Shetterly Action. On September 6, 2024, the plaintiff in the Daboul Action voluntarily discontinued the action. Due to the early stage of this proceeding, the Company cannot reasonably estimate the potential range of loss, if any. The Company believes there are substantial defenses to these claims.
Cybersecurity Action
On August 22, 2024, Maria Ballesteros, individually and on behalf of others similarly situated, filed a complaint against Ambulnz NY, LLC, a subsidiary of the Company (“Ambulnz NY”), in the U.S. District Court for the Southern District of New York arising from a data security incident that the Company experienced in April 2024 (the “Cybersecurity Action”). The Cybersecurity Action alleges negligence, negligence per se, breach of fiduciary duty, breach of implied contract and violations of California’s Unfair Competition Law, the California Privacy Act and the California Consumer Records Act, and seeks various forms of monetary and injunctive relief. At the time of this filing, Ambulnz NY still has time to respond to the complaint and is participating in early mediation with the plaintiff. Due to the early stage of this proceeding, the Company cannot reasonably estimate the potential range of loss, if any. The Company maintains cybersecurity insurance coverage to limit its exposure to losses relating to cybersecurity incidents, including costs arising from litigation such as the Cybersecurity Action. The Company intends to vigorously defend itself against these claims if they cannot be resolved during mediation.
20. Risk and Uncertainties
Risks, Impacts and Uncertainties
The Company’s current business plan assumes increased demand for Mobile Health Services. Demand for such services was accelerated by the pandemic, but is also being driven by longer-term secular factors, such as the increasing desire on the part of patients to receive treatments outside of traditional settings, such as doctor’s offices and hospitals.
Government Contracts
In recent years, the Company’s government contract work has represented a substantial portion of its overall revenue, and maintaining and continuing to grow this revenues stream is an important part of the Company’s growth strategy. However, government contract work is subject to risks and uncertainties. Government contract work subjects the Company to government audits, investigations and proceedings, which could also lead to the Company to being barred from government work or subjected to fines if it is determined that a statute, rule, regulation, policy or contractual provision has been violated. Audits can also lead to adjustments to the amount of contract costs that the Company believes are reimbursable or to the ultimate amount the Company may be paid under the agreement. Furthermore, a loss of government contract work, if not offset by revenues from new or other existing customers, could have a material adverse effect on the Company’s business, financial condition, and results of operations.
38

Table of Contents
DocGo Inc. and Subsidiaries
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
21. Subsequent Events
Line of Credit
On October 20, 2024, the Company’s unconditional and irrevocable letter of credit from a financial institution in the amount of $1,080,000 automatically renewed for a one-year period ending October 20, 2025. The letter of credit renews automatically for successive one-year periods, unless earlier terminated by the institution.
Effective November 1, 2024, the Company converted its $15,000,000 base rate loan under the terms of the Revolving Facility to a 6-month term SOFR loan, maturing on May 1, 2025.
Series C Preferred Stock Purchase
On November 1, 2024, the Company made a $5,000,000 cash payment to Firefly Health, Inc., a Delaware corporation, in exchange for 798,305 shares of Series C preferred stocks, at a purchase price of $6.26327 per share.
39

Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited Condensed Consolidated Financial Statements and the accompanying notes included elsewhere in this Quarterly Report on Form 10-Q. The discussion and analysis below contain certain forward-looking statements about our business and operations that are subject to risks, uncertainties and other factors described in the sections entitled “Risk Factors” included in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023, and as may be updated in this and other subsequent Quarterly Reports on Form 10-Q. These risks, uncertainties and other factors could cause our actual results to differ materially from those expressed in, or implied by, the forward-looking statements. Please refer to the section below entitled “Cautionary Note Regarding Forward-Looking Statements."
Unless the context requires otherwise, references to the “Company,” “we,” “us,” and “our” refer to the business and operations of DocGo Inc. and its consolidated subsidiaries. Certain figures included in this section, such as interest rates and other percentages, have been rounded for ease of presentation. Percentage figures included in this section have, in some cases, been calculated on the basis of such rounded figures. For this reason, percentage amounts in this section may vary slightly from those obtained by performing the same calculations using the figures in our unaudited Condensed Consolidated Financial Statements or in the accompanying notes. Certain other amounts that appear in this section may similarly not sum due to rounding.
Cautionary Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), regarding, among other things, the plans, strategies, outcomes and prospects, both business and financial, of the Company. These statements are based on the beliefs and assumptions of our management. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, the Company cannot assure you that it will achieve or realize these plans, intentions, outcomes, results or expectations. Accordingly, you should not place undue reliance on such statements. All statements other than statements of historical fact are forward-looking. Forward-looking statements include, but are not limited to, statements concerning our possible or assumed future actions; business strategies, plans and goals; future events; future results of operations, including revenues, expenses or performance; financing needs; business trends; results of operations; objectives and intentions with respect to future operations, services and products, including our geographic expansion; the provision of services under existing contracts, including winding down of migrant-related services; M&A activity; workforce growth; leadership transitions; cash position and liquidity; our share repurchase program; expected impacts of macroeconomic factors, including inflationary pressures and the interest rate environment; our competitive position and opportunities, including our ability to realize the benefits from our operating model and conditions in the healthcare services market; our ability to improve gross margins; cost-containment measures; legislative and regulatory actions; the impact of legal proceedings and compliance risk; the impact on our business and reputation in the event of information technology system failures, network disruptions, cybersecurity incidents or losses or unauthorized access to, or release of, confidential information; the ability of the Company to comply with laws and regulations regarding data privacy and protection; and any statements or assumptions underlying the foregoing. In some cases, these statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “might,” “will,” “should,” “could,” “can,” “would,” “design,” “potential,” “seeks,” “plans,” “scheduled,” “anticipates,” “intends” or the negative of these terms or similar expressions.
Forward-looking statements are inherently subject to substantial risks, uncertainties and assumptions, many of which are beyond our control, and which may cause our actual results or outcomes, or the timing of our results or outcomes, to differ materially from those contained in our forward-looking statements. including, but not limited to the following: impacts related to accelerated wind down of migrant-related services; our ability to expand our programs with insurance partners, hospital systems, municipalities and other strategic partners; our ability to successfully implement our business strategy, including delivering value to shareholders via buybacks, funding new strategic relationships and potentially repaying our line of credit; our ability to establish, maintain and grow customer relationships; our ability to execute projects to the satisfaction of our customers; our ability to grow demand for our care gap closure programs and our cash balances; our reliance on and ability to maintain our contractual relationships with our healthcare provider partners and clients; our ability to compete effectively in a highly competitive industry, including conditions in the healthcare transportation and mobile health services markets; our ability to maintain existing contracts; our reliance on government contracts, including changes in government spending on healthcare and other social services; recent revenue growth derived from a small number of large customers; our ability to effectively manage our growth; our financial performance and future prospects; our ability to deliver on our business strategies or models, plans and goals; our ability to expand geographically; our
40

Table of Contents
M&A activity and success of our acquisition strategy; our ability to retain our workforce and management personnel and successfully manage leadership transitions; the availability of healthcare professionals and other personnel; changes in the cost of labor; our ability to collect on customer receivables; our ability to maintain our cash position; risks associated with our share repurchase program; overall macroeconomic and geopolitical conditions, including the interest rate environment, the inflationary environment, the potential recessionary environment, regional conflict and tensions, financial institution instability and the prospect of a shutdown of the U.S. federal government; production schedules of our suppliers; our ability to obtain or maintain operating licenses; potential changes in federal, state or local government policies regarding immigration and asylum seekers; expected impacts of geopolitical instability; our competitive position and opportunities, including our ability to realize the benefits from our operating model; our ability to improve gross margins; our ability to implement and deliver on cost-containment measures and ongoing cost rationalization initiatives; legislative and regulatory actions; the impact of legal proceedings and compliance risk; volatility of our stock price; the impact on our business and reputation in the event of information technology system failures, network disruptions, cyber incidents or losses or unauthorized access to, or release of, confidential information; our ability to comply with laws and regulations regarding data privacy and protection and other risk factors that are described herein, as well as the risks discussed in Item 1A “Risk Factors” of Part I in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and that are otherwise described or updated from time to time in our filings with the SEC.
Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report on Form 10-Q.
In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Quarterly Report on Form 10-Q, and, while we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.
The forward-looking statements made in this Quarterly Report on Form 10-Q are based on events or circumstances as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this Quarterly Report on Form 10-Q to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect new information or the occurrence of unanticipated events, except as and to the extent required by law. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments.
Overview
The Company is a mobile healthcare services company that uses proprietary dispatch and communication technology to help provide (i) quality mobile, in-person medical treatment directly to patients in the comfort of their homes, workplaces and other non-traditional locations; and (ii) medical transportation in major metropolitan cities in the United States and the United Kingdom.
The Company derives revenue primarily from two operating segments:
•Mobile Health Services: The services offered by this segment include a wide variety of healthcare services performed at homes, offices and other locations and event services such as on-site healthcare support at sporting events and concerts. This segment also provides total care management solutions to large, typically underserved population groups, primarily through arrangements with municipalities, which include healthcare services as well as ancillary services, such as shelter.
•Transportation Services: The services offered by this segment encompass both emergency response and non-emergency transport services. Non-emergency transport services include ambulance transports and wheelchair transports. Net revenue from Transportation Services is derived from the transportation of patients based on billings to third party payors and healthcare facilities.
For the three months ended September 30, 2024, the Company recorded net income of $4.5 million, compared to net income of $4.6 million in the three months ended September 30, 2023.
41

Table of Contents
For the nine months ended September 30, 2024, the Company recorded net income of $21.0 million, compared to net income of $2.1 million in the nine months ended September 30, 2023.
Factors Affecting Our Results of Operations
Our operating results and financial performance are influenced by a variety of factors, including, among others, our ability to establish, maintain and grow customer relationships; our ability to execute projects to the satisfaction of our customers; conditions in the healthcare transportation and mobile health services markets; changes in government spending on healthcare and other social services; availability of healthcare professionals and other personnel; changes in the cost of labor; our competitive environment; overall macroeconomic and geopolitical conditions, including the interest rate environment, the inflationary environment, the potential recessionary environment, regional conflict and tensions, financial institution instability and the prospect of a shutdown of the U.S. federal government; production schedules of our suppliers; our ability to obtain or maintain operating licenses; and the success of our acquisition strategy. Some of these key factors are briefly discussed below. Future revenue growth and improvement in operating results will be largely contingent on our ability to penetrate new markets and further penetrate existing markets, which is subject to a number of uncertainties, many of which are beyond our control.
Healthcare Services Market
The Mobile Health Services market is dependent on several factors, including increased patient acceptance of services that are provided outside of traditional healthcare facilities, such as in homes, businesses or other designated locations; healthcare coverage of the various Mobile Health Services; and continued desire on the part of government and municipal entities to fund programs to assist currently underserved patient segments via “population health” programs. These programs have increased in number, scale and scope since the beginning of COVID-19. While COVID-19 testing and vaccination programs have been dramatically scaled back from their levels at the pandemic’s peak, there have been expansions of these population health programs into other areas, such as the provision of healthcare and related services to recent migrants and asylum seekers.
The Transportation Services market is highly dependent on patients requiring transportation after surgeries and other medical procedures and treatments. The Company primarily focuses on the non-emergency medical transport market, which includes services that are provided to patients who need assistance getting to and from medical appointments. Key drivers of this market are the increase in chronic conditions and the number of elective surgeries as well as the ongoing aging of the population, as the older demographics tend to be much more frequent consumers of medical transportation services. We believe the market will also grow if hospitals and other healthcare facilities continue to outsource more of their transportation needs to independent providers, such as the Company, allowing these facilities to concentrate their efforts on their core competencies.
Overall Economic Conditions in the Markets in Which We Operate
Economic changes both nationally and locally in our markets may impact our financial performance. Unfavorable changes in demographics, healthcare coverage of Mobile Health Services and Transportation Services, interest rates, inflation rates or ambulance manufacturing; a weakening of the national economy or of any regional or local economy in which we operate; and other factors beyond our control could adversely affect our business.
Our Ability to Control Expenses
We pay close attention to the management of our working capital and operating expenses. Some of our most significant operating expenses are labor costs, medical supplies and vehicle-related costs, such as fuel, maintenance, repair and insurance. Insurance costs include premiums paid for coverage as well as reserves for estimated losses within the Company’s insurance policy deductibles. We employ our proprietary technology to help drive improvements in productivity per transport and per shift. We regularly analyze our workforce productivity to help achieve the optimum, cost-efficient labor mix for our locations. This involves managing the mix of company-employed labor and subcontracted labor as well as full-time and part-time employees.
Inflation
The inflation rate in the United States, as measured by the Consumer Price Index, has moderated in 2024, after trending up since early 2021. This data is reported monthly, showing year-over-year changes in prices across a basket of goods and services. Through the first nine months of 2024, the inflation rate has been 3.1%, lower than the 4.1% rate in 2023, 8.0% in 2022 and 4.7% in 2021. As the inflation rate has moderated and there have been emerging signs of a pending economic
42

Table of Contents
slowdown, the U.S. Federal Reserve implemented an interest rate cut of 0.50%, lowering its benchmark rate to the current level of 4.75%-5.00%, after implementing four interest rate hikes in 2023. The inflation rate has had an impact on the Company’s expenses in several areas, including wages, fuel and medical and other supplies. This has had the impact of compressing gross profit margins, as the Company is generally unable to pass these higher costs on to its customers, particularly in the short term. Looking to the remainder of 2024, we anticipate that the inflation rate will continue to be moderate, with additional interest rate cuts a possibility before the end of the year. If inflation is above the levels that the Company anticipates, gross margins could be below plan and our business, operating results and cash flows may be adversely affected.
Trip Volumes and Average Trip Price
A “trip” is defined as an instance where the Company completes the transportation of a patient to a specific destination, for which we are able to charge a fee. This metric does not include instances where a trip is ordered and subsequently either canceled (by the customer) or declined (by the Company). As trip volume represents the most basic unit of transportation service provided by the Company, the Company believes it is a good measure of the level of demand for the Company’s Transportation Services and is used by management to monitor and manage the scale of the business.
The average trip price is calculated by dividing the aggregate revenue from the total number of trips by the total number of trips and is an important indicator of the effective rate at which the Company is being compensated for its provision of Transportation Services.
Revenues generated from programs under which the Company is paid a fixed hourly or daily rate for the use of a fully staffed and equipped ambulance do not factor in the trip counts or average trip prices mentioned above. We expect these fixed rate, “leased hour” programs to continue to account for an increasing proportion of the Transportation Services segment’s revenues in the future.
Acquisitions
Historically, we have pursued an acquisition strategy to obtain enhanced capabilities or licenses to offer Mobile Health Services or Transportation Services. Future acquisitions may also include companies that may help drive revenue, profitability, cash flow and stockholder value.
During the nine months ended September 30, 2024, the Company did not complete any acquisitions. During the nine months ended September 30, 2023, the Company completed three acquisitions for an aggregate purchase price of $34.2 million.
Investing in R&D and Enhancing Our Customer Experience
Our performance is dependent on the investments we make in research and development (“R&D”), including our ability to attract and retain highly skilled R&D personnel. We intend to develop and introduce innovative new software services, integrations with third-party products and services, mobile applications and other new offerings. If we fail to innovate and enhance our brand and our products, our market position and revenue may be adversely affected.
Regulatory Environment
The Company is subject to federal, state and local regulations, including healthcare and emergency medical services laws and regulations and tax laws and regulations. The Company’s current business plan assumes no material change in these laws and regulations. In the event that any such change occurs, compliance with new laws and regulations may significantly affect the Company’s operations and cost of doing business.
Government Contracts
In recent years, the Company’s government contract work has represented a substantial portion of its overall revenue, and maintaining and continuing to grow this revenues stream is an important part of the Company’s growth strategy. However, government contract work is subject to risks and uncertainties. For example, starting in the second quarter of 2023, the Company began providing services to the recent migrant population in New York City and in upstate New York. Some of these services were provided pursuant to a contract with an ending date during the second quarter of 2024. A portion of that contract has been extended through December 31, 2024, while other services began to wind down in May 2024. While the exact timing of the wind-down of the remaining services is still subject to change, the wind-down of sites in both New York City and in upstate New York is well underway and the Company expects that the revenues from these migrant-
43

Table of Contents
related projects will be significantly lower in the final three months of 2024 than they were in any of the first three quarters of the year.
In addition, government contract work subjects the Company to government audits, investigations and proceedings, which could lead to the Company to being barred from government work or subjected to fines if it is determined that a statute, rule, regulation, policy or contractual provision has been violated. Audits can also lead to adjustments to the amount of contract costs that the Company believes are reimbursable or to the ultimate amount the Company may be paid under the agreement. Furthermore, a loss of government contract work, if not offset by revenues from new or other existing customers, could have a material adverse effect on the Company’s business, financial condition and results of operations.
Components of Results of Operations
Our business consists of three reportable segments — Mobile Health Services, Transportation Services and Corporate. All revenues and cost of revenues are contained within the Mobile Health Services and Transportation Services segments. Accordingly, revenues and cost of revenues are discussed below on a consolidated level and are also broken down between Mobile Health Services and Transportation Services. Operating expenses are discussed on a consolidated level and broken down among all three segments. The Company evaluates the performance of each of its segments based primarily on its results of operations. Accordingly, other income and expenses not included in results of operations are only included in the discussion of consolidated results of operations.
Revenues
The Company’s revenues consist of services provided by its Mobile Health Services segment and its Transportation Services segment.
Cost of Revenues
Cost of revenues consists primarily of revenues-generating wages paid to employees, fees paid to subcontractors, medical supplies, vehicle insurance costs (including insurance premiums and costs incurred under the insurance deductibles), maintenance, fuel and facility rent. We expect cost of revenues to continue to rise as we grow our business.
Operating Expenses
General and Administrative Expenses
General and administrative expenses consist primarily of salaries, bad debt expense, insurance expense, consultant fees and professional fees for accounting services. We expect our general and administrative expenses to increase as we continue to scale our business and grow headcount and as a result of operating as a public company, including our compliance with SEC rules and regulations, audit activities, additional insurance expenses, investor relations activities and other administrative and professional services.
Depreciation and Amortization
The Company depreciates its assets using the straight-line method over the estimated useful lives of the respective assets. Amortization of intangibles consists of amortization of definite-lived intangible assets over their respective useful lives.
Legal and Regulatory Expenses
Legal and regulatory expenses include legal fees, consulting fees related to healthcare compliance and legal settlements.
Technology and Development Expenses
Technology and development expenses, net of capitalization, consist primarily of costs incurred in the design and development of the Company’s proprietary technology, third-party software and technologies. We expect technology and development expenses to increase in future periods to support our growth, including our intent to continue investing in the optimization, accuracy and reliability of our dispatch and communication platform and driving efficiency in our operations. These expenses may vary from period to period as a percentage of revenue, depending primarily upon when we choose to make more significant investments, particularly when entering new business lines or customer sales channels.
44

Table of Contents
Sales, Advertising and Marketing Expenses
Our sales, advertising and marketing expenses consist of costs directly associated with our sales and marketing activities, which primarily include sales commissions, marketing programs, trade shows and promotional materials and general branding. We expect our sales, advertising and marketing expenses to continue to increase over time as we increase our marketing activities, grow our domestic and international operations and continue to build brand awareness.
Interest Expense
Interest expense consists primarily of interest on our outstanding borrowings under our outstanding notes payable and financing obligations, including our Revolving Facility.
45

Table of Contents
Results of Operations
Comparison of the Three Months Ended September 30, 2024 and 2023

| Three Months Ended September 30, |  | Change $ |  | Change %
$ in Millions | 2024 |  | 2023 |  |
| Actual Results |  | % of Total Revenues |  | Actual Results |  | % of Total Revenues |  |  |  |
Revenues, net | $ | 138.7 |  |  | 100.0 | % |  | $ | 186.6 |  |  | 100.0 | % |  | $ | (47.9) |  |  | (25.7) | %
Expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of revenues (exclusive of depreciation and amortization, which is shown separately below) | 88.8 |  |  | 64.0 | % |  | 131.5 |  |  | 70.5 | % |  | (42.7) |  |  | (32.5) | %
Operating expenses: |  |  |  |  |  |  |  |  |  |  |
General and administrative | 28.8 |  |  | 20.8 | % |  | 33.6 |  |  | 18.0 | % |  | (4.8) |  |  | (14.3) | %
Depreciation and amortization | 4.2 |  |  | 3.0 | % |  | 4.3 |  |  | 2.3 | % |  | (0.1) |  |  | (2.3) | %
Legal and regulatory | 3.3 |  |  | 2.4 | % |  | 3.5 |  |  | 1.9 | % |  | (0.2) |  |  | (5.7) | %
Technology and development | 3.1 |  |  | 2.2 | % |  | 3.2 |  |  | 1.7 | % |  | (0.1) |  |  | (3.1) | %
Sales, advertising and marketing | 0.4 |  |  | 0.3 | % |  | 1.7 |  |  | 0.9 | % |  | (1.3) |  |  | (76.5) | %
Total expenses | 128.6 |  |  | 92.7 | % |  | 177.8 |  |  | 95.3 | % |  | (49.2) |  |  | (27.7) | %
Income from operations | 10.1 |  |  | 7.3 | % |  | 8.8 |  |  | 4.7 | % |  | 1.3 |  |  | 14.8 | %
Other income (expense): |  |  |  |  |  |  |  |  |  |  |
Interest (expense) income, net | (0.5) |  |  | (0.4) | % |  | 0.3 |  |  | 0.2 | % |  | (0.8) |  |  | (266.7) | %
Change in fair value of contingent liability | — |  |  | — | % |  | 0.2 |  |  | 0.1 | % |  | (0.2) |  |  | (100.0) | %
Loss on equity method investments | (0.1) |  |  | (0.1) | % |  | (0.1) |  |  | (0.1) | % |  | — |  |  | — | %
(Loss) gain on remeasurement of operating and finance leases | — |  |  | — | % |  | — |  |  | — | % |  | — |  |  | — | %
Loss on disposal of fixed assets | — |  |  | — | % |  | — |  |  | — | % |  | — |  |  | — | %
Other income (expense) | (0.4) |  |  | (0.3) | % |  | — |  |  | — | % |  | (0.4) |  |  | (100.0) | %
Total other income (expense) | (1.0) |  |  | (0.7) | % |  | 0.4 |  |  | 0.2 | % |  | (1.4) |  |  | (350.0) | %
Net income before income tax provision | 9.0 |  |  | 6.5 | % |  | 9.2 |  |  | 4.9 | % |  | (0.2) |  |  | (2.2) | %
Provision for income taxes | (4.5) |  |  | (3.2) | % |  | (4.5) |  |  | (2.4) | % |  | — |  |  | — | %
Net income | 4.5 |  |  | 3.2 | % |  | 4.7 |  |  | 2.5 | % |  | (0.2) |  |  | (4.3) | %
Net loss attributable to noncontrolling interests | (1.0) |  |  | (0.7) | % |  | (0.1) |  |  | (0.1) | % |  | (0.9) |  |  | (900.0) | %
Net income attributable to stockholders of DocGo Inc. and Subsidiaries | $ | 5.5 |  |  | 4.0 | % |  | $ | 4.8 |  |  | 2.6 | % |  | $ | 0.7 |  |  | 14.6 | %

46

Table of Contents
Revenues
Consolidated
For the three months ended September 30, 2024, total revenues were $138.7 million, a decrease of $47.9 million, or 25.7%, compared to the three months ended September 30, 2023.
Mobile Health Services
For the three months ended September 30, 2024, Mobile Health Services revenues were $90.7 million, a decrease of $48.6 million, or 34.9%, compared to the three months ended September 30, 2023. The decline in revenues was due to the ongoing wind-down of migrant-related services, which had ramped up sharply in the third quarter of 2023 and peaked in the first quarter of 2024. Starting in the second quarter of 2023, the Company began providing services to the recently arrived migrant population in New York City and in upstate New York. These projects, which included both medical and non-medical services, such as shelter and security, expanded throughout the third and fourth quarters of 2023 and into the first quarter of 2024. However, some of these services were provided pursuant to a contract with an ending date during the second quarter of 2024. A portion of that contract has been extended through December 31, 2024, while other services began to wind down in May 2024. While the exact timing of the wind-down of the remaining services is still subject to change, this process is well underway and the Company expects that the revenues from these migrant-related projects will be lower in the final three months of 2024 than in the final three months of 2023. As such, while we expect to launch new Mobile Health Services projects during the fourth quarter, these are expected be outweighed by a decline in revenues from migrant-related projects and we expect that overall Mobile Health Services revenues will be significantly lower in the fourth quarter of 2024 than in the fourth quarter of 2023.
Transportation Services
For the three months ended September 30, 2024, Transportation Services revenues were $48.0 million, an increase of $0.8 million, or 1.7%, compared to the three months ended September 30, 2023. This increase was due to an 8.5% increase in trip volumes, to 69,776 trips in the three months ended September 30, 2024, from 64,321 trips for the three months ended September 30, 2023. The increase in trip volumes was due to a combination of growth in the Company’s customer base in certain core markets and increased volumes with existing customers. Our average trip price decreased to $404 in the three months ended September 30, 2024, from $409 in the three months ended September 30, 2023. The decline in the average trip price in the 2024 period reflected a shift in mix toward lower-priced transports when compared to the same period in 2023. However, the average trip price remains well above the levels of early 2022, reflecting a shift in mix toward higher-priced transports with existing customers, as well as the acquisition of licenses to provide higher acuity transports that earn higher prices per trip.
Cost of revenues
For the three months ended September 30, 2024, total cost of revenues (exclusive of depreciation and amortization) decreased by 32.5% compared to the three months ended September 30, 2023, while revenues decreased by approximately 25.7%. Cost of revenues as a percentage of revenues decreased to 64.0% in the three months ended September 30, 2024 from 70.5% in the three months ended September 30, 2023.
Total cost of revenues in the three months ended September 30, 2024 decreased by $42.7 million compared to the same period in 2023. This decrease was primarily attributable to an $8.2 million decrease in total compensation, a $21.1 million decline in subcontracted labor costs and a $10.7 million decline in medical and related supplies, all of which were driven by the Mobile Health Services segment, due to the ongoing wind-down of migrant-related projects during the quarter; a $2.8 million decrease in lab fees; and a $0.1 million net increase in other cost of revenues categories.
For the Mobile Health Services segment, cost of revenues (exclusive of depreciation and amortization) in the three months ended September 30, 2024 amounted to $55.5 million, down 44.1% from $99.3 million in the three months ended September 30, 2023. Cost of revenues as a percentage of revenues decreased to 61.2% from 71.2% in the prior year period, despite the decline in Mobile Health Services revenues, due to the absence of certain project ramp-up costs in the form of higher overtime rates and a greater proportion of higher-cost subcontracted labor that were recorded in the prior year period.
For the Transportation Services segment, cost of revenues (exclusive of depreciation and amortization) in the three months ended September 30, 2024 amounted to $33.3 million, up 3.4% from $32.2 million in the three months ended September 30, 2023. Cost of revenues as a percentage of revenues increased to 69.4% from 68.3% in the prior year quarter,
47

Table of Contents
as the increase in cost of revenues outpaced the small increase in revenues. Total compensation increased by 4% year-over-year, reflecting increased field headcount, as the Company seeks to reduce its reliance on subcontractors. Costs for subcontractors were essentially unchanged from the prior year period, but declined from the levels recorded in the second quarter of 2024, reflecting a planned reduction in the number of ambulance trips that were completed by subcontractors in instances where the Company previously did not have sufficient personnel capacity to provide the requested services.
Operating expenses
For the three months ended September 30, 2024, the Company recorded $39.8 million of operating expenses compared to $46.4 million for the three months ended September 30, 2023, a decrease of 14.2%. As a percentage of revenue, operating expenses increased from 24.9% in the third quarter of 2023 to 28.7% in the third quarter of 2024, reflecting the decrease in revenues described above. The decrease of $6.6 million of operating expenses related to a $2.7 million decline in total compensation, a $1.1 million decline in commissions, and a $4.7 million decrease in travel-related expenses, all due to the ongoing wind-down of the Mobile Health Services segment’s migrant-related projects. These declines were partially offset by a net $1.9 million increase spread across a variety of other operating expense categories. The Company anticipates that operating expenses will continue to fluctuate based upon the levels of revenues that are generated.
For the Mobile Health Services segment, operating expenses in the three months ended September 30, 2024 were $13.2 million, down from $19.0 million in the three months ended September 30, 2023. Operating expenses as a percentage of revenues increased to 14.6% in the third quarter of 2024, from 13.4% in the third quarter of 2023, reflecting the drop in Mobile Health Services revenues in relation to the ongoing wind-down of migrant-related projects in New York.
For the Transportation Services segment, operating expenses in the three months ended September 30, 2024 were $14.8 million, compared to $14.5 million in the three months ended September 30, 2023. Operating expenses as a percentage of revenues increased to 30.8% for the three months ended September 30, 2024 from 30.6% in the three months ended September 30, 2023, despite the increased revenues in the current year period, reflecting increases in non-field headcount, such as dispatch and back office departments, as well as higher insurance costs, due to a larger vehicle fleet.
For the Corporate segment, which represents primarily shared services that are not contained within the entities included in either the Mobile Health Services or Transportation Services segments, operating expenses in the three months ended September 30, 2024 were $11.8 million, compared to $12.9 million in the three months ended September 30, 2023. Corporate expenses amounted to approximately 8.5% of total consolidated revenues in the third quarter of 2024, compared to 6.9% in the third quarter of 2023, reflecting the decline in total consolidated revenues, which outweighed the effect of corporate expense reduction programs implemented at the end of 2023 and in early 2024.
Interest (expense) income, net
For the three months ended September 30, 2024, the Company recorded $0.5 million of interest expense, net compared to $0.3 million of interest income, net in the three months ended September 30, 2023. Interest expenses on borrowings under the Revolving Facility outweighed interest earned on balances in the Company’s interest-bearing accounts in the three months ended September 30, 2024.
Change in fair value of contingent liability
During the three months ended September 30, 2024, the Company recorded a loss for the change in fair value of contingent consideration of $44,520 compared to a gain of $159,974 in the three months ended September 30, 2023.
Loss on equity method investments
During the three months ended September 30, 2024, the Company recorded a loss on equity method investments of $0.1 million, representing its share of the losses incurred by an entity in which the Company has a minority interest. During the three months ended September 30, 2023, the Company also recorded a loss on equity method investments of $0.1 million.
Loss on disposal of fixed assets
During the three months ended September 30, 2024, the Company recorded a loss on the disposal of fixed assets of $28,681, compared to a loss on the disposal of fixed assets of $9,983 during the three months ended September 30, 2023.
48

Table of Contents
Other income (expense)
During the three months ended September 30, 2024, the Company recorded other expense of $0.4 million, compared to other income of $43,353 in the three months ended September 30, 2023.
Provision for income taxes
During the three months ended September 30, 2024, the Company recorded an income tax provision of $4.5 million, compared to an income tax provision of $4.5 million in the three months ended September 30, 2023. The slightly lower tax expense in the 2024 period was due to a small decline in pretax income in the 2024 period.
Net loss attributable to noncontrolling interests
For the three months ended September 30, 2024, the Company had net loss attributable to noncontrolling interests of approximately $1.0 million, compared to net loss attributable to noncontrolling interests of approximately $0.1 million for the three months ended September 30, 2023.
Comparison of the Nine Months Ended September 30, 2024 and 2023
49

Table of Contents

| Nine Months Ended September 30, |  | Change $ |  | Change %
$ in Millions | 2024 |  | 2023 |  |
| Actual Results |  | % of Total Revenues |  | Actual Results |  | % of Total Revenues |  |  |  |
Revenues, net | $ | 495.7 |  |  | 100.0 | % |  | $ | 425.0 |  |  | 100.0 | % |  | $ | 70.7 |  |  | 16.6 | %
Expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of revenues (exclusive of depreciation and amortization, which is shown separately below) | 322.6 |  |  | 65.1 | % |  | 296.3 |  |  | 69.7 | % |  | 26.3 |  |  | 8.9 | %
Operating expenses: |  |  |  |  |  |  |  |  |  |  |
General and administrative | 103.7 |  |  | 20.9 | % |  | 93.6 |  |  | 22.0 | % |  | 10.1 |  |  | 10.8 | %
Depreciation and amortization | 12.6 |  |  | 2.5 | % |  | 11.8 |  |  | 2.8 | % |  | 0.8 |  |  | 6.8 | %
Legal and regulatory | 11.6 |  |  | 2.3 | % |  | 9.6 |  |  | 2.3 | % |  | 2.0 |  |  | 20.8 | %
Technology and development | 7.9 |  |  | 1.6 | % |  | 7.7 |  |  | 1.8 | % |  | 0.2 |  |  | 2.6 | %
Sales, advertising and marketing | 1.1 |  |  | 0.2 | % |  | 2.6 |  |  | 0.6 | % |  | (1.5) |  |  | (57.7) | %
Total expenses | 459.5 |  |  | 92.7 | % |  | 421.6 |  |  | 99.2 | % |  | 37.9 |  |  | 9.0 | %
Income from operations | 36.2 |  |  | 7.3 | % |  | 3.4 |  |  | 0.8 | % |  | 32.8 |  |  | 964.7 | %
Other income (expense): |  |  |  |  |  |  |  |  |  |  |
Interest (expense) income, net | (1.4) |  |  | (0.3) | % |  | 1.7 |  |  | 0.4 | % |  | (3.1) |  |  | (182.4) | %
Change in fair value of contingent liability | (0.4) |  |  | (0.1) | % |  | 0.2 |  |  | — | % |  | (0.6) |  |  | (300.0) | %
Loss on equity method investments | (0.2) |  |  | — | % |  | (0.3) |  |  | (0.1) | % |  | 0.1 |  |  | 33.3 | %
(Loss) gain on remeasurement of operating and finance leases | — |  |  | — | % |  | — |  |  | — | % |  | — |  |  | — | %
Gain (loss) on disposal of fixed assets | — |  |  | — | % |  | (0.2) |  |  | — | % |  | 0.2 |  |  | 100.0 | %
Other income (expense) | 0.1 |  |  | — | % |  | (0.7) |  |  | (0.2) | % |  | 0.8 |  |  | 114.3 | %
Total other income (expense) | (1.9) |  |  | (0.4) | % |  | 0.7 |  |  | 0.2 | % |  | (2.6) |  |  | (371.4) | %
Net income before income tax provision | 34.3 |  |  | 6.9 | % |  | 4.1 |  |  | 1.0 | % |  | 30.2 |  |  | 736.6 | %
Provision for income taxes | (13.3) |  |  | (2.7) | % |  | (2.0) |  |  | (0.5) | % |  | (11.3) |  |  | (565.0) | %
Net income | 21.0 |  |  | 4.2 | % |  | 2.1 |  |  | 0.5 | % |  | 18.9 |  |  | 900.0 | %
Net income (loss) attributable to noncontrolling interests | (2.2) |  |  | (0.4) | % |  | 2.8 |  |  | 0.7 | % |  | (5.0) |  |  | (178.6) | %
Net income (loss) attributable to stockholders of DocGo Inc. and Subsidiaries | $ | 23.2 |  |  | 4.7 | % |  | $ | (0.7) |  |  | (0.2) | % |  | $ | 23.9 |  |  | 3414.3 | %

Revenues
Consolidated
For the nine months ended September 30, 2024, total revenues were $495.7 million, an increase of $70.7 million, or 16.6%, compared to the nine months ended September 30, 2023.
Mobile Health Services
For the nine months ended September 30, 2024, Mobile Health Services revenues were $351.3 million, an increase of $59.0 million, or 20.2%, compared to the nine months ended September 30, 2023. The increase in revenues was primarily
50

Table of Contents
due to an expansion in services offered by the Mobile Health Services segment, particularly in the government customer sector. Specifically, starting in the second quarter of 2023, the Company began providing services to the recently arrived migrant population in New York City and in upstate New York. These projects, which included both medical and non-medical services, such as shelter and security, expanded throughout the third and fourth quarters of 2023 and into the first quarter of 2024. However, some of these services were provided pursuant to a contract with an ending date during the second quarter of 2024. A portion of that contract has been extended through December 31, 2024, while other services began to wind down in May 2024, with the wind-down accelerating, as expected, during the third quarter of 2024. While the exact timing of the wind-down of the remaining services is still subject to change, the process is well underway and the Company expects that the revenues from these migrant-related projects will be significantly lower in the fourth quarter of 2024 than in any of the first three quarters of the year. As such, while we expect to launch new Mobile Health Services projects during the last quarter of the year, these are expected to be outweighed by a decline in revenues from migrant-related projects and we expect that overall Mobile Health Services revenues will be significantly lower in the fourth quarter of 2024 than in the fourth quarter of 2023.
Transportation Services
For the nine months ended September 30, 2024, Transportation Services revenues were $144.4 million, an increase of $11.7 million, or 8.8%, compared to the nine months ended September 30, 2023. This increase was due to a 15.1% increase in trip volumes, to 213,475 trips in the nine months ended September 30, 2024, from 185,404 trips for the nine months ended September 30, 2023. The increase in trip volumes was due to a combination of growth in the Company’s customer base in certain core markets and increased volumes with existing customers. Our average trip price declined to $399 in the nine months ended September 30, 2024, from $405 in the nine months ended September 30, 2023. The decline in the average trip price in the 2024 period reflected a small shift in mix toward lower-priced transports when compared to the first nine months of 2023. However, the average trip price remains well above the levels of early 2022, reflecting a shift in mix toward higher-priced transports with existing customers, as well as the acquisition of licenses to provide higher acuity transports that earn higher prices per trip.
Cost of revenues
For the nine months ended September 30, 2024, total cost of revenues (exclusive of depreciation and amortization) increased by 8.9% compared to the nine months ended September 30, 2023, while revenues increased by approximately 16.6%. Cost of revenues as a percentage of revenues decreased to 65.1% in the nine months ended September 30, 2024 from 69.7% in the nine months ended September 30, 2023.
Total cost of revenues in the nine months ended September 30, 2024 increased by $26.3 million compared to the same period in 2023. This increase was primarily attributable to a $12.8 million increase in subcontracted labor costs, primarily driven by projects in both segments that required more personnel than the Company was able to initially provide through its existing staff; a $6.3 million increase in medical and related supplies, also related to an increase in projects, particularly in the first six months of 2024; and a $7.2 million net increase in other cost of revenues categories, including insurance.
For the Mobile Health Services segment, cost of revenues (exclusive of depreciation and amortization) in the nine months ended September 30, 2024 amounted to $223.2 million, up 9.3% from $204.1 million in the nine months ended September 30, 2023. Cost of revenues as a percentage of revenues decreased to 63.5% from 69.8% in the prior year period, due to an increase in revenues and the absence of certain project ramp-up costs in the form of higher overtime rates and a greater proportion of subcontracted labor that were recorded in the prior year period.
For the Transportation Services segment, cost of revenues (exclusive of depreciation and amortization) in the nine months ended September 30, 2024 amounted to $99.4 million, up 7.8% from $92.2 million in the nine months ended September 30, 2023. Cost of revenues as a percentage of revenues decreased to 68.8% from 69.5% in the prior year quarter, reflecting the impact of increased revenues from standby contracts (for which we are paid a daily or hourly rate) and the overall increase in revenue.
Operating expenses
For the nine months ended September 30, 2024, the Company recorded $136.9 million of operating expenses compared to $125.3 million for the nine months ended September 30, 2023, an increase of 9.3%. As a percentage of revenue, operating expenses decreased from 29.5% in the first nine months of 2023 to 27.6% in the first nine months of 2024, reflecting the increase in revenues described above. The increase of $11.6 million of operating expenses related primarily to a $0.9 million increase in depreciation and amortization due to an increase in assets to support revenue growth, capitalized software amortization and assets that were added as part of acquisitions that the Company completed during 2023; a $0.6
51

Table of Contents
million increase in IT infrastructure, driven by the Company’s business and headcount expansion and acquisitions; a $1.9 million increase in professional fees, including higher audit fees resulting from the growth of the business; a $3.5 million increase in bad debt expense, reflecting the growth of the business and related increase in accounts receivable; and a net $4.7 million increase spread across a variety of other operating expense categories. The Company anticipates that operating expenses will continue to fluctuate based upon the levels of revenues that are generated.
For the Mobile Health Services segment, operating expenses in the nine months ended September 30, 2024 were $47.9 million, up from $36.1 million in the nine months ended September 30, 2023. Operating expenses as a percentage of revenues increased to 13.6% in the first nine months of 2024, from 12.3% in the first nine months of 2023, reflecting significant expenditures that were made in the second half of 2023 and the early part of 2024 in the expansion of services, particular in relation to the migrant-related projects in New York; as well as the continued buildout of the Mobile Health Services management infrastructure.
For the Transportation Services segment, operating expenses in the nine months ended September 30, 2024 were $46.1 million, compared to $39.6 million in the nine months ended September 30, 2023. Operating expenses as a percentage of revenues increased to 31.9% for the nine months ended September 30, 2024 from 29.9% in the nine months ended September 30, 2023, despite the increased revenues in the current year period, reflecting increases in non-field headcount, such as dispatch and back office departments, as well as higher insurance costs, due to a larger vehicle fleet during 2024 to date.
For the Corporate segment, which represents primarily shared services that are not contained within the entities included in either the Mobile Health Services or Transportation Services segments, operating expenses in the nine months ended September 30, 2024 were $42.9 million, compared to $49.6 million in the nine months ended September 30, 2023. Corporate expenses amounted to approximately 8.7% of total consolidated revenues in the first nine months of 2024, compared to 11.7% in the first nine months of 2023, reflecting the increase in total consolidated revenues as well as some corporate expense reduction programs implemented at the end of 2023 and in early 2024.
Interest (expense) income, net
For the nine months ended September 30, 2024, the Company recorded $1.4 million of interest expense, net compared to $1.7 million of interest income, net in the nine months ended September 30, 2023. Interest expenses on borrowings under the Revolving Facility outweighed interest earned on balances in the Company’s interest-bearing accounts in the nine months ended September 30, 2024, while average cash balances in these accounts were also lower when compared to the nine months ended September 30, 2024.
Change in fair value of contingent liability
During the nine months ended September 30, 2024, the Company recorded a loss for the change in fair value of contingent consideration of $0.4 million compared to a $0.2 million gain related to a change in fair value recorded in the nine months ended September 30, 2023.
Loss on equity method investments
During the nine months ended September 30, 2024, the Company recorded a loss on equity method investments of $0.2 million, representing its share of the losses incurred by an entity in which the Company has a minority interest. During the nine months ended September 30, 2023, the Company recorded a loss on equity method investments of $0.3 million.
Gain (loss) on disposal of fixed assets
During the nine months ended September 30, 2024, the Company recorded a gain on the disposal of fixed assets of $36,717 compared to a loss on the disposal of fixed assets of $163,452 during the nine months ended September 30, 2023.
Other income (expense)
During the nine months ended September 30, 2024, the Company recorded other income of $0.1 million, compared to other expense of $0.7 million in the nine months ended September 30, 2023.
Provision for income taxes
During the nine months ended September 30, 2024, the Company recorded an income tax provision of $13.3 million, compared to an income tax provision of $2.0 million in the nine months ended September 30, 2023. The increased tax
52

Table of Contents
expense in the 2024 period was due to the recording of significantly higher pretax income in the 2024 period, as compared to the 2023 period.
Net income (loss) attributable to noncontrolling interests
For the nine months ended September 30, 2024, the Company had a net loss attributable to noncontrolling interests of approximately $2.2 million, compared to net income attributable to noncontrolling interests of approximately $2.8 million for the nine months ended September 30, 2023.
Liquidity and Capital Resources
Between the inception of the Company’s wholly owned subsidiary Ambulnz and the Business Combination, Ambulnz completed three equity financing transactions as its principal source of liquidity. In November 2021, upon the completion of the Business Combination and the PIPE Financing, the Company received proceeds of approximately $158.1 million, net of transaction expenses. Generally, the Company has utilized proceeds from the equity financing transactions and the Business Combination to finance operations, invest in assets, make acquisitions and fund accounts receivable. The Company has also funded these activities through operating cash flows. Despite the fact that the Company generated net income and operating cash flow for the nine months ended September 30, 2024, operating cash flows are not always sufficient to meet immediate obligations arising from current operations. For example, as the business has grown, the Company’s expenditures for human capital and supplies have expanded accordingly, and the timing of the payments for payroll and to associated vendors, compared to the timing of receipts of cash from customers, frequently results in the need to use existing cash balances to fund working capital needs. During the nine months ended September 30, 2024, as a greater proportion of the Company’s overall revenues were generated through services provided to municipal customers with long payment cycles, and expenditures made by the Company to allow for the provision of these services were substantial, near-term operating cash flows were not always sufficient to meet these demands for working capital, leading to fluctuations in the Company’s cash balances. As these invoices are collected, the Company expects cash flows to be sufficient for near term working capital needs.
The Company’s future working capital needs depend on many factors, including the overall growth of the Company and the various payment terms that are negotiated with customers and vendors. The Company’s future capital requirements depend on many factors, including potential acquisitions, the Company’s level of investment in technology and ongoing technology development, and rate of growth in existing markets and into new markets. Capital requirements might also be affected by factors outside of the Company’s control, such as interest rates, rising inflation and other monetary and fiscal policy changes to the manner in which the Company currently operates. If the Company’s growth rate is higher than is currently anticipated, resulting in greater-than-anticipated capital requirements, the Company might need to, or choose to, raise additional capital through debt or equity financings. This last factor has been evident at different times during the second half of 2023 and during the first quarter of 2024, leading to a draw down in the Company’s credit line during the fourth quarter of 2023 and during the first quarter of 2024, as described below.
On November 1, 2022, the Company entered into the Credit Agreement, which provides for the Revolving Facility in the initial aggregate principal amount of $90.0 million. The Revolving Facility includes the ability for the Company to request an increase to the commitment by an additional amount of up to $50.0 million, though no lender (nor the lenders collectively) is obligated to increase its respective commitments. Borrowings under the Revolving Facility bear interest at a per annum rate equal to (i) at the Company’s option, (x) the base rate or (y) the adjusted term SOFR rate, plus (ii) the applicable margin. The applicable margins are based on the Company’s consolidated net leverage ratio, adjusted on a quarterly basis. The initial applicable margins were 1.25% for an adjusted term SOFR loan and 0.25% for a base rate loan and are updated based on the Company’s consolidated net leverage ratio. The Revolving Facility matures on November 1, 2027 and is secured by a first-priority lien on substantially all of the Company’s present and future personal assets and intangible assets. The Revolving Facility is subject to certain financial covenants, such as a net leverage ratio and interest coverage ratio, as defined in the Credit Agreement. On October 19, 2023, the Company drew down $25.0 million under the Revolving Facility. On February 8, 2024, the Company drew down an additional $15.0 million. On February 27, 2024, the Company repaid all amounts then outstanding under the Revolving Facility. However, in March 2024, the Company once again drew down under the Revolving Facility, and there was a total of $30.0 million outstanding as of the date of this Quarterly Report on Form 10-Q.
Considering the foregoing, the Company anticipates that its existing balances of cash and cash equivalents, future expected cash flows generated from its operations and amounts available under the Revolving Facility will be sufficient to satisfy operating requirements for at least the next twelve months. Looking beyond the next twelve months, the Company
53

Table of Contents
anticipates that expected future cash flows, amounts available under the Revolving Facility and proceeds from potential additional financings will be sufficient to satisfy any operating and potential investing requirements.
Capital Resources
Working capital as of September 30, 2024 and December 31, 2023 was as follows:

| September 30 |  | December 31 |  | Change $ |  | Change %
$ in Millions | 2024 |  | 2023 |  |
Working capital |  |  |  |  |  |  |
Current assets | $ | 328.3 |  |  | $ | 338.9 |  |  | $ | (10.6) |  |  | (3.1) | %
Current liabilities | 150.2 |  |  | 170.1 |  |  | (19.9) |  |  | (11.7) | %
Total working capital | $ | 178.1 |  |  | $ | 168.8 |  |  | $ | 9.3 |  |  | 5.5 | %

As of September 30, 2024, available cash totaled $89.5 million, which represented an increase of $30.2 million compared to December 31, 2023, reflecting a decline in accounts receivable during the nine months ended September 30, 2024, as the Company collected some of its larger invoices. As of September 30, 2024, working capital amounted to $178.1 million, which represented an increase of $9.3 million compared to December 31, 2023, as an increase in cash and a decline in accrued liabilities outweighed a decline in accounts receivable. Current assets declined by $10.6 million, due to a drop in prepaid expenses. However, this was outweighed by the decline in current liabilities in the nine months ended September 30, 2024, due to lower accrued liabilities, reflecting lower invoices and accrued liabilities in the current period for certain expenses, such as subcontracted labor, and as the Company paid down a significant amount of its accrued liabilities during the year-to-date period.
Cash Flows
Cash flows as of the nine months ended September 30, 2024 and 2023 were as follows:

| Nine Months Ended September 30, |  | Change $ |  | Change %
$ in Millions | 2024 |  | 2023 |  |
Cash flow summary |  |  |  |  |  |  |
Net cash provided by (used in) operating activities | $ | 57.4 |  |  | $ | (58.3) |  |  | $ | 115.7 |  |  | 198.5 | %
Net cash used in investing activities | (5.3) |  |  | (26.9) |  |  | 21.6 |  |  | 80.3 | %
Net cash used in financing activities | (16.3) |  |  | (11.9) |  |  | (4.4) |  |  | (37.0) | %
Effect of exchange rate changes | 0.5 |  |  | 0.2 |  |  | 0.3 |  |  | 150.0 | %
Net increase (decrease) in cash | $ | 36.3 |  |  | $ | (96.9) |  |  | $ | 133.2 |  |  | 137.5 | %

Operating Activities
During the nine months ended September 30, 2024, operating activities provided $57.4 million of cash, aided by net income of $21.0 million. Non-cash charges amounted to $21.5 million and included $7.7 million in depreciation of property and equipment and right-of-use assets, $4.9 million from amortization of intangible assets, $9.7 million of stock compensation expense, bad debt expense of $3.8 million, a loss of $0.2 million from an investment that is accounted for under the equity method and a change in the fair value of contingent consideration of $0.4 million. These were partially offset by $5.2 million in deferred taxes. Changes in assets and liabilities resulted in approximately $14.9 million in positive operating cash flow, as a $19.8 million decline in accounts receivable, reflecting collections of invoices from large municipal customers, a $12.3 million decrease in prepaid expenses and other current assets and a $15.3 million increase in accounts payable outweighed a $31.5 million decline in accrued liabilities and a $1.0 million increase in other assets.
During the nine months ended September 30, 2023, operating activities used $58.3 million of cash, despite net income of $2.1 million. Non-cash charges amounted to $28.1 million and included $7.5 million in depreciation of property and equipment and right-of-use assets, $4.3 million from amortization of intangible assets, $15.2 million of stock compensation expense, a $0.2 million loss on the disposal of assets, a loss of $0.3 million from an investment that is accounted for under the equity method, and $1.0 million in deferred taxes. These were partially offset by a $0.3 million reduction in bad debt
54

Table of Contents
expense and a non-cash gain of $0.2 million resulting from a reduction in the fair value of contingent consideration. Changes in assets and liabilities resulted in approximately $88.4 million in negative operating cash flow, as a $103.5 million increase in accounts receivable, reflecting the growth of the business and primarily driven by an increased amount of business with municipalities, which tend to have longer payment cycles, a $12.6 million decrease in accounts payable, and a $0.3 million increase in prepaid expenses and other current assets were partially offset by a $27.3 million increase in accrued liabilities and a $0.7 million decline in other assets.
Investing Activities
During the nine months ended September 30, 2024, investing activities used $5.3 million of cash and consisted of the acquisition of property and equipment totaling approximately $2.9 million, the acquisition of intangibles in the amount of $2.2 million and an equity method investment in the amount of $0.3 million, partially offset by $0.1 million in cash proceeds from the disposal of property and equipment.
During the nine months ended September 30, 2023, investing activities used $26.9 million of cash and consisted of the acquisition of property and equipment totaling approximately $4.4 million, the acquisition of intangibles in the amount of $2.5 million, the acquisition of businesses in the amount of $20.2 million, and an equity method investment in the amount of $0.2 million, partially offset by $0.3 million in cash proceeds from the disposal of property and equipment.
Financing Activities
During the nine months ended September 30, 2024, financing activities used $16.3 million of cash, as $45.0 million in proceeds from the Revolving Facility were mostly offset by $40.0 million in repayments of the Revolving Facility. In addition, the Company spent approximately $11.1 million on its share repurchase program, $3.1 million in payments under the terms of a finance lease, $3.0 million in payments of amounts due to seller, $1.8 million in the acquisition of noncontrolling interest, $1.6 million in earnout payments on contingent liabilities, $0.3 million in dividends paid to a noncontrolling interest and $0.4 million in taxes related to shares withheld for employee taxes.
During the nine months ended September 30, 2023, financing activities used $11.9 million of cash, primarily due to a $8.4 million decrease in amounts due to seller, relating to payments made for acquisitions that were completed in the second half of 2022 and second quarter of 2023; $2.3 million in payments on obligations under the terms of finance leases; $2.2 million in payments for taxes related to shares withheld for employee taxes; and $0.5 million in repayments of notes payable. These amounts were partially offset by $1.5 million in proceeds from the exercise of stock options.
Future minimum annual maturities of notes payable as of September 30, 2024 are as follows (in thousands):

| Notes Payable
2024, remaining | $ | 6.5 |
2025 | 26.5 |
2026 | 14.6 |
Total maturities | 47.6 |
Current portion of notes payable | (26.3) |
Long-term portion of notes payable | $ | 21.3 |

55

Table of Contents
Future minimum lease payments under finance leases as of September 30, 2024 are as follows (in millions):

| Finance Leases
2024, remaining | $ | 1.3 |
2025 | 5.0 |
2026 | 4.2 |
2027 | 2.9 |
2028 | 1.7 |
Thereafter | 0.4 |
Total future minimum lease payments | 15.5 |
Less effects of discounting | (1.5) |
Present value of future minimum lease payments | $ | 14.0 |

Future minimum lease payments under operating leases as of September 30, 2024 are as follows (in millions):

| Operating Leases
2024, remaining | $ | 1.1 |
2025 | 4.4 |
2026 | 3.6 |
2027 | 2.4 |
2028 | 1.8 |
Thereafter | 1.2 |
Total future minimum lease payments | 14.5 |
Less effects of discounting | (1.6) |
Present value of future minimum lease payments | $ | 12.9 |

Critical Accounting Estimates
Basis of Presentation
The Company’s unaudited Condensed Consolidated Financial Statements are presented in conformity with U.S. GAAP and pursuant to the rules and regulations of the SEC. The unaudited Condensed Consolidated Financial Statements include the accounts and operations of the Company and its subsidiaries. All intercompany accounts and transactions are eliminated upon consolidation. Noncontrolling interests in the unaudited Condensed Consolidated Financial Statements represent the portion of consolidated joint ventures and VIEs in which the Company does not have direct equity ownership.
The Business Combination was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, the Company was treated as the “acquired” company for financial reporting purposes. Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of Ambulnz stock for the net assets of the Company, accompanied by a recapitalization. The net assets of the Company are stated at historical cost, with no goodwill or other intangible assets recorded. The consolidated assets, liabilities and results of operations prior to the Reverse Recapitalization are those of Ambulnz. The shares and corresponding capital amounts and earnings per share available for common stockholders prior to the Business Combination have been retroactively restated as shares reflecting the exchange ratio (645.1452 to 1) established in the Business Combination. Further, Ambulnz was determined to be the accounting acquirer in the Business Combination, and as such, the Business Combination is considered a business combination under ASC 805 and was accounted for using the acquisition method of accounting.
Principles of Consolidation
The Company’s unaudited Condensed Consolidated Financial Statements include the accounts of DocGo Inc. and its subsidiaries. All significant intercompany transactions and balances have been eliminated in these unaudited Condensed Consolidated Financial Statements.
56

Table of Contents
The Company holds variable interests in legal entities that contract with physicians and other health professionals that provide services on behalf of the Company. These entities are considered VIEs since they do not have sufficient equity to finance their activities without additional subordinated financial support. An enterprise having a controlling financial interest in a VIE must consolidate the VIE if it is the primary beneficiary, meaning it has (1) the power to direct the activities of the VIE that most significantly impacts the VIE’s economic performance (power) and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE (benefits). The Company has the power and rights to control all activities of its VIEs and funds and absorbs all losses of its VIEs. The Company has determined that it is the primary beneficiary of its VIEs and therefore appropriately consolidates its VIEs.
Net income (loss) for the Company’s VIEs was $(67,785) and $(103,378) for the three months ended September 30, 2024 and 2023, respectively, and $(425,668) and $16,839 for the nine months ended September 30, 2024 and 2023, respectively. Total assets amounted to $11,844,062 and $4,364,274 as of September 30, 2024 and December 31, 2023, respectively. Total liabilities were $12,717,312 and $4,811,857 as of September 30, 2024 and December 31, 2023, respectively. The Company’s VIEs’ total stockholders’ deficit was $873,250 and $447,583 as of September 30, 2024 and December 31, 2023, respectively.
Business Combination
The Company accounts for its business combinations under the provisions of ASC 805-10, which requires that the acquisition method of accounting be used for all business combinations. Assets acquired and liabilities assumed, including noncontrolling interests, are recorded at the date of acquisition at their respective fair values. ASC 805-10 also specifies criteria that intangible assets acquired in a business combination must meet to be recognized and reported apart from goodwill.
Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. If the business combination provides for contingent consideration, the Company records the contingent consideration at fair value at the acquisition date and any changes in fair value after the acquisition date are accounted for as measurement-period adjustments. Changes in fair value of contingent consideration resulting from events after the acquisition date, such as earn-outs, are recognized as follows: 1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or 2) if the contingent consideration is classified as a liability, the changes in fair value are recognized in earnings. For transactions that are business combinations, the Company evaluates the existence of goodwill or a gain from a bargain purchase. The Company capitalizes acquisition-related costs and fees associated with asset acquisitions and immediately expenses acquisition-related costs and fees associated with business combinations.
The estimated fair value of net assets to be acquired, including the allocation of the fair value to identifiable assets and liabilities, is determined using established valuation techniques. Management uses assumptions on the basis of historical knowledge of the business and projected financial information of the target. These assumptions may vary based on future events, perceptions of different market participants and other factors outside the control of management, and such variations may be significant to estimated values.
Goodwill and Indefinite-Lived Intangible Assets
Goodwill represents the excess of the total purchase consideration over the fair value of the identifiable assets acquired and liabilities assumed in a business combination. Goodwill is not amortized but is tested for impairment at the reporting unit level annually on December 31 or more frequently if events or changes in circumstances indicate that it is more likely than not to be impaired. These events include: (i) severe adverse industry or economic trends; (ii) significant company-specific actions, including exiting an activity in conjunction with restructuring of operations; (iii) current, historical or projected deterioration of our financial performance; or (iv) a sustained decrease in our market capitalization, as indicated by our publicly quoted share price, below our net book value.
On February 3, 2023, Health commenced an ABC pursuant to California law. An ABC is a liquidation process governed by state law (California law in this instance) that is an alternative to a bankruptcy case under federal law. Prior to commencing the ABC, Health ceased business operations and all of its employees were terminated and treated in accordance with California law. In the ABC, all of Health’s assets were transferred to the Assignee, who acts as a fiduciary for creditors and in a capacity equivalent to that of a bankruptcy trustee. The Assignee is responsible for liquidating the assets. Similar to a bankruptcy case, there was a claims process. Creditors of Health received notice of the ABC and a proof of claim form and were required to submit a proof of claim in order to participate in distribution of net liquidation proceeds by the Assignee.
57

Table of Contents
Based on such filing for Health, the Company impaired the goodwill assigned to that reporting unit as of December 31, 2022 by approximately $5.1 million.
Revenue Recognition
On January 1, 2019, the Company adopted ASC 606.
To determine revenue recognition for contractual arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (1) identify each contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when (or as) the relevant performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will be able to collect the consideration it is entitled to in exchange for the goods or services the Company provides to the customer.
The Company generates revenues from the provision of (1) Mobile Health Services and (2) Transportation Services. For both Mobile Health Services and Transportation Services, the customer simultaneously receives and consumes the benefits provided by the Company as the performance obligations are fulfilled. Therefore, the Company satisfies performance obligations immediately. The Company has utilized the “right to invoice” expedient, which allows an entity to recognize revenue in the amount of consideration to which the entity has the right to invoice when the amount that the Company has the right to invoice corresponds directly to the value transferred to the customer.
The transaction price associated with the Company’s contracts with customers is generally determined based on fixed and determinable amounts of consideration as specified in a contract, which includes a fixed base rate and fixed mileage rate. For transportation services arrangements with billings to third party payors and healthcare facilities, this may also include variable consideration in instances where it is considered probable that a significant reversal of cumulative revenue recognized will not occur. For these services, revenues are recorded net of estimated contractual allowances for claims subject to contracts with responsible paying entities. The Company estimates contractual allowance at the time of billing based on contractual terms, historical collections or other arrangements. The Company also estimates the amount unbilled at month end and recognizes such amounts as revenue, based on available data and customer history. The Company utilizes the expected value method when estimating its variable consideration. The assumptions utilized in estimating variable consideration include the Company’s previous experience with similar contracts and history of collection rates on prior trips that have been performed. The Company reevaluates its variable consideration at each reporting period.
Income Taxes
Income taxes are recorded in accordance with ASC 740, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or its tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.
Please see Note 2, “Summary of Significant Accounting Policies” to the unaudited Condensed Consolidated Financial Statements.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
We are exposed to certain market risks, including those relating to changes in interest rates and foreign currency exchange rates. We do not enter into instruments for trading or speculative purposes.
Interest Rate Risk
We are subject to interest rate risk relating to our cash equivalents and borrowings under our Revolving Facility, which bear interest at a per annum rate equal to (i) at our option, (x) the base rate or (y) the adjusted term SOFR rate, plus (ii) the
58

Table of Contents
applicable margin. The applicable margins are based on the Company’s consolidated net leverage ratio, adjusted on a quarterly basis. As of December 31, 2023, there was a $25,000,000 outstanding balance on the Revolving Facility. The Company drew down an additional $15,000,000 on February 8, 2024 under the Revolving Facility. On February 27, 2024, the Company paid the $40,000,000 Revolving Facility balance. On March 4, 2024, the Company drew down $15,000,000 and made an additional $15,000,000 draw on March 18, 2024. As of September 30, 2024, the outstanding balance of the Revolving Facility was $30,000,000 and the unused portion of the Revolving Facility was $60,000,000. While the applicable interest rate is set for a specific term when amounts are drawn down under the terms of the Revolving Facility, any subsequent draws on the Revolving Facility may be subject to a higher or lower interest rate, depending upon, among other things, the then-prevailing SOFR rate. We have not utilized interest rate hedging or other strategies in an attempt to mitigate our interest rate risk. A hypothetical 10% change in interest rates during the nine months ended September 30, 2024 would have had a neutral net impact on our unaudited Condensed Consolidated Financial Statements, as changes in amounts paid for interest expense would have offset changes in interest income earned on cash balances.
Foreign Exchange Risk
We operate our business primarily within the U.S. and currently execute a majority of our transactions in U.S. dollars. However, we are exposed to limited foreign exchange risk as a result of our U.K. operations. The foreign exchange gain (loss) for the three months ended September 30, 2024 and 2023 were $934,774 and $(582,471), respectively, and $828,613 and $66,965 for the nine months ended September 30, 2024 and 2023, respectively. We have not utilized hedging strategies with respect to such foreign exchange exposure. This limited foreign currency translation risk is not expected to have a material impact on our consolidated financial statements. A hypothetical 10% change in the applicable foreign exchange rate would have resulted in a change in total revenues of approximately 0.9% and 0.6% for the three and nine months ended September 30, 2024, respectively, and a change in total assets of approximately 0.3% for the nine months ended September 30, 2024.
Concentrations of Risk and Significant Clients
Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash and accounts receivable. Although we deposit our cash with multiple financial institutions in the United States and in foreign countries, our deposits, at times, may exceed federally insured limits. We do not believe we are exposed to significant credit risk due to the financial strength of the depository institutions in which the funds are held.
With respect to accounts receivable, the Company had one customer that accounted for approximately 41% of revenues and 34% of net accounts receivable and another customer that accounted for 21% of revenues and 44% of net accounts receivable for the three months ended September 30, 2024. The Company had one customer that accounted for approximately 36% of revenues and 34% of net accounts receivable and another customer that accounted for 31% of revenues and 44% of net accounts receivable for the nine months ended September 30, 2024. The Company had one customer that accounted for approximately 33% of revenues and 36% of net accounts receivable and another customer that accounted for 32% of revenues and 28% of net accounts receivable for the three months ended September 30, 2023. One customer accounted for approximately 37% of revenues and 28% of net accounts receivable and another customer accounted for approximately 17% of revenues and 36% of net accounts receivable for the nine months ended September 30, 2023. We perform ongoing evaluations of customers’ financial condition, creditworthiness and payment performance. Based on these evaluations, we consider whether or not the accounts receivable exposure to any specific customer is within an acceptable range for that customer.
Item 4. Controls and Procedures
Management’s Evaluation of Disclosure Controls and Procedures
Based on our management’s evaluation (with the participation of our principal executive officer and principal financial officer), as of the end of the period covered by this Quarterly Report on Form 10-Q, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
59

Table of Contents
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating the disclosure controls and procedures and internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
60

Table of Contents
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
We and other participants in the healthcare industry are subject to legal proceedings, claims and litigation arising in the ordinary course of our business. Descriptions of certain legal proceedings to which we are a party are contained in Note 19, “Legal Proceedings” to our unaudited Condensed Consolidated Financial Statements and are incorporated herein.
In addition, from time to time, in the ordinary course of business and like others in our industry, we receive requests for information from government agencies in connection with their regulatory or investigational authority. These requests can include subpoenas or demand letters for documents to assist the government in audits or investigations. We review such requests and notices and take what we believe to be appropriate action. We have been subject to certain requests for information and investigations in the past and could be subject to such requests for information and investigations in the future.
Item 1A. Risk Factors
Factors that could materially and adversely affect our business, financial condition and/or results of operations are described in the Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”). Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business, financial condition and/or results of operations. As of the date of this Quarterly Report on Form 10-Q, there have been no material changes to the risk factors disclosed in the 2023 Form 10-K.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Unregistered Sales of Equity Securities
On March 31, 2023, Holdings acquired 51% of the outstanding shares of common stock of CRMS, a provider of cardiac implantable electronic device remote monitoring and virtual care management services. The closing consideration of $10,000,000 consisted of $9,000,000 in cash and $1,000,000 worth of shares of Common Stock issued in a private placement transaction. The Company also agreed to pay additional consideration following the initial closing, including the True-up Payment to be paid in 2024 based on the attainment of full-year 2023 EBITDA targets.
On May 29, 2024, the Company made a portion of the True-up Payment in the amount of $1,000,000 in cash. On July 19, 2024, the Company also issued $1,814,345 in Common Stock, or 578,350 shares, in a private placement, constituting the remainder of the True-up Payment.
The foregoing transaction did not involve any underwriters, underwriting discounts or commissions, or any public offering. Under the terms of the agreement, the Company issued and sold the shares of Common Stock in a private placement to accredited investors, in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act. The Company relied on this exemption from registration based in part as each accredited investor was aware of the terms of the transaction, the securities issued contained restrictive legends regarding resale and transfer, and the transaction was not publicly solicited or advertised.
Share Repurchases
On January 30, 2024, the Board of Directors authorized the Prior Repurchase Program, pursuant to which the Company could purchase up to $36,000,000 in shares of Common Stock during a six-month period that ended July 30, 2024. The Prior Repurchase Program did not oblige the Company to repurchase a specific number of shares.
On August 5, 2024, following the expiration of the Prior Repurchase Program on July 30, 2024, the Board effectively extended the Prior Repurchase Program by authorizing the New Repurchase Program, pursuant to which the Company may purchase up to $26,000,000 in shares of Common Stock, which was the approximate amount remaining under the Prior Repurchase Program at its expiration. The New Repurchase Program expires on December 31, 2024 and may be suspended, extended, modified or discontinued at any time without prior notice.
Under the terms of the New Repurchase Program, the Company may purchase shares of Common Stock on a discretionary basis from time to time through open market repurchases or privately negotiated transactions or through other means, including by entering into Rule 10b5-1 trading plans or accelerated share repurchase programs, in each case, during an “open window” and when the Company does not possess material non-public information.
61

Table of Contents
The timing, manner, price and amount of shares repurchased under the New Repurchase Program will depend on a variety of factors, including stock price, trading volume, market conditions, corporate and regulatory requirements and other general business considerations. The New Repurchase Program does not oblige the Company to repurchase a specific number of shares.
Repurchases under the New Repurchase Program may be funded from the Company’s existing cash and cash equivalents, future cash flow or proceeds of borrowings or debt offerings.
As of September 30, 2024, $24.7 million remained available for share repurchases pursuant to the New Repurchase Program.
Information regarding shares of Common Stock repurchased during the three months ended September 30, 2024 is as follows:

Month |  | Total Number of Shares Purchased |  | Average Price Paid per Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans |  | Approximate Dollar Value of Shares that May Yet be Purchased Under the Plans |
July 1 through 31, 2024 |  | — |  |  | $ | — |  |  | — |  |  | $ | 26,271,021 |  | (1)
August 1 through 31, 2024 |  | 233,565 |  |  | $ | 3.59 |  |  | 233,565 |  |  | $ | 25,160,539 |  |
September 1 through 30, 2024 |  | 122,548 |  |  | $ | 3.67 |  |  | 122,548 |  |  | $ | 24,710,935 |  |
Total |  | 356,113 |  |  | $ | 3.62 |  |  | 356,113 |  |  | $ | 24,710,935 |  |

(1) Amount remaining under the Prior Repurchase Program upon its expiration on July 30, 2024.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
(c) Trading Plans
During the three months ended September 30, 2024, none of our directors or officers (as defined in Rule 16a-1 under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 105b-1 trading arrangement” (as those terms are defined in Item 408 of Regulation S-K).
62

Table of Contents
Item 6. Exhibits

Exhibit Number |  | Description
3.1 |  | Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K, filed with the SEC on November 12, 2021).
3.2 |  | Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 of the Company’s Quarterly Report on Form 10-Q, filed with the SEC on November 6, 2023).
10.1 |  | Amended and Restated Form of Indemnification Agreement, by and between the Company and its officers and directors (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on September 30, 2024).
10.2 |  | Consulting Agreement, dated September 27, 2024, by and between the Company and Steven Katz (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on September 30, 2024).
31.1* |  | Certification of the Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) of the Exchange Act.
31.2* |  | Certification of the Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) of the Exchange Act.
32.1** |  | Certification of the Principal Executive Officer Pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2** |  | Certification of the Principal Financial Officer Pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS* |  | Inline XBRL Instance Document.
101.SCH* |  | Inline XBRL Taxonomy Extension Schema Document.
101.CAL* |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF* |  | Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB* |  | Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE* |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 |  | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

* Filed herewith.
** Furnished herewith.
63

Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| DocGo Inc.
Date: November 7, 2024 | By: | /s/ Lee Bienstock
|  | Lee Bienstock
|  | Chief Executive Officer

Date: November 7, 2024 | By: | /s/ Norman Rosenberg
|  | Norman Rosenberg
|  | Chief Financial Officer and Treasurer

64